Compound containing oxazolidinone structure, preparation method therefor and use thereof

By developing compounds as shown in formula (I) that bind to different sites of bacterial type II topoisomerases, the problems of drug resistance and side effects of quinolone drugs have been solved, achieving broad-spectrum antibacterial activity and effective bacterial inhibition.

WO2026233430A1PCT designated stage Publication Date: 2026-11-12SHANGHAI QINGRUN PHARMA TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095664
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-04-30
Filing Date
2026-05-08
Publication Date
2026-11-12

Smart Images

  • Figure CN2026095664_12112026_PF_FP_ABST
    Figure CN2026095664_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed in the present invention are a compound containing an oxazolidinone structure, a preparation method therefor and the use thereof. Specifically provided is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound of the present invention has one or more of the following: (1) a new structure; (2) a good inhibitory activity against mycoplasma pneumoniae; (3) a good inhibitory activity against Gram-positive bacteria; (4) a good inhibitory activity against Gram-negative bacteria; (5) a good metabolic stability in human liver microsomes; (6) a relatively low inhibitory effect on human cardiac potassium ion channels and a high cardiac safety; (7) a good in-vivo antibacterial efficacy; and (8) a weak inhibitory activity against acetylcholinesterase and a good selectivity.
Need to check novelty before this filing date? Find Prior Art

Description

Compounds containing oxazolidinone structures, their preparation methods and applications

[0001] This application claims priority to Chinese patent applications filed on May 9, 2025 (2025105985652), September 11, 2025 (202511298369X), November 14, 2025 (2025116794165), February 13, 2026 (2026102166108), and April 30, 2026 (2026). The full text of the aforementioned Chinese patent applications is incorporated herein by reference. Technical Field

[0002] This invention relates to the field of pharmaceutical technology, and more specifically to compounds containing an oxazolidinone structure, their preparation methods, and their applications. Background Technology

[0003] The World Health Organization (WHO) has identified antibiotic resistance as one of the top ten global public health threats affecting humanity. In 2019, multidrug-resistant infections (MDRs) caused 4.95 million deaths, and if the lack of new antimicrobial drugs targeting resistance continues, it is estimated that 10 million people will die each year by 2050.

[0004] Generally, bacteria can be classified into Gram-positive, Gram-negative, and atypical pathogens such as mycoplasma. Antibiotics effective against all these pathogens are considered broad-spectrum antibiotics. Bacterial type II topoisomerases (including DNA cyclotransferase and topoisomerase IV) are widely present in these bacteria and are essential for regulating the topological structure of bacterial DNA. DNA cyclotransferase mainly regulates the supercoiled state of the bacterial genome by relaxing (i.e., removing) positive supercoils and generating negative supercoils in the relaxed DNA; topoisomerase IV mainly removes tangles on DNA and can also relax both positive and negative DNA supercoils. Inhibiting the biological activities of both can prevent the normal passage of bacterial DNA. Therefore, quinolone drugs, as inhibitors of topoisomerases, possess extremely broad-spectrum antibacterial activity, have been widely used for over 40 years, and are listed by the World Health Organization as one of the five "most priority" antibacterial drugs. However, quinolone drugs have various clinical side effects, such as neuropsychiatric reactions, cardiotoxicity, and effects on pediatric cartilage development. Furthermore, amino acid mutations at the type II topoisomerase binding site have led to widespread resistance to quinolone drugs. For example, in 2021, nearly one-third of clinical Neisseria gonorrhoeae isolates in the United States were resistant to ciprofloxacin, and in some parts of Asia, this figure exceeded 90%. There is an urgent global need to develop new antibacterial drugs with stronger antibacterial activity and greater effectiveness against strains resistant to existing antibiotics.

[0005] In recent years, a class of compounds known as "novel bacterial topoisomerase inhibitors (NBTIs)" have been discovered, binding to bacterial type II topoisomerase sites different from those of quinolone drugs. These novel mechanisms of action and structural features do not exhibit the side effects associated with quinolone drugs, while also avoiding bacterial resistance. One such drug, Gepotidacin, was approved by the US FDA in 2025 for the treatment of uncomplicated urinary tract infections (uUTI), becoming the first innovative oral antibiotic for uUTI in nearly 30 years. BWC0977 possesses broader-spectrum anti-Gram-positive and Gram-negative activity and is currently in Phase I clinical trials (WO2018225097A1). Further development of novel antibacterial drugs with good, broad-spectrum antibacterial activity remains necessary. Summary of the Invention

[0006] This invention provides a novel compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for its preparation, and its application.

[0007] The present invention solves the technical problem of the present invention through the following technical solution:

[0008] This invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0009] in,

[0010] X and Y are each independently N or CH;

[0011] X1 is either N or CR7;

[0012] X, X1, and Y are not all CH at the same time;

[0013] U is CH2, O, or S;

[0014] V is CH2, O, or NH;

[0015] Z is CH2 or C(O);

[0016] L1 is -(CR1R2) x -; x is 1, 2, 3, or 4;

[0017] L2 is -(CR3R4) y -; y is 0, 1, 2, 3 or 4;

[0018] L3 is -L-(W) m -; m is 0, 1, or 2;

[0019] W is C 2-6 imidene group, C 2-6 Ethyne group, C 3-8 Cycloalkylene or 4-8 membered heterocycloalkylene; the C 2-6imidene group, C 2-6 Ethyne group, C 3-8 The cycloalkylene and 4-8-membered heteroalkylene are each independently and optionally substituted by one or more R5s at any position;

[0020] L represents the key, O, S, or NR6;

[0021] R and R6 are independently hydrogen and C, respectively. 1-6 Alkyl, C 3-8 Cycloalkyl, 4-8 membered heterocyclic groups, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl, C 1-6 Alkylamino C 1-6 Alkyl or C 1-6 Alkoxy;

[0022] R', R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen, hydroxyl, amino, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl or C 1-6 Alkoxy;

[0023] Alternatively, R1 and R2 together with the carbon atom they are connected to form a 4-8 membered heterocycle or a C ring. 3-8 A carbon ring; or, R and R', along with the atoms between them, form a 4-8 membered heterocycle; or, R and one of R1, along with the atoms between them, form a 4-8 membered heterocycle; or, R' and one of R1, along with the atoms between them, form a 4-8 membered heterocycle or C. 3-8 A carbon ring; or, R and one of R3 and the atoms between them together form a 4-8 membered heterocycle; the 4-8 membered heterocycle and C 3-8 Each carbon ring is independently and optionally replaced by one or more R5s at any position;

[0024] R5 can be independently deuterium, halogen, hydroxyl, amino, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogenated C 1-6 Alkyl, hydroxyl C 1- 6-alkyl, amino C 1-6 Alkyl or C 1-6 Alkoxy;

[0025] R7 is hydrogen, halogen, or C. 1-6 alkyl;

[0026] M is selected from the following groups:

[0027] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring;

[0028] Rings B and C are independently benzene rings, 5-6 membered heteroaryl rings, 4-8 membered heterocycles, and C rings, respectively. 3-4 Carbon ring or C 6-8 Carbon rings;

[0029] The B' ring and C' ring are each independently a benzene ring, a 5-6 membered heteroaryl ring, a 4-8 membered heterocycle, or a C' ring. 3-8 Carbon rings;

[0030] R a R b and R c Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, hydroxyl, mercapto, amino, cyano, oxo, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, C 6-10 Aryl C 1-6 Alkyl, 5-10 membered heteroaryl C 1-6 Alkyl, -N(R) e )2、-OR e -SO2R e -C(O)R e -C(O)OR e -C(O)N(R) e )2、-OC(O)R e -NR f C(O)R e or -NR f C(O)N(R e )2; wherein, the C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, C 3- 8-cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, C 6-10 Aryl C1-6 Alkyl and 5-10 heteroaryl C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position;

[0031] R d Each can be independently selected as deuterium, halogen, cyano, or C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 Alkyne group, oxo group, -N(R) e )2、-OR e -SO2R e -C(O)R e -C(O)OR e -C(O)N(R) e )2、-OC(O)R e -NR f C(O)R e or -NR f C(O)N(R e )2;

[0032] R e Each independently is hydrogen, C 1-6 Alkyl, phenyl, 5-6 membered heteroaryl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by 1 to 3 groups selected from halogen, hydroxyl, amino, cyano, carboxyl, oxo, C 1- 6-alkyl, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 1-6 Alkoxy, C 1-6 Alkylamino, hydroxyl C 1-6 Alkyl or amino C 1-6 The alkyl substituents can be substituted at any position;

[0033] R f Each is independently hydrogen or C 1-6 alkyl;

[0034] n, v, and u can each be independently chosen as 0, 1, 2, 3, 4, 5, or 6;

[0035] Furthermore, the compound described in formula (I) satisfies any of the following conditions:

[0036] 1) R and R', along with the atoms between them, together form a 4-8 membered heterocycle; or R and one of R1, along with the atoms between them, together form a 4-8 membered heterocycle; or R' and one of R1, along with the atoms between them, together form a 4-8 membered heterocycle or C. 3-8 Carbon rings; the 4-8 membered heterocycles and C 3-8 Each carbon ring is independently and optionally replaced by one or more R5s at any position;

[0037] 2) m is 1, W is C 3-8 Cycloalkylene;

[0038] 3) m is 1, W is a 4-8 member heterocyclic alkyl group, X is N, and Y is N;

[0039] 4) R and one of R3 and the atoms between them together form a 4-8 membered heterocycle, where X is N and Y is N; the 4-8 membered heterocycle is optionally substituted by one or more R5s at any position;

[0040] 5) R1 and R2, together with the carbon atom they are attached to, form 4-8 membered heterocycles or C rings. 3-8 Carbon ring.

[0041] In some embodiments, certain groups in the compound represented by formula (I) or its pharmaceutically acceptable salt have the following definitions, and the definitions of groups not mentioned are as described in any embodiment of the invention (hereinafter referred to as "in some embodiments"):

[0042] In some implementations, X is N.

[0043] In some implementations, Y is N.

[0044] In some implementations, X1 is CR7.

[0045] In some implementations, U is O or S, preferably O.

[0046] In some implementations, V is O or NH, preferably NH.

[0047] In some implementations, Z is C(O).

[0048] In some implementations, L1 is -(CR1R2). x -; x is 1, 2 or 3, preferably 1 or 2.

[0049] In some implementations, L2 is -(CR3R4). y -; y is 0, 1, 2 or 3, preferably 0, 1 or 2.

[0050] In some implementations, L3 is -L-(W). m -; m is 0 or 1.

[0051] In some implementations, W is C 3-8 Cycloalkylene or 4-8 membered heterocycloalkylene, preferably C 3-8 Monocyclic cycloalkylene or 4-8 membered monocyclic heterocyclic cycloalkylene, more preferably C 3-6 Monocyclic cycloalkyl or 4-6-membered monocyclic heterocyclic alkyl, more preferably C 3-4 Monocyclic cyclohexane or 4-5 membered monocyclic heterocyclic cyclohexane, most preferably C3 monocyclic cyclohexane or 4 membered monocyclic heterocyclic cyclohexane; wherein the C 3-8 Cycloalkylene (preferably C16) 3-8 Monocyclic cycloalkylene, more preferably C 3-6 Monocyclic cycloalkyl, more preferably C 3-4 The monocyclic cycloalkyl group (most preferably a C3 monocyclic cycloalkyl group) and the 4-8-membered heterocyclic cycloalkyl group (preferably a 4-8-membered monocyclic cycloalkyl group, more preferably a 4-6-membered monocyclic cycloalkyl group, more preferably a 4-5-membered monocyclic cycloalkyl group, and most preferably a 4-membered monocyclic cycloalkyl group) are each independently and optionally substituted by one or more R5 groups at any position.

[0052] In some implementations, L is a connecting key or O, preferably a connecting key.

[0053] In some implementations, L stands for connector key, O, or NR6.

[0054] In some implementations, R and R6 are each independently hydrogen and C. 1-6 Alkyl or C 3-8 Cycloalkyl.

[0055] In some implementations, R is hydrogen, C 1-6 Alkyl or C 3-6 Cycloalkyl.

[0056] In some implementations, R is hydrogen.

[0057] In some implementations, R6 is hydrogen or C 1-6 alkyl.

[0058] In some implementations, R6 is hydrogen.

[0059] In some implementations, R', R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen, hydroxyl, amino, or C. 1-6 Alkyl, hydroxyl C 1-6 Alkyl or amino C 1-6Alkyl groups, preferably hydrogen, deuterium, halogens (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl.

[0060] In some implementations, R1 is hydrogen, deuterium, halogen, or C. 1-6 Alkyl group, preferably hydrogen.

[0061] In some implementations, R' is H.

[0062] In some implementations, R2 is hydrogen, deuterium, a halogen (e.g., F or Cl), or C. 1-6 alkyl.

[0063] In some implementations, R2 is hydrogen.

[0064] In some implementations, R3 is hydrogen, deuterium, halogen, or C. 1-6 Alkyl group, preferably hydrogen.

[0065] In some implementations, R4 is hydrogen, deuterium, a halogen (e.g., F or Cl), or C. 1-3 alkyl.

[0066] In some implementations, R4 is hydrogen.

[0067] In some embodiments, R1 and R2, together with the carbon atom they are connected to, form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle) or C 3-8 Carbon ring (preferably C) 3-8 Monocyclic carbon ring, more preferably C 3-6 The 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle) comprises 1-2 heteroatoms or heteroatom groups, wherein the heteroatoms or heteroatom groups are selected from one or more of N, NH, S and O; the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle) and C 3-8 Carbon ring (preferably C) 3-8 Monocyclic carbon ring, more preferably C 3-6 Each monocyclic carbon ring is independently and optionally replaced by one or more R5s at any position.

[0068] In some implementations, R1 and R2 together with the carbon atom they are connected to form a 4-8 membered heterocycle or C ring. 3-8 The carbon ring is preferably a 4-8 member monocyclic heterocyclic ring or a C ring. 3-8 Monocyclic carbon rings, more preferably 4-6 membered monocyclic heterocyclic rings or C 3-6The 4-6 membered heterocycle comprises 1-2 heteroatoms or heteroatom groups selected from N, NH, S, and O; the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle) and C 3-8 Carbon ring (preferably C) 3-8 Monocyclic carbon ring, more preferably C 3-6 Each monocyclic carbon ring is independently and optionally replaced by one or more R5s at any position.

[0069] In some implementations, R1 and R2 together with the carbon atom they are bonded to form C 3-6 Monocyclic carbon rings, for example:

[0070] In some implementations, R1 and R2, together with the carbon atom they are connected to, form a 4-6 membered monocyclic heterocycle, for example:

[0071] In some embodiments, R and R', and the atoms therebetween, together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle); the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle) is optionally substituted by one or more R5s at any position.

[0072] In some embodiments, R and R', and the atoms between them together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle); the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) is optionally substituted by one or more R5s at any position.

[0073] In some embodiments, R and R', and the atoms therebetween, together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle); the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) contains 1-2 heteroatoms or heteroatom groups selected from one or more of N, NH, S and O, and contains at least one N atom; the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) is optionally substituted by one or more R5s at any position.

[0074] In some embodiments, R and R', and the atoms between them together form a 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle); the 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle) contains 1-2 heteroatoms or heteroatom groups selected from N, NH, S and O, and contains at least 1 N atom; the 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle) is optionally replaced by 1-3 R5s at any position.

[0075] In some embodiments, R and R' and the atoms between them together form a 4-5 membered heterocycle (preferably a 4-5 membered monocyclic heterocycle); the 4-5 membered heterocycle (preferably a 4-5 membered monocyclic heterocycle) contains one N atom; the 4-5 membered heterocycle (preferably a 4-5 membered monocyclic heterocycle) is optionally replaced by 1-3 R5 atoms at any position.

[0076] In some embodiments, R and R', and the atoms between them together form a 4-membered monocyclic heterocycle; the 4-membered monocyclic heterocycle contains one N atom; the 4-membered monocyclic heterocycle is optionally replaced by 1-3 R5 atoms at any position.

[0077] In some embodiments, R and one of R1 and the atoms between them together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle); the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) is optionally substituted by one or more R5s at any position.

[0078] In some embodiments, R and one of R1 and the atoms therebetween together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle); the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle) is optionally replaced by one or more R5s at any position.

[0079] In some embodiments, R and one of R1 and the atoms between them together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle); the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) contains 1-2 heteroatoms or heteroatom groups selected from one or more of N, NH, S and O, and contains at least one N atom; the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) is optionally substituted by one or more R5s at any position.

[0080] In some embodiments, R and one of R1 and the atoms between them together form a 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle); the 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle) contains 1-2 heteroatoms or heteroatom groups selected from N, NH, S and O, and contains at least 1 N atom; the 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle) is optionally replaced by 1-3 R5s at any position.

[0081] In some embodiments, R and one of R1, along with the atoms between them, together form a 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle); the 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle) contains one heteroatom selected from N.

[0082] In some embodiments, R' and one of R1, along with the atoms between them, together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle) or C 3-8 Carbon ring (preferably C) 3-8 Monocyclic carbon ring, more preferably C 3-6 Monocyclic carbon ring); the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle) and C 3-8 Carbon ring (preferably C) 3-8 Monocyclic carbon ring, more preferably C 3-6 Each monocyclic carbon ring is independently and optionally replaced by one or more R5s at any position.

[0083] In some embodiments, R' and one of R1, along with the atoms between them, together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) or C. 3-8 Carbon ring (preferably C) 3-8 Monocyclic carbon ring); the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) and C 3-8 Carbon ring (preferably C) 3-8 Each monocyclic carbon ring is independently and optionally replaced by one or more R5s at any position.

[0084] In some embodiments, R' and one of R1, along with the atoms between them, together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) or C. 3-8 Carbon ring (preferably C) 3-8 The 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) comprises 1-2 heteroatoms or heteroatom groups, wherein the heteroatoms or heteroatom groups are selected from one or more of N, NH, S, and O; the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) and C 3-8 Carbon ring (preferably C) 3-8 Each monocyclic carbon ring is independently and optionally replaced by one or more R5s at any position.

[0085] In some embodiments, R' and one of R1, along with the atoms between them, together form a 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle) or C. 3-6 Carbon ring (preferably C) 3-6 The 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle) contains 1-2 heteroatoms or heteroatom groups selected from N, NH, S, and O; the 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle) and C 3-6 Carbon ring (preferably C) 3-6 Each monocyclic carbon ring can be independently and optionally replaced by 1-3 R5s at any position.

[0086] In some implementations, R' and one of R1, along with the atoms between them, together form C. 3-8 Carbon ring (preferably C) 3-8 Monocyclic carbon ring, more preferably C 3-6 (single-ring carbon ring); the C 3-8 Carbon ring (preferably C) 3-8 Monocyclic carbon ring, more preferably C 3-6 The monocyclic carbon ring is optionally replaced by one or more R5s at any position.

[0087] In some implementations, R' and one of R1, along with the atoms between them, together form C. 3-5 Carbon ring (preferably C) 3-5 (monocyclic carbon ring), the C 3-5 Carbon ring (preferably C) 3-5 A monocyclic carbon ring is optionally replaced by 1-3 R5s at any position.

[0088] In some embodiments, R' and one of R1, along with the atoms between them, together form a C4 monocyclic carbon ring, which is optionally replaced by 1-3 R5 atoms at any position.

[0089] In some embodiments, R and one of R3 and the atoms therebetween together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle); the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle, more preferably a 4-6 membered monocyclic heterocycle) is optionally substituted by one or more R5s at any position.

[0090] In some embodiments, R and one of R3 and the atoms between them together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle); the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) is optionally substituted by one or more R5s at any position.

[0091] In some embodiments, R and one of R3 and the atoms between them together form a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle); the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) contains 1-2 heteroatoms or heteroatom groups selected from one or more of N, NH, S and O, and contains at least one N atom; the 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) is optionally substituted by one or more R5s at any position.

[0092] In some embodiments, R and one of R3 and the atoms between them together form a 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle); the 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle) contains 1-2 heteroatoms or heteroatom groups selected from N, NH, S and O, and contains at least 1 N atom; the 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle) is optionally replaced by 1-3 R5s at any position.

[0093] In some embodiments, R and one of R3 and the atoms between them together form a 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle); the 4-6 membered heterocycle (preferably a 4-6 membered monocyclic heterocycle) contains one heteroatom selected from N.

[0094] In some implementations, R5 is deuterium, halogen, hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, amino C 1-6 Alkyl or C 1-6 Alkyl group.

[0095] In some embodiments, R5 is deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl.

[0096] In some implementations, R7 is H, F, Cl or -CH3, preferably H or F.

[0097] In some implementations, R7 is H.

[0098] In some implementations, M is selected from the following groups:

[0099] Preferred (preferred) ).

[0100] In some implementations, M is selected from the following groups:

[0101] Preferred

[0102] In some implementations, ring A is a benzene ring.

[0103] In some embodiments, each of the heterocyclic alkyl groups, heterocyclic groups, and heterocycles may independently contain one, two, or three heteroatoms or heterogroups selected from N, NH, O, and S, preferably saturated monocyclic rings.

[0104] In some embodiments, each of the heterocycles contains one, two, or three heteroatoms or heterogroups selected from N, NH, O, and S, preferably a saturated monocycle, and more preferably containing at least one N atom.

[0105] In some embodiments, each of the heteroaryl rings and heteroaryl groups independently contains one, two, or three heteroatoms or heterogroups selected from N, NH, O, and S, preferably monocyclic.

[0106] In some embodiments, each of the heteroaryl rings and heteroaryl groups contains one, two, or three heteroatoms or heterogroups selected from N, NH, O, and S, preferably containing at least one N.

[0107] In some embodiments, ring B and ring C are each independently a benzene ring, a 5-6 membered heterocyclic ring, or a 4-8 membered heterocyclic ring (preferably a 4-8 membered monocyclic heterocyclic ring, more preferably a 4-6 membered monocyclic heterocyclic ring); preferably a 5-6 membered heterocyclic ring or a 4-8 membered heterocyclic ring (preferably a 4-8 membered monocyclic heterocyclic ring, more preferably a 4-6 membered monocyclic heterocyclic ring).

[0108] In some embodiments, ring B and ring C are each independently a benzene ring, a 5-6 membered heteroaromatic ring, or a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle); preferably a 5-6 membered heteroaromatic ring or a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle).

[0109] In some embodiments, the B' ring and C' ring are each independently a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) or a C' ring. 3-8 Carbon ring (preferably C) 3-8 Monocyclic carbon rings, such as 4-8 membered monocyclic heterocyclic rings.

[0110] In some implementation schemes, R a R b and R c Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, hydroxyl, amino, cyano, oxo, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, -N(R) e )2、-OR e -C(O)R e -C(O)OR eor -C(O)N(R) e )2; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position.

[0111] In some implementation schemes, R a R b and R c Each independently is C 1-6 Alkyl, C 1-6 Alkoxy, halogen, hydroxyl, cyano, or oxo group, preferably each independently C 1-6 Alkyl, halogen, hydroxyl or oxo group.

[0112] In some implementation schemes, R a R b and R c Each independently is C 1-6 Alkyl, C 1-6 Alkoxy, halogen, or oxo group.

[0113] In some implementation schemes, R a Each independently is C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2- 6-olefin, C 2-6 Alkyne, halogen, hydroxyl, amino, cyano, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl, C 3-8 cycloalkyl C 1- 6-alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, -N(R) e )2、-OR e -C(O)R e -C(O)OR e or -C(O)N(R) e )2; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position.

[0114] In some implementation schemes, R a Each independently is C 1-6 Alkyl, C 1-6 Alkoxy, halogen, or cyano group, for example, halogen, preferably each independently of C 1-6 Alkyl group.

[0115] In some implementation schemes, R a Each is independently a halogen (e.g., fluorine or chlorine), cyano, C 1-6 Alkoxy (e.g., methoxy) or C 1- 6-alkyl (e.g., methyl).

[0116] In some implementation schemes, R a Each independently is C 1-6 Alkyl groups (e.g., methoxy groups).

[0117] In some implementation schemes, R a Each is an independent halogen (e.g., fluorine).

[0118] In some implementation schemes, R b Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, hydroxyl, amino, cyano, oxo, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, -N(R) e )2、-OR e -C(O)R e -C(O)OR e or -C(O)N(R) e )2; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position.

[0119] In some implementation schemes, R b Each independently is C 1-6 Alkyl, C 1-6 Alkyl, halogen, hydroxyl, cyano, or oxo group; more preferably, each independently has a C group.1-6 Alkyl, hydroxyl, or oxo group.

[0120] In some implementation schemes, R b Each is independently an oxygen group, C 1-6 Alkyl (e.g., methyl), halogen (e.g., chlorine), cyano, or C 1-6 Alkyl groups (e.g., methoxy groups).

[0121] In some implementation schemes, R b Each independently is C 1-6 Alkyl groups (e.g., methoxy groups).

[0122] In some implementation schemes, R b Each independently is C 1-6 Alkyl (e.g., methyl).

[0123] In some implementation schemes, R c Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, hydroxyl, amino, cyano, oxo, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, -N(R) e )2、-OR e -C(O)R e -C(O)OR e or -C(O)N(R) e )2; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position.

[0124] In some implementation schemes, R a R b and R c In, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6Each alkyl group is independently and optionally surrounded by 1-3 R groups. d Replace in any position.

[0125] In some implementation schemes, R a R b and R c Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen (e.g., F or Cl), cyano, oxo, or -C(O)N(R) e )2; wherein, the C 1- 6-alkyl groups are optionally surrounded by one or more R d Replace in any position.

[0126] In some implementation schemes, R a R b and R c Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen (e.g., F or Cl), hydroxyl, cyano, oxo, or -C(O)N(R) e )2;R e Each is independently hydrogen or C 1-6 alkyl.

[0127] In some implementation schemes, R a Each independently is C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2- 6-olefin, C 2-6 Alkyne, halogen (e.g., F or Cl), cyano, or -C(O)N(R) e )2; wherein, the C 1-6 Alkyl groups are optionally surrounded by one or more R d Replace in any position.

[0128] In some implementation schemes, R a R b and R c Each can be independently selected as C 1-6 Alkyl, C 1-6Alkyl group, halogen (e.g., F or Cl), cyano group, oxo group or -C(O)N(R) e )2.

[0129] In some implementation schemes, R a Each independently is C 1-6 Alkyl, C 1-6 Alkyl, halogen (e.g., F or Cl), cyano, or -C(O)N(R) e )2.

[0130] In some implementation schemes, R d Each can be independently chosen as deuterium, halogen (e.g., F or Cl), cyano, or C. 1-6 Alkyl, oxo, -N(R) e )2、-OR e or -SO2R e .

[0131] In some implementation schemes, R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e .

[0132] In some implementation schemes, R e Each is independently hydrogen or C 1-6 alkyl.

[0133] In some implementation schemes, R f It is hydrogen or C 1-6 alkyl.

[0134] In some implementations, n, v, and u are each independently selected as 0, 1, 2, 3, or 4, preferably 0, 1, 2, or 3.

[0135] In some implementations, n is 0, 1, or 2; preferably 0 or 1.

[0136] In some implementations, n is 0, 1, or 2, preferably 1.

[0137] In some implementations, n is 1.

[0138] In some implementations, v is 0, 1, 2 or 3; preferably 2.

[0139] In some implementations, v is 0, 1, 2 or 3, preferably 1 or 2.

[0140] In some implementations, u is 0.

[0141] In some implementation schemes, In this context, U is CH2, O, or S; V is CH2, O, or NH; Z is CH2 or C(O); X and Y are each independently N or CH; X1 is N or CR7; X, X1, and Y are not simultaneously CH; and when U and V are both O and Z is CH2, X is N; the definition of R7 is as described above.

[0142] In some implementation schemes, In this context, U is O or S, V is NH, Z is C(O), X1 is N or CR7, and X and Y are each independently N or CH; X, X1, and Y are not simultaneously CH; the definition of R7 is as described above.

[0143] In some implementation schemes, In this context, U is CH2, O, or S; V is CH2; Z is CH2; X1 is N or CR7; X and Y are each independently N or CH; X, X1, and Y are not simultaneously CH; and R7 is defined as described above.

[0144] In some implementation schemes, In this context, U represents CH2, O, or S; V represents CH2 or O; Z represents CH2; X1 represents CR7; X represents N; Y represents N or CH; and the definition of R7 is as described above.

[0145] In some implementation schemes, In this context, U represents O or S, V represents NH, Z represents C(O), X1 represents CR7, X represents N, Y represents N, and R7 is defined as described above.

[0146] In some implementation schemes, for X1 is N or CR7, X and Y are each independently N or CH; U is CH2, O or S, V is CH2 or O; X, X1 and Y are not simultaneously CH; Z and R7 are defined as described above.

[0147] In some implementation schemes, for X1 is N or CR7, and X and Y are each independently N or CH; X, X1, and Y are not all CH at the same time; the definitions of U, V, Z, and R7 are as described above.

[0148] In some implementation schemes, for

[0149] In some implementation schemes, for

[0150] In some implementation schemes, for Preferred

[0151] In some implementations, in L1, R1 is H or deuterium; R2 is H or deuterium.

[0152] In some implementations, L1 is -CH2- or -(CH2)2-.

[0153] In some implementations, in L2, R3 is H, deuterium, F, -OH, -NH2, or -CH3; and R4 is H, deuterium, F, or -CH3.

[0154] In some implementations, in L2, R3 is H, deuterium, or F; and R4 is H, deuterium, or F.

[0155] In some implementations, L2 is -CH2-, -(CH2)2-, or -CF2-CH2-.

[0156] In some implementations, L2 is -CH2-.

[0157] In some implementations, L3 is -L-(W)m-; L is a connecting key, O, or NR6, preferably a connecting key or O; m is 0 or 1; W is C 3-6 Cycloalkylene (preferably C16) 3-6 Monocyclic cycloalkylene, more preferably C 3-4 Monocyclic cyclohexane, more preferably C3 monocyclic cyclohexane, or 3-6 membered heterocyclic cyclohexane (preferably 3-6 membered monocyclic cyclohexane, more preferably 4-5 membered monocyclic cyclohexane, more preferably 4 membered monocyclic cyclohexane); the C 3-6 Cycloalkylene (preferably C16) 3-6 Monocyclic cycloalkylene, more preferably C 3-4 Each of the monocyclic cycloalkyl groups (more preferably C3 monocyclic cycloalkyl groups) or 3-6 heterocyclic cycloalkyl groups (preferably 3-6 monocyclic cycloalkyl groups, more preferably 4-5 monocyclic cycloalkyl groups, more preferably 4 monocyclic cycloalkyl groups) is independently and optionally substituted by one or more R5 groups at any position.

[0158] In some implementations, in L3, L is connected to M, (W) m Connected to L2.

[0159] In some implementations, in L3, m is 0 and L is 0.

[0160] In some implementations, in L3, m is 0; L is the connection key.

[0161] In some implementations, in L3, m is 1 and W is... o can be 0, 1, 2, or 3.

[0162] In some implementations, in L3, m is 1 and W is...

[0163] In some implementations, in L3, m is 1 and W is... o can be 0, 1, 2, or 3.

[0164] In some implementations, in L3, m is 1 and W is...

[0165] In some implementations, L in L3 represents a linking bond, O, NH, or N (CH3).

[0166] In some implementations, L3 is -O-, -NH-, -NCH3-, (End a is connected to M, and end b is connected to L2) (Connect end a to M, connect end b to L2) or (End a is connected to M, and end b is connected to L2).

[0167] In some implementations, M is Among them, ring A and ring R a The definitions of n are as described above.

[0168] In some embodiments, ring A is a benzene ring, pyridine ring, pyrimidine ring, pyrazine ring, or pyridazine ring.

[0169] In some implementations, M is

[0170] in,

[0171] A1 is N or CR a-1 A2 is N or CR a-2 A4 represents N or CR a-4 A6 is N or CR a-6 ;

[0172] R a-1 R a-2 R a-3 R a-4 and R a-6 Each independently is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, hydroxyl, mercapto, amino, cyano, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, C 3-8cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, C 6-10 Aryl C 1-6 Alkyl, 5-10 membered heteroaryl C 1-6 Alkyl, -N(R) e )2、-OR e -SO2R e -C(O)R e -C(O)OR e -C(O)N(R) e )2、-OC(O)R e -NR f C(O)R e or -NR f C(O)N(R e )2; wherein, the C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, C 3- 8-cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, C 6-10 Aryl C 1-6 Alkyl and 5-10 heteroaryl C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position;

[0173] Preferably, R a-1 R a-2 R a-3 R a-4 and R a-6 Each independently is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, hydroxyl, amino, cyano, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, -N(R) e )2、-OR e -C(O)R e -C(O)OR e or -C(O)N(R) e)2; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position;

[0174] More preferably, R a-1 R a-2 R a-3 R a-4 and R a-6 Each can be independently chosen as hydrogen or C. 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1- 6-alkyl, halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, cyano or -C(O)N(R) e )2; wherein, the C 1-6 Alkyl groups are optionally surrounded by one or more R d Replace in any position;

[0175] More preferably, R a-1 R a-2 R a-3 R a-4 and R a-6 Each can be independently chosen as hydrogen or C. 1-6 Alkyl, C 1-6 Alkyl, halogen (e.g., F or Cl), cyano, or -C(O)N(R) e )2;

[0176] R d Each can be independently selected as deuterium, halogen, cyano, or C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 Alkyne group, oxo group, -N(R) e )2、-OR e -SO2R e -C(O)R e -C(O)OR e -C(O)N(R) e )2、-OC(O)R e -NR f C(O)R e or -NR f C(O)N(R e )2;

[0177] Preferably, R d Each can be independently chosen as deuterium, halogen (e.g., F or Cl), cyano, or C. 1-6 Alkyl, oxo, -N(R) e )2、-OR e or -SO2R e ;

[0178] More preferably, R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;

[0179] R e Each independently is hydrogen, C 1-6 Alkyl, phenyl, 5-6 membered heteroaryl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by 1 to 3 groups selected from halogen, hydroxyl, amino, cyano, carboxyl, oxo, C 1- 6-alkyl, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 1-6 Alkoxy, C 1-6 Alkylamino, hydroxyl C 1-6 Alkyl or amino C 1-6 The alkyl substituents can be substituted at any position;

[0180] Preferably, R e Each can be either hydrogen or C independently. 1-6 alkyl;

[0181] R f It is hydrogen or C 1-6 alkyl.

[0182] In some implementations, M is Wherein, ring D is phenyl, 5-6 membered heteroaryl, or 4-8 membered heterocyclic; p is 0, 1, 2, 3, or 4; A1 is N or CR. a-1 A2 is N or CR a-2 A4 represents N or CR a-4 A6 is N or CR a-6 ;R a-1 Ra-2 R a-4 and R a-6 Each independently is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, halogen, hydroxyl, amino, cyano, C 3-8 Cycloalkyl, 3-8 membered heterocyclic or 5-6 membered heteroaryl; R d The definition is as described above.

[0183] In some implementations, M is

[0184] In some implementations, M is Among them, ring A, ring B, and ring R a R b The definitions of n and v are as described above.

[0185] In some implementations, M is

[0186] Where A0 is N or C; A1 is N or CR a-1 A2 is N or CR a-2 A3 is N or CR a-3 A4 represents N or CR a-4 ; B ring, R a-1 R a-2 R a-3 R a-4 R b The definitions of v and v are as described above.

[0187] In some implementation schemes, ring B is a 5-6 membered heteroaromatic ring, a 4-7 membered monocyclic heterocyclic ring, a 6-8 membered bridged heterocyclic ring, a C4 carbon ring, or a C4 carbon ring. 6-8 Spirocarbon rings or 6-8 quintile spiroheterocyclic rings;

[0188] In some implementations, ring B is a 5-6 membered heteroaromatic ring or a 4-7 membered monocyclic heterocycle;

[0189] In some implementations, the B ring is a 5-6 membered heteroaromatic ring or a 5-7 membered monocyclic heterocyclic ring.

[0190] In some implementations, M is

[0191] Where A1 is N or CR a-1 A2 is N or CR a-2 A3 is N or CR a-3 A4 represents N or CR a-4B1 is N or CR b-1 B2 is N or CR b-2 B3 is N or CR b-3 B4 is N or CR b-4 B5 is C(R) b-5 )2 or NR b-5’ B6 is the connector key, O, S, C(R) b- 6)2 or NR b-6’ B7 represents C(O), O, S, and C(R). b-7 )2 or NR b-7’ ; q is 0, 1, or 2; R b-0 The definition is the same as R a ;R b-1 R b-2 R b-3 R b-4 R b-5 R b-6 and R b-7 The definition is the same as R a-1 ;R a R a-1 R a-2 R a-3 and R a-4 The definition is as described above; v is 1, 2, 3, or 4;

[0192] R b-5’ R b-6’ and R b-7’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl groups are optionally surrounded by one or more R d Replace in any position;

[0193] R d Each can be independently selected as deuterium, halogen, cyano, or C. 1-6 Alkyl, oxo, -N(R) e )2、-OR e or -SO2R e ;

[0194] R e Each is independently hydrogen or C 1-6 alkyl.

[0195] In some implementation schemes, R a-1 R a-2 R a-3 R a-4 R b-1 R b-2 R b-3 R b-4 R b-5 R b-6 R b-7 Each can be independently hydrogen, halogen (e.g., F or Cl), cyano, hydroxyl, amino, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, 5-6 membered heteroaryl, -N(R) e )2、-OR e -C(O)R e -C(O)OR e or -C(O)N(R) e )2; wherein, the C 1-6 Alkyl groups are optionally surrounded by one or more R d Replace in any position;

[0196] R b-0 Halogen (e.g., F or Cl), cyano, hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, 5-6 membered heteroaryl, -N(R) e )2、-OR e -C(O)R e -C(O)OR e or -C(O)N(R) e )2; wherein, the C 1-6 Alkyl groups are optionally surrounded by one or more R d Replace in any position;

[0197] R b-5’ R b-6’ and R b-7’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl groups are optionally surrounded by one or more R d Replace in any position;

[0198] R d Each can be independently selected as deuterium, cyano, oxo, or -N(R) e )2、-OR e or -SO2R e ;

[0199] R e Each is independently hydrogen or C 1-6 alkyl.

[0200] In some implementations, M is

[0201] Where A1 is N or CR a-1 A2 is N or CR a-2 A3 is N or CR a-3 A4 represents N or CR a-4 B1 is N or CR b-1 B2 is N or CR b-2 B3 is N or CR b-3 B4 is N or CR b-4 B6 is the connector key, O, S, C(R) b-6 )2 or NR b-6’ B7 represents C(O), O, S, and C(R). b-7 )2 or NR b-7’ ; q is 0, 1, or 2; R a-1 R a-2 R a-3 R a-4 R b-1 R b-2 R b-3 R b-4 R b-5’ Rb-6 R b-6’ R b-7 and R b-7’ The definition is as described above.

[0202] In some implementation schemes, for

[0203] In some implementation schemes, for

[0204] In some implementation schemes, for

[0205] In some implementation schemes, for

[0206] In some implementation schemes, for

[0207] In some implementation schemes, for

[0208] In some implementation schemes, for

[0209] In some implementation schemes, for

[0210] In some implementation schemes, for

[0211] In some implementation schemes, R a-1 R a-2 R a-3 and R a-4 Each is independently H, halogen, cyano, C 1-6 Alkoxy, C 1-6 Alkyl or hydroxyl.

[0212] In some implementation schemes, R a-1 R a-2 R a-3 and R a-4 Each is independently H or halogen.

[0213] In some implementation schemes, R a-1 R a-2 R a-3 and R a-4 Each is independently H, halogen, or C1-6 Alkoxy; R b-1 R b-2 R b-3 R b-4 R b-6 and R b-7 Each independently represents H and C. 1-6 Alkyl, halogen, hydroxyl, cyano, C 1-6 alkoxy or oxo groups, such as H, C 1-6 Alkyl, hydroxyl, or oxo group.

[0214] In some implementation schemes, R a-2 Halogen (e.g., fluorine or chlorine), cyano, C 1-6 Alkyl groups (e.g., methoxy groups), C 1-6 Alkyl (e.g., methyl) or hydroxyl.

[0215] In some implementation schemes, R a-2 It is a halogen (e.g., fluorine).

[0216] In some implementation schemes, R a-3 It is H or a halogen (e.g., fluorine or chlorine).

[0217] In some implementation schemes, R a-4 It is an H or cyano group.

[0218] In some implementation schemes, R b-1 R b-2 R b-3 R b-4 R b-6 and R b-7 Each independently represents H and C. 1-6 Alkyl, halogen, cyano or C 1-6 Alkyl group.

[0219] In some implementation schemes, R b-1 R b-2 R b-3 R b-4 R b-6 and R b-7 Each independently is H or C 1-6 Alkyl group.

[0220] In some implementation schemes, R b-1 Each independently is H or C 1-6 Alkyl (e.g., methyl).

[0221] In some implementation schemes, R b-2 Each can be independently H, halogen (e.g., chlorine), cyano, or C. 1-6 Alkyl (e.g., methyl) or C 1-6 Alkyl groups (e.g., methoxy groups).

[0222] In some implementation schemes, R b-3 Each can be H or a halogen (e.g., fluorine) independently.

[0223] In some implementation schemes, R b-4 Each is independently represented by H.

[0224] In some implementation schemes, R b-5’ R b-6’ R b-7’ R c-4’ and R c-5’ Each independently is H or C 1-6 alkyl.

[0225] In some implementation schemes, R b-5’ C 1-6 Alkyl (e.g., methyl).

[0226] In some implementations, M is

[0227] in,

[0228] A1 is N or CH; A2 is N or CR a-2 A4 represents N or CR a-4 B1 is N or CH; B4 is N or CR b-4 B6 is a connecting key, O, S, CH2, or NR. b-6’ B7 represents C(O), O, S, and C(R). b-7 )2 or NR b-7’ ;

[0229] R a-2 R a-3 R a-4 R b-2 R b-3 R b-4 and R b-7 Each is independently hydrogen, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl or -C(O)N(R) e )2; The C 1-6 Alkyl groups are optionally surrounded by one or more R d Replace in any position;

[0230] R b-5’R b-6’ and R b-7’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position;

[0231] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0232] In some implementation schemes, R a-2 R a-3 R a-4 R b-2 R b-3 and R b-4 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;

[0233] R b-7 It is hydrogen or C 1-6 alkyl;

[0234] R b-5’ R b-6’ and R b-7’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace in any position;

[0235] Rd Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0236] In some implementations, A1 is N or CH; A2 is N or CR. a-2 A4 represents N or CR a-4 B1 is N or CH; B4 is N or CR b-4 B6 is CH2; B7 is O, S, or NR. b-7’ ;

[0237] R a-2 R a-3 R a-4 R b-2 R b-3 and R b-4 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;

[0238] R b-5’ and R b-7’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace in any position;

[0239] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0240] In some implementations, M is selected from

[0241] in,

[0242] Where A4 is N or CR a-4 B4 is N or CRb-4 ;

[0243] R a-2 R a-3 R a-4 R b-3 and R b-4 Each is independently hydrogen, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl or -C(O)N(R) e )2; The C 1-6 Alkyl groups are optionally surrounded by one or more R d Replace in any position;

[0244] R b-5’ For hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position;

[0245] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl;

[0246] Preferably, R a-2 R a-3 R a-4 R b-3 and R b-4 Each is independently hydrogen, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6alkynyl or -C(O)N(R) e )2;

[0247] R b-5’ For hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace in any position;

[0248] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl;

[0249] More preferably, A4 is N or CR a-4 B4 is N or CR b-4 ;

[0250] R a-2 R a-3 R a-4 R b-3 and R b-4 Each is independently hydrogen, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;

[0251] R b-5’ For hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace in any position;

[0252] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0253] In some implementations, M is

[0254] In some implementations, M is

[0255] In some implementations, M is

[0256] In some implementations, M is

[0257] in,

[0258] A1 is N or CR a-1 A2 is N or CR a-2 A3 is N or CR a-3 A4 represents N or CR a-4 B1 is N or CR b-1 B2 is N or CR b-2 B3 is N or CR b-3 B6 is a connecting key, O, S, CH2, or NR. b-6’ B7 represents C(O), O, S, and C(R). b-7 )2 or NR b-7’ q is 0, 1, or 2;

[0259] R a-1 R a-2 R a-3 R a-4 R b-1 R b-2 R b-3 and R b-7 Each is independently hydrogen, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl or -C(O)N(R) e )2; The C 1-6 Alkyl groups are optionally surrounded by one or more R d Replace in any position;

[0260] R b-6’ and Rb-7’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position;

[0261] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0262] In some implementation schemes, R a-1 R a-2 R a-3 R a-4 R b-1 R b-2 R b-3 and R b-7 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;

[0263] R b-6’ and R b-7’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace in any position;

[0264] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2Re ;R e Each is independently hydrogen or C 1-6 alkyl.

[0265] In some implementations, M is

[0266] In some implementations, M is Among them, ring A, ring B', ring C, and ring R a R b R c The definitions of , n, v and u are as described above.

[0267] In some implementations, M is

[0268] Where A1 is N or CR a-1 A2 is N or CR a-2 A3 is N or CR a-3 A4 represents N or CR a-4 B5 is C(R) b-5 )2 or NR b- 5’ ; C ring, R a-1 R a-2 R a-3 R a-4 R b-5 R b-5’ R c The definitions of u are as described above; preferably, the C ring is a 5-6 member heteroaromatic ring or a 4-7 member monocyclic heterocyclic ring.

[0269] In some implementations, M is

[0270] Where A1 is N or CR a-1 A2 is N or CR a-2 A4 represents N or CR a-4 B5 is C(R) b-5 )2 or NR b-5’ C1 is N or CR c-1 C2 is N or CR c-2 C3 is N or CR c-3 C4 is O, S, or NR. c-4’ ;R c-1 R c-2 and R c-3 The definition is the same as R a-1 ;R a-1 R a-2 R a-3 Ra-4 and R b-5 The definition is as stated above;

[0271] R b-5’ and R c-4’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position;

[0272] R d Each can be independently selected as deuterium, halogen, cyano, or C. 1-6 Alkyl, oxo, -N(R) e )2、-OR e or -SO2R e ;

[0273] R e Each is independently hydrogen or C 1-6 alkyl.

[0274] In some implementation schemes, R a-1 R a-2 R a-3 R a-4 R b-5 R c-1 R c-2 and R c-3 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl or -C(O)N(R) e )2; The C 1-6 Alkyl groups are optionally surrounded by one or more R d Replace in any position;

[0275] R b-5’ and R c-4’ Each independently is hydrogen, C1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position;

[0276] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;

[0277] R e Each is independently hydrogen or C 1-6 alkyl.

[0278] In some implementation schemes, R a-1 R a-2 R a-3 R a-4 R c-1 R c-2 and R c-3 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;R b- 5 represents hydrogen or C. 1-6 alkyl;

[0279] R b-5’ and R c-4’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace in any position;

[0280] R d Each independently constitutes deuterium, -N(R) e )2、-ORe or -SO2R e ;

[0281] R e Each is independently hydrogen or C 1-6 alkyl.

[0282] In some implementations, M is

[0283] In some implementations, M is Among them, ring A, ring B, ring C, and ring R a R b R c The definitions of , n, v and u are as described above.

[0284] In some implementations, M is Where A1 is N or CR a-1 A3 is N or CR a-3 A4 represents N or CR a-4 ; Ring B, Ring C, R a-1 R a-3 R a-4 R b R c The definitions of v and u are as described above.

[0285] In some implementations, ring B is a 5-6 membered heteroaromatic ring or a 4-7 membered monocyclic heterocyclic ring; ring C is a benzene ring, a 5-6 membered heteroaromatic ring, a 4-7 membered monocyclic heterocyclic ring, or a C4 carbon ring.

[0286] In some implementations, the C ring is a 5-6 membered heteroaromatic ring or a 4-7 membered monocyclic heterocyclic ring.

[0287] In some implementations, M is

[0288] Where A1 is N or CR a-1 A3 is N or CR a-3 A4 represents N or CR a-4 B1 is N or CR b-1 B2 is N or CR b-2 B3 is N or CR b-3 B4 is N or CR b-4 B5 is C(R) b-5 )2 or NR b-5’ B6 is the connector key, O, S, C(R) b-6 )2 or NR b-6’ B7 represents C(O), O, S, and C(R). b-7 )2 or NR b-7’The C ring is a 5-6 membered heteroaromatic ring or a 4-7 membered monocyclic heterocycle; R a-1 R a-3 R a-4 R b-1 R b- 2. R b-3 R b-4 R b-5 R b-5’ R b-6 R b-6’ R b-7 R b-7’ R c The definitions of u and u are as described above.

[0289] In some implementations, M is

[0290] in,

[0291] A4 is N or CR a-4 B1 is N or CR b-1 B4 is N or CR b-4 C4 is O, S, or NR. c-4’ C5 is the connecting key, O, S, C(R) c-5 )2 or NR c-5’ t is 0, 1, or 2; R c-5 The definition is the same as R a-1 ;R a-1 R a-3 R a-4 R b-1 R b-2 R b-3 and R b-4 The definition is as stated above;

[0292] R b-5’ R c-4’ and R c-5’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position;

[0293] R dEach can be independently selected as deuterium, halogen, cyano, or C. 1-6 Alkyl, oxo, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0294] In some implementations, A4 is N or CR a-4 B1 is N or CH; B4 is N or CH; C4 is O, S, or NR. c-4’ C5 is a connecting bond, O, S, CH2, or NR. c-5’ t is 0, 1, or 2;

[0295] R a-3 R a-4 R b-2 and R b-3 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl or -C(O)N(R) e )2; The C 1-6 Alkyl groups are optionally surrounded by one or more R d Replace in any position;

[0296] R b-5’ R c-4’ and R c-5’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position;

[0297] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2Re ;R e Each is independently hydrogen or C 1-6 alkyl.

[0298] In some implementation schemes, R a-3 R a-4 R b-2 and R b-3 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;

[0299] R b-5’ R c-4’ and R c-5’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace in any position;

[0300] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0301] In some implementations, M is

[0302] In some implementations, M is Among them, ring A, ring B, ring C', and ring R a R b R c The definitions of , n, v and u are as described above.

[0303] In some implementations, M is

[0304] Where A2 is N or CR a-2 A3 is N or CR a-3 A4 represents N or CR a-4 B2 is N or CRb-2 B3 is N or CR b-3 B4 is N or CR b-4 B6 is the connector key, O, S, C(R) b-6 )2 or NR b-6’ B7 represents C(O), O, S, and C(R). b-7 )2 or NR b-7’ ;R a-2 R a-3 R a-4 R b-2 R b-3 R b-4 R b-6 R b-7 R b-6’ R b-7’ R c The definitions of u are as described above; the C' ring is a 4-7 member monocyclic heterocyclic ring, preferably a 5-7 member monocyclic heterocyclic ring.

[0305] In some implementations, M is

[0306] Where A4 is N or CR a-4 B4 is N or CR b-4 B6 is the connector key, O, S, C(R) b-6 )2 or NR b-6’ B7 represents C(O), O, S, and C(R). b-7 )2 or NR b-7’ C5 is the connecting key, O, S, C(R) c-5 )2 or NR c-5’ C6 is C(R) c-6 )2; t is 0, 1, or 2; R c-6 and R c- The definition of 7 is the same as that of R. a-1 ;R a-1 R a-2 R a-3 R a-4 R b-3 R b-4 R b-6 R b-7 R c-5 The definitions of and are as described above;

[0307] R b-6’ R b-7’ and R c-5’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position;

[0308] R d Each can be independently selected as deuterium, halogen, cyano, or C. 1-6 Alkyl, oxo, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0309] In some implementations, A4 is N or CH; B4 is N or CH; B6 is a linker, O, S, CH2, or NR. b-6’ B7 is C(O), O, S, CH2, or NR. b-7’ C5 is a connecting bond, O or CH2; C6 is C(R) c-6 )2; t is 0, 1, or 2;

[0310] R a-2 R a-3 R b-3 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl or halogenated C 1-6 Alkoxy;

[0311] R b-6’ R b-7’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally marked with 1-3 R's. d Replace in any position;

[0312] R c-6 It is hydrogen, halogen (e.g., F or Cl) or C 1-6 Alkyl; R c-7 It is hydrogen, hydroxyl or C 1-6 alkyl;

[0313] R dEach independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0314] In some implementations, M is

[0315] In some implementation schemes, R, R6, R', R1, R2, R3, R4, R5, R7, R a R b R c R d R e R f R a-1 R a-2 R a-3 R a-4 R a-6 R b-0 R b-1 R b-2 R b-3 R b-4 R b-5 R b-5’ R b-6 R b-6’ R b-7 R b-7’ R c-1 R c-2 R c-3 R c- 4’ R c-5 R c-5’ R c-6 and R c-7 In the middle, the "C" mentioned 1-6 Alkyl group, halogenated C 1-6 Alkyl group, hydroxyl group 1-6 Alkyl", "amino C" 1-6 Alkyl", C 1-6 Alkylamino C 1-6 Alkyl", C 3-8 cycloalkyl C 1-6 Alkyl group, 3-8 membered heterocyclic C 1-6 Alkyl", C 6-10 Aryl C 1-6 "alkyl" and "5-10 heteroaryl C" 1-6 C in "alkyl" 1-6 Each alkyl group is independently C10. 1-4 Alkyl group. The C... 1-4Each alkyl group is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, preferably methyl, ethyl, isopropyl, n-propyl, or n-butyl, such as methyl.

[0316] In some implementation schemes, R, R6, R', R1, R2, R3, R4, R5, R a R b R c R e R a-1 R a-2 R a-3 R a-4 R a-6 R b-0 R b-1 R b-2 R b-3 R b-4 R b-5 R b-6 R b-7 R c-1 R c-2 R c-3 R c-5 R c-6 and R c-7 In the middle, the "C" mentioned 1-6 "alkoxy" and "halogenated C" 1-6 The C in "alkoxy" 1-6 Each alkoxy group is independently C 1-4 Alkyl groups. The C 1-4 Each alkyl group is independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy, for example, methoxy.

[0317] In some implementation schemes, R', R1, R2, R3, R4, R5, R7, R a R b R c R d R e R a-1 R a-2 R a-3 R a-4 R a-6 R b-0 R b-1 R b-2 R b-3 R b-4 R b-5 R b-6 R b-7 R c-1 R c-2 R c-3 Rc-5 R c-6 and R c-7 In this context, each of the halogens is independently F, Cl, Br, or I, for example, F or Cl.

[0318] In some implementation schemes, R, R6, R', R1, R2, R3, R4, R5, R a R b R c R d R e R a-1 R a-2 R a-3 R a- 4. R a-6 R b-0 R b-1 R b-2 R b-3 R b-4 R b-5 R b-6 R b-7 R c-1 R c-2 R c-3 R c-5 R c-6 and R c-7 In the text, the "halogenated C" 1-6 Alkyl and Halogenated C 1-6 The halogen in the "alkoxy group" is independently F, Cl, Br or I, for example F or Cl.

[0319] In some implementation schemes, R', R1, R2, R3, R4, R5, R a R b R c R d R a-1 R a-2 R a-3 R a-4 R a-6 R b- 0, R b-1 R b-2 R b-3 R b-4 R b-5 R b-6 R b-7 R c-1 R c-2 R c-3 R c-5 R c-6 and R c-7 In, the C 2-6Each alkenyl group can be independently vinyl, propenyl, butenyl, butadienyl, pentadienyl, or hexadienyl, for example, vinyl or propenyl.

[0320] In some implementation schemes, R', R1, R2, R3, R4, R5, R a R b R c R d R a-1 R a-2 R a-3 R a-4 R a-6 R b- 0, R b-1 R b-2 R b-3 R b-4 R b-5 R b-6 R b-7 R c-1 R c-2 R c-3 R c-5 R c-6 and R c-7 In, the C 2-6 The alkynyl groups are independently ethynyl, propynyl, butynyl, and 3-methylbutynyl.

[0321] In some implementation schemes, R, R6, R a R b R c R e R a-1 R a-2 R a-3 R a-4 R a-6 R b-0 R b-1 R b-2 R b-3 R b-4 R b-5 R b-5’ R b-6 R b-6’ R b-7 R b-7’ R c-1 R c-2 R c-3 R c-4’ R c-5 R c-5’ R c-6 and R c-7 In the middle, the "C" mentioned 3-8 "Cycloalkyl" and "C" 3-8 cycloalkyl C1-6 C in "alkyl" 3-8 Each cycloalkyl group is independently a monocyclic or bicyclic cycloalkyl group. Preferably, the C 3-8 Each cycloalkyl group is independently C10. 3-6 Cycloalkyl. More preferably, the C 3-6 Cycloalkyl group is C 3-6 Monocyclic cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0322] In some embodiments, in R and R6, the 4-8 membered heterocyclic groups are each independently a 4-8 membered monocyclic heterocyclic group or a 5-8 membered bicyclic heterocyclic group having one, two, or three heteroatoms or heterogroups selected from N, NH, S, and O. Preferably, the 4-8 membered heterocyclic group is a 4-6 membered heterocyclic group. More preferably, the 4-6 membered heterocyclic group is a 4-6 membered monocyclic heterocyclic group.

[0323] In some implementation schemes, R a R b R c R e R a-1 R a-2 R a-3 R a-4 R a-6 R b-0 R b-1 R b-2 R b-3 R b-4 R b- 5. R b-5’ R b-6 R b-6’ R b-7 R b-7’ R c-1 R c-2 R c-3 R c-4’ R c-5 R c-5’ R c-6 and R c-7 In the text, the "3-8 membered heterocyclic group" and "3-8 membered heterocyclic group C" are mentioned. 1-6 The 3-8 membered heterocyclic groups in the "alkyl" group are each independently a 3-8 membered monocyclic heterocyclic group or a 5-8 membered bicyclic heterocyclic group having one, two, or three heteroatoms or heteroatom groups selected from N, NH, S, and O. Preferably, the 3-8 membered heterocyclic group is a 4-6 membered heterocyclic group. More preferably, the 4-6 membered heterocyclic group is a 4-6 membered monocyclic heterocyclic group.

[0324] In some implementation schemes, R a R b R c Ra-1 R a-2 R a-3 R a-4 R a-6 R b-0 R b-1 R b-2 R b-3 R b-4 R b-5 R b-6 R b-7 R c-1 R c-2 R c-3 R c-5 R c-6 and R c-7 In the middle, the "C" mentioned 6-10 "Aryl" and "C" 6-10 Aryl C 1-6 C in "alkyl" 6-10 The aryl group is either phenyl or naphthyl.

[0325] In some implementation schemes, R a R b R c R a-1 R a-2 R a-3 R a-4 R a-6 R b-0 R b-1 R b-2 R b-3 R b-4 R b-5 R b-6 R b-7 R c-1 R c-2 R c-3 R c-5 R c-6 and R c-7 In the text, the "5-10 heteroaryl" and "5-10 heteroaryl C" are mentioned. 1-6 The 5-10 membered heteroaryl groups in the "alkyl" group are each independently a monocyclic or bicyclic heteroaryl group having one, two, or three heteroatoms or heterogroups selected from N, NH, S, and O. Preferably, the 5-10 membered heteroaryl group is a 5-6 membered heteroaryl group.

[0326] In some implementation schemes, R e R a-1 R a-2 R a-3 R a-4 R a-6 R b-0 R b-1R b-2 R b-3 R b-4 R b-5 R b-6 R b- 7. R c-1 R c-2 R c-3 R c-5 R c-6 and R c-7 In this context, the 5-6 membered heteroaryl group is a 5-6 membered heteroaryl group having one, two, or three heteroatoms or heteroatom groups selected from N, NH, S, and O.

[0327] In some implementations, R, R6, and R e In the middle, the "C" mentioned 1-6 "alkylamino" and "C" 1-6 Alkylamino C 1-6 C in "alkyl" 1-6 Each alkylamino group is independently C10. 1-4 Alkylamino. The C 1-4 Each alkylamino group can be independently methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, or tert-butylamino.

[0328] In some implementations, in W, the C 2-6 The imide group is C 2-4 Subalkenyl. The C... 2-4 The imide group is -CH=CH-, -CH=CHCH2-, -C(CH2)=CH-, -CH=CHCH2CH2-, -CH2CH=CHCH2-, -C(CH2)=C(CH2)- or -C(CH2)=CHCH2-.

[0329] In some implementations, in W, the C 2-6 The acetylinyl group is C 2-4 Alynyl group. The C... 2-4 The ethynyl group is -C≡C-, -C≡C-CH2-, -C≡C-CH2-CH2-, -CH2-C≡C-CH2- or

[0330] In some implementations, in W, the C 3-8 The cycloalkylene group is a monocyclic or bicyclic cycloalkylene group. Preferably, the C 3-8 Cycloalkylene is C 3-6 Cycloalkylene. More preferably, the C 3-6 Cycloalkylene is C 3-6 Monocyclic cycloalkylene compounds, such as cyclopropylene, cyclobutylene, cyclopentylene, and cyclohexylene.

[0331] In some embodiments, in W, the 4-8 membered heterocyclic alkyl group is a 4-8 membered monocyclic heterocyclic alkyl group or a 5-8 membered bicyclic heterocyclic alkyl group having one, two, or three heteroatoms or heterogroups selected from N, NH, S, and O. Preferably, the 4-8 membered heterocyclic group is a 4-6 membered heterocyclic group. More preferably, the 4-6 membered heterocyclic group is a 4-6 membered monocyclic heterocyclic group.

[0332] In some embodiments, the 4-8 membered heterocycles in the B ring, C ring, B' ring, and C' ring, as well as the 4-8 membered heterocycles in the following statements: "R1 and R2 together with the carbon atoms they are connected to form a 4-8 membered heterocycle", "R and R' together with the atoms between them form a 4-8 membered heterocycle", "R and one of the R1s are connected to each other to form a 4-8 membered heterocycle", "R' and one of the R1s together with the atoms between them form a 4-8 membered heterocycle", and "R and one of the R3s together with the atoms between them form a 4-8 membered heterocycle", are each independently a 4-8 membered monocyclic heterocycle or a 5-8 membered bicyclic heterocycle having one, two, or three heteroatoms or heterogroups selected from N, NH, S, and O.

[0333] In some embodiments, the 4-8 membered heterocycles in rings B, C, B', and C', as well as the 4-8 membered heterocycles in the following statements: "R1 and R2 together with their commonly connected carbon atoms form a 4-8 membered heterocycle", "R and R' together with the atoms between them form a 4-8 membered heterocycle", "R and one of R1 are interconnected to form a 4-8 membered heterocycle", "R' together with one of R1 and the atoms between them form a 4-8 membered heterocycle", and "R together with one of R3 and the atoms between them form a 4-8 membered heterocycle", are each independently a 4-8 membered monocyclic heterocycle or a 5-8 membered bicyclic heterocycle having one or two heteroatoms or heterogroups selected from one or more of N, NH, S, and O.

[0334] In some embodiments, the 4-8 membered heterocycles in “R1 and R2 together with the carbon atoms they are connected to form a 4-8 membered heterocycle”, “R and R' together with the atoms between them form a 4-8 membered heterocycle”, “R and one of R1 are connected to each other to form a 4-8 membered heterocycle”, “R' together with one of R1 and the atoms between them form a 4-8 membered heterocycle”, and “R together with one of R3 and the atoms between them form a 4-8 membered heterocycle” are each independently a 4-6 membered heterocycle, preferably a 4-5 membered heterocycle, such as a 4 membered heterocycle; the 4-8 membered heterocycles in ring B, ring C, ring B' and ring C' are each independently a 4-7 membered monocyclic heterocycle or a 6-8 membered bicyclic heterocycle, preferably a 5-7 membered monocyclic heterocycle, a 6-8 membered bridged heterocycle or a 6-8 membered spirocyclic heterocycle.

[0335] In some implementations, the C in rings B' and C' 3-8The carbon ring, along with R1 and R2 and the carbon atoms they are connected to, forms a C ring. 3- The 8-carbon rings "R" and "R1" along with the atoms between them together form C. 3-8 The C in "carbon ring" 3-8 Each carbon ring is independently a monocyclic or bicyclic carbon ring. Preferably, the C 3-8 The carbon ring is C 3-6 Carbon ring, more preferably C 3-5 Carbon ring.

[0336] In some implementations, in rings B and C, the C ring... 3-4 Each carbon ring is an independent monocyclic carbon ring, such as a C3 carbon ring or a C4 carbon ring.

[0337] In some implementations, in rings B and C, the C ring... 6-8 Each carbon ring is independently a monocyclic or bicyclic carbon ring. Preferably, the C 6-8 The carbon ring is C 6-8 Spiral carbon ring.

[0338] In some embodiments, each of the 5-6 membered heteroaromatic rings in ring A, ring B, ring C, ring B', and ring C' is independently a 5-6 membered heteroaromatic ring having one, two, or three heteroatoms or heteroatom groups selected from N, NH, S, and O.

[0339] In some embodiments, each of the 5-6 membered heteroaromatic rings in ring A, ring B, ring C, ring B', and ring C' independently has one or two heteroatoms or heterogroups selected from one or more of N, NH, S, and O.

[0340] The compound shown in formula (I) can be any of the following schemes:

[0341] Option 1 for X1 is N or CR7; X and Y are each independently N or CH; U is CH2, O or S; V is CH2 or O; X, X1 and Y are not simultaneously CH; and the compound as described in formula (I) satisfies any of the following conditions:

[0342] 1) R and R', along with the atoms between them, together form a 4-8 membered heterocycle; or R and one of R1, along with the atoms between them, together form a 4-8 membered heterocycle; or R' and one of R1, along with the atoms between them, together form a 4-8 membered heterocycle or C. 3-8 Carbon rings; the 4-8 membered heterocycles and C 3-8 Each carbon ring is independently and optionally replaced by one or more R5s at any position;

[0343] 2) m is 1, W is C 3-8Cycloalkylene;

[0344] 3) m is 1, W is a 4-8 member heterocyclic alkyl group, X is N, and Y is N;

[0345] 4) R and one of R3, along with the atoms between them, form a 4-8 membered heterocycle, where X is N and Y is N; the 4-8 membered heterocycle and C 3-8 Each carbon ring is independently and optionally replaced by one or more R5s at any position;

[0346] 5) R1 and R2, together with the carbon atom they are attached to, form 4-8 membered heterocycles or C rings. 3-8 Carbon rings;

[0347] The definitions of other groups are as described above.

[0348] Option 2, for X1 is N or CR7; X and Y are each independently N or CH; X, X1, and Y are not simultaneously CH; and the compound as described in formula (I) satisfies any of the following conditions:

[0349] I) R and R', along with the atoms between them, together form a 4-8 membered heterocycle; or R and one of R1, along with the atoms between them, together form a 4-8 membered heterocycle; or R' and one of R1, along with the atoms between them, together form a 4-8 membered heterocycle or C. 3-8 A carbon ring; or R1 and R2 together with the carbon atoms they are attached to form a 4-8 membered heterocycle or a carbon ring. 3-8 A carbon ring; or R and one of R3 and the atoms between them together form a 4-8 membered heterocycle; the 4-8 membered heterocycle and C 3-8 Each carbon ring is independently and optionally replaced by one or more R5s at any position;

[0350] II) m is 1, W is C 3-8 Cycloalkylene or 4-8 membered heterocycloalkylene;

[0351] The definitions of other groups are as described above.

[0352] Option 3, for X1 is N or CR7, X and Y are each independently N or CH; U is O or S; V is CH or O; X, X1, and Y are not simultaneously CH; and in the compound as described in formula (I), R' and one of R1 and the atoms between them together form a 4-8 membered heterocycle or C 3-8 Carbon rings; the 4-8 membered heterocycles and C 3-8 Each carbon ring is independently and optionally substituted by one or more R5s at any position; the definitions of other groups are as described above.

[0353] Option 4, for X is N; X1 is N or CR7; and in the compound as described in formula (I), R' and one of R1 and the atoms between them together form a 4-8 membered heterocycle or C 3-8 Carbon rings; the 4-8 membered heterocycles and C 3- Each of the eight carbon rings is independently and optionally substituted by one or more R5 groups at any position; the definitions of other groups are as described above.

[0354] In some implementations, L2 is -(CR3R4). y -; y is 0, 1, 2, or 3, L3 is -L-(W) m -; m is 0, L is a connector, O or NR6;

[0355] For example, L2 is -(CR3R4) y -, where y is 1, 2, or 3, and L3 is -L-(W). m -, m is 0, L is the connection key;

[0356] For example, L2 is -(CR3R4) y -; y is 1 or 2, L3 is -L-(W) m -; m is 0, L is the connection key;

[0357] For example, L2 is -(CR3R4) y -; y is 1 or 2, L3 is -L-(W) m -; m is 0, L is 0;

[0358] For example, L2 is -(CR3R4) y -; y is 1 or 2, L3 is -L-(W) m -; m is 0, L is NR6.

[0359] In some implementations, L2 is -(CR3R4). y -; y is 0, 1, 2, or 3, L3 is -L-(W) m -; m is 1, W is C 3-8 Cycloalkylene or 4-8 membered heterocyclic alkylene, where L is a linking bond or O;

[0360] For example, L2 is -(CR3R4) y -; y is 0, L3 is -L-(W) m -; m is 1, W is C 3-8 Cycloalkylene, where L is O;

[0361] For example, L2 is -(CR3R4) y -; y is 1, L3 is -L-(W) m-; m is 1, W is C 3-8 Cycloalkylene, where L represents a linking bond;

[0362] For example, L2 is -(CR3R4) y -; y is 0, L3 is -L-(W) m -; m is 1, W is a 4-8 membered heterocyclic alkyl group, and L is a linking bond;

[0363] For example, L2 is -(CR3R4) y -; y is 1, L3 is -L-(W) m -; m is 1, W is C 3-8 Cycloalkylene, where L is O;

[0364] For example, L2 is -(CR3R4) y -; y is 0, L3 is -L-(W) m -; m is 1, W is C 3-8 Cycloalkylene, where L is the linking bond.

[0365] In some implementations, L2 is -(CR3R4). y -, where y is 1, 2, or 3, and L3 is -L-(W). m - where m is 0, L is a connecting bond, and R' and one of R1, along with the atoms between them, form a 4-8 membered heterocycle or C. 3-8 Carbon ring.

[0366] In some implementations, L2 is -(CR3R4). y -; y is 1, 2, or 3, R and one of R3, along with the atoms between them, form a 4-8 membered heterocycle; L3 is -L-(W). m -; m is 0, L is 0;

[0367] For example, L2 is -(CR3R4) y -; y is 1, R and one of R3 and the atoms between them together form a 4-8 membered heterocycle; L3 is -L-(W). m -; m is 0, L is 0.

[0368] In some implementation schemes, for (For example (Right now )or (Right now ))

[0369] Among them, L 1-1 For -(CR1R2) x -; x is 1 or 2; L2-1 For -(CR3R4) y -; y is 0, 1, 2 or 3; w is 0, 1 or 2; z is 1 or 2; L1, L2, L3, L, R, R', R1, R2, R3 and R4 are defined as in any embodiment of this invention.

[0370] In some embodiments, the compound represented by formula (I) may be a compound represented by formula (II), formula (III) (e.g., formula (III-1) or formula (III-2)), formula (IV), formula (V) or formula (VI):

[0371] (For example (Right now )or (Right now ))

[0372] Among them, L 1-1 For -(CR1R2) x -; x is 1 or 2; L 2-1 For -(CR3R4) y -; y is 0, 1, 2 or 3; w is 0, 1 or 2 (preferably 1 or 2); z is 1 or 2; X, Y, U, V, Z, L1, L2, L3, L, M, R, R', R1, R2, R3 and R4 are defined as described above; in the compounds shown in formulas (III-1) and (III-2), x is 1 and w is 1; or x is 2 and w is 2 (preferably x is 1 and w is 1; or x is 2 and w is 2; R1 is H and R2 is H).

[0373] In some embodiments, in the compound represented by formula (II),

[0374] X is either N or CH;

[0375] Y is N;

[0376] U is either O or S;

[0377] V is either O or NH;

[0378] Z is CH2 or C(O);

[0379] L1 is -(CR1R2) x -; x is 1 or 2;

[0380] w is 1 or 2;

[0381] L2 is -(CR3R4) y -; y is 0, 1, 2, or 3;

[0382] L3 is -L-(W)m -; m is 0, 1, or 2;

[0383] L stands for connector or O;

[0384] W is C 3-8 Monocyclic cycloalkylene or 4-8 membered monocyclic heterocyclic cycloalkylene; the C 3-8 The monocyclic cycloalkyl group and the 4-8 membered monocyclic heterocyclic cycloalkyl group are each independently and optionally substituted by one or more R5s at any position;

[0385] R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen, hydroxyl, amino, or C. 1-6 alkyl;

[0386] R5 is deuterium, halogen, hydroxyl, amino, or C. 1-6 alkyl;

[0387] M is

[0388] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring;

[0389] The B ring is a benzene ring, a 5-6 membered heteroaromatic ring, or a 4-8 membered monocyclic heterocycle;

[0390] R a and R b Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2- 6-Alkyne, halogen, cyano, oxo, or -C(O)N(R) e )2; C is the preferred choice. 1-6 Alkyl, C 1-6 Alkyl, halogen, cyano, oxo, or -C(O)N(R) e )2;

[0391] R e Each is independently hydrogen or C 1-6 alkyl;

[0392] n and v are each independently 0, 1, 2, 3 or 4.

[0393] In some embodiments, in the compound represented by formula (II),

[0394] X is N or CH, preferably N;

[0395] Y is N;

[0396] U can be O or S, preferably O;

[0397] V is either O or NH, preferably NH;

[0398] Z is CH2 or C(O), preferably C(O);

[0399] L1 is -(CR1R2) x -; x is 1 or 2;

[0400] w is 1 or 2;

[0401] L2 is -(CR3R4) y -; y is 0, 1, or 2;

[0402] L3 is -L-(W) m -; m is 0 or 1;

[0403] L stands for connector or O;

[0404] W is C 3-8 Monocyclic cycloalkylene, preferably C 3-4 Monocyclic cycloalkylene;

[0405] R1, R2, R3 and R4 are each independently hydrogen or halogen (e.g. F or Cl), preferably hydrogen;

[0406] M is

[0407] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring;

[0408] Ring B is a 5-6 membered heteroaromatic ring or a 4-8 membered monocyclic heterocyclic ring, preferably a 4-8 membered monocyclic heterocyclic ring;

[0409] R a It is a halogen or cyano group, preferably a halogen (e.g., F or Cl);

[0410] R b C 1-6 Alkyl, halogen (e.g., F or Cl), or oxo group, preferably C 1-6 Alkyl or oxo group; for example, R b It consists of methyl and oxo groups;

[0411] n can be 0, 1, or 2, preferably 0 or 1;

[0412] v can be 0, 1, 2 or 3, preferably 2.

[0413] In some embodiments, in the compound represented by formula (II),

[0414] X is either N or CH;

[0415] Y is N;

[0416] U is either O or S;

[0417] V is either O or NH;

[0418] Z is CH2 or C(O);

[0419] L1 is -(CR1R2) x -; x is 1 or 2;

[0420] w is 1 or 2;

[0421] L2 is -(CR3R4) y -; y is 0, 1, 2, or 3;

[0422] L3 is -L-(W) m -; m is 0, 1, or 2;

[0423] L stands for connector or O;

[0424] W is C 3-8 Monocyclic cycloalkylene or 4-8 membered monocyclic heterocyclic cycloalkylene; the C 3-8 The monocyclic cycloalkyl group and the 4-8 membered monocyclic heterocyclic cycloalkyl group are each independently and optionally substituted by one or more R5s at any position;

[0425] R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0426] R5 is deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0427] M is

[0428] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring;

[0429] The B ring, C ring, and C' ring are each independently a benzene ring, a 5-6 membered heteroaromatic ring, or a 4-8 membered monocyclic heterocycle;

[0430] R a R b and R c Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, hydroxyl, cyano, oxo, or -C(O)N(R) e )2, C is the preferred choice 1-6 Alkyl, C 1-6Alkyl group, halogen (e.g., F or Cl), cyano group, oxo group or -C(O)N(R) e )2;

[0431] R e Each is independently hydrogen or C 1-6 alkyl;

[0432] n, v, and u are each independently 0, 1, 2, 3, or 4.

[0433] In some embodiments, in the compound represented by formula (II),

[0434] X is N or CH, preferably N;

[0435] Y is N;

[0436] U can be O or S, preferably O;

[0437] V is either O or NH, preferably NH;

[0438] Z is CH2 or C(O), preferably C(O);

[0439] L1 is -(CR1R2) x -; x is 1 or 2;

[0440] w is 1 or 2;

[0441] L2 is -(CR3R4) y -; y is 0, 1, or 2;

[0442] L3 is -L-(W) m -; m is 0 or 1;

[0443] L stands for connector or O;

[0444] W is C 3-8 Monocyclic cycloalkylene, preferably C 3-4 Monocyclic cycloalkylene;

[0445] R1, R2, R3 and R4 are each independently hydrogen or halogen (e.g. F or Cl), preferably hydrogen;

[0446] M is

[0447] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring;

[0448] Ring B is a 5-6 membered heteroaromatic ring or a 4-8 membered monocyclic heterocyclic ring, preferably a 4-8 membered monocyclic heterocyclic ring;

[0449] The C ring and C' ring are each independently 4-8 member monocyclic heterocyclic rings;

[0450] R a C1-6 Alkyl, C 1-6 Alkyl, hydroxyl, halogen, or cyano group; preferably halogen (e.g., F or Cl);

[0451] R b Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkyl, hydroxyl, halogen (e.g., F or Cl), or oxo group, preferably C 1-6 Alkyl or oxo group, such as R b It consists of methyl and oxo groups;

[0452] R c C 1-6 Alkyl or halogen (e.g., F or Cl);

[0453] n can be 0, 1, or 2, preferably 0 or 1;

[0454] v can be 0, 1, 2 or 3, preferably 2;

[0455] u can be 0, 1, or 2, preferably 0.

[0456] In some embodiments, in the compound represented by formula (II),

[0457] X is N or CH, preferably N;

[0458] Y is N;

[0459] U can be O or S, preferably O;

[0460] V is either O or NH, preferably NH;

[0461] Z is CH2 or C(O), preferably C(O);

[0462] L1 is -(CR1R2) x -; x is 1 or 2;

[0463] w is 1 or 2;

[0464] L2 is -(CR3R4) y -; y is 0, 1, or 2;

[0465] L3 is -L-(W) m -; m is 0 or 1;

[0466] L stands for connector or O;

[0467] W is C 3-6 Monocyclic cycloalkylene, preferably C 3-4 Monocyclic cycloalkylene;

[0468] R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0469] M is

[0470] A1 is N or CH; A2 is N or CR a-2 A3 is N or CR a-3 A4 represents N or CR a-4 B1 is N or CH; B2 is N or CR b-2 B3 is N or CR b-3 B4 is N or CR b-4 B6 is CH2; B7 is O, S, or NR. b-7’ C4 is O, S, or NR. c-4’ C5 is the connecting key, O, S, C(R) c-5 )2 or NR c-5’ C6 is C(R) c-6 )2; q and t are each independently 0, 1 or 2;

[0471] R a-2 R a-3 R a-4 R b-2 R b-3 R b-4 R c-5 and R c-6 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;

[0472] R b-5’ R b-7’ R c-4’ and R c-5’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace in any position;

[0473] R d Each independently constitutes deuterium, -N(R) e)2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0474] In some embodiments, in the compound represented by formula (II),

[0475] X is N or CH, preferably N;

[0476] Y is N;

[0477] U can be O or S, preferably O;

[0478] V is NH;

[0479] Z is C(O);

[0480] L1 is -(CR1R2) x -; x is 1 or 2, preferably 1;

[0481] w is 1 or 2, preferably 1;

[0482] L2 is -(CR3R4) y -; y is 0, 1, or 2, preferably 2;

[0483] L3 is -L-(W) m -; m is 0 or 1, preferably 0;

[0484] L can be a connecting key or O, preferably O;

[0485] W is C 3-6 Monocyclic cycloalkylene, preferably C 3-4 Monocyclic cycloalkylene;

[0486] R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0487] M is Preferred

[0488] A1 is N or CH; A2 is N or CR a-2 A4 represents N or CR a-4 B1 is N or CH; B2 is N or CR b-2 B3 is N or CR b-3 B4 is N or CR b-4 B6 is CH2; B7 is O, S, or NR. b-7’ C4 is O, S, or NR. c-4’C5 is a linker; C6 is CH2; t is 0, 1, or 2;

[0489] R a-2 R a-3 R a-4 R b-2 R b-3 and R b-4 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;

[0490] R b-5’ R b-7’ and R c-4’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace at any position; R b-5’ R b-7’ and R c-4’ Each is independently preferred to be hydrogen or C 1-6 alkyl;

[0491] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0492] In some embodiments, in the compound represented by formula (II),

[0493] X is either N or CH;

[0494] Y is N;

[0495] U is either O or S;

[0496] V is either O or NH;

[0497] Z is CH2 or C(O);

[0498] L1 is -(CR1R2) x -; x is 1 or 2;

[0499] w is 1 or 2;

[0500] L2 is -(CR3R4) y -; y is 0, 1, 2, or 3;

[0501] L3 is -L-(W) m -; m is 0, 1, or 2;

[0502] L represents a connecting bond, O, or NR6; R6 represents hydrogen or C. 1-6 Alkyl group; preferably, L is a linking bond, O, NH or N (CH3); more preferably, L is a linking bond or O;

[0503] W is C 3-8 Monocyclic cycloalkylene or 4-8 membered monocyclic heterocyclic cycloalkylene; the C 3-8 The monocyclic cycloalkyl group and the 4-8 membered monocyclic heterocyclic cycloalkyl group are each independently and optionally substituted by one or more R5s at any position;

[0504] R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0505] R5 is deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0506] M is

[0507] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring;

[0508] The B ring, C ring, and C' ring are each independently a benzene ring, a 5-6 membered heteroaromatic ring, or a 4-8 membered monocyclic heterocycle;

[0509] R a R b and R c Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen (e.g., F or Cl), hydroxyl, cyano, oxo, or -C(O)N(R) e )2, C is the preferred choice 1-6 Alkyl, C 1-6 Alkyl group, halogen (e.g., F or Cl), hydroxyl group, cyano group, oxo group or -C(O)N(R) e )2;

[0510] R eEach is independently hydrogen or C 1-6 alkyl;

[0511] n, v, and u are each independently 0, 1, 2, 3, or 4.

[0512] In some embodiments, in the compound represented by formula (II),

[0513] X is N or CH, preferably N;

[0514] Y is N;

[0515] U can be O or S, preferably O;

[0516] V is either O or NH, preferably NH;

[0517] Z is CH2 or C(O), preferably C(O);

[0518] L1 is -(CR1R2) x -; x is 1 or 2;

[0519] w is 1 or 2;

[0520] L2 is -(CR3R4) y -; y is 0, 1, or 2;

[0521] L3 is -L-(W) m -; m is 0 or 1;

[0522] L represents a connecting bond, O, or NR6; R6 represents hydrogen or C. 1-6 Alkyl group; preferably, L is a linking bond, O, NH or N (CH3); more preferably, L is a linking bond or O;

[0523] W is C 3-8 Monocyclic cycloalkylene, preferably C 3-4 Monocyclic cycloalkylene;

[0524] R1, R2, R3 and R4 are each independently hydrogen or halogen (e.g. F or Cl), preferably hydrogen;

[0525] M is

[0526] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring;

[0527] Ring B is a 5-6 membered heteroaromatic ring or a 4-8 membered monocyclic heterocyclic ring, preferably a 4-8 membered monocyclic heterocyclic ring;

[0528] The C ring and C' ring are each independently 4-8 member monocyclic heterocyclic rings;

[0529] R a C 1-6 Alkyl, C1-6 Alkyl, hydroxyl, halogen or cyano, preferably hydroxyl or halogen (e.g. F or Cl);

[0530] R b Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkyl, hydroxyl, halogen (e.g., F or Cl), or oxo group, preferably C 1-6 Alkyl or oxo group, such as R b It consists of methyl and oxo groups;

[0531] R c C 1-6 Alkyl or halogen (e.g., F or Cl);

[0532] n can be 0, 1, or 2, preferably 0 or 1;

[0533] v can be 0, 1, 2 or 3, preferably 2;

[0534] u can be 0, 1, or 2, preferably 0.

[0535] In some embodiments, in the compound represented by formula (II),

[0536] X is N or CH, preferably N;

[0537] Y is N;

[0538] U can be O or S, preferably O;

[0539] V is either O or NH, preferably NH;

[0540] Z is CH2 or C(O), preferably C(O);

[0541] L1 is -(CR1R2) x -; x is 1 or 2;

[0542] w is 1 or 2;

[0543] L2 is -(CR3R4) y -; y is 0, 1, or 2;

[0544] L3 is -L-(W) m -; m is 0 or 1;

[0545] L represents a connecting bond, O, or NR6; R6 represents hydrogen or C. 1-6 Alkyl group; preferably, L is a linking bond, O, NH or N (CH3); more preferably, L is a linking bond or O;

[0546] W is C 3-6 Monocyclic cycloalkylene; preferably C 3-4 Monocyclic cycloalkylene;

[0547] R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0548] M is

[0549] A1 is N or CH; A2 is N or CR a-2 A3 is N or CR a-3 A4 represents N or CR a-4 B1 is N or CH; B2 is N or CR b-2 B3 is N or CR b-3 B4 is N or CR b-4 B6 is CH2; B7 is O, S, or NR. b-7’ C4 is O, S, or NR. c-4’ C5 is the connecting key, O, S, C(R) c-5 )2 or NR c-5’ C6 is C(R) c-6 )2; q and t are each independently 0, 1 or 2;

[0550] R a-2 R a-3 R a-4 R b-2 R b-3 R b-4 R c-5 and R c-6 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;

[0551] R b-5’ R b-7’ R c-4’ and R c-5’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace in any position;

[0552] R dEach independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0553] In some embodiments, in the compound represented by formula (II),

[0554] X is N or CH, preferably N;

[0555] Y is N;

[0556] U can be O or S, preferably O;

[0557] V is NH;

[0558] Z is C(O);

[0559] L1 is -(CR1R2) x -; x is 1 or 2, preferably 1;

[0560] w is 1 or 2; preferably 1;

[0561] L2 is -(CR3R4) y -; y is 0, 1, or 2, preferably 2;

[0562] L3 is -L-(W) m -; m is 0 or 1, preferably 0;

[0563] L represents a connecting bond, O, or NR6; R6 represents hydrogen or C. 1-6 Alkyl group; preferably, L is a linking bond, O, NH or N (CH3); more preferably, L is a linking bond or O; more preferably, L is O;

[0564] W is C 3-6 Monocyclic cycloalkylene, preferably C 3-4 Monocyclic cycloalkylene;

[0565] R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0566] M is Preferred More preferably

[0567] A1 is N or CH; A2 is N or CR a-2 A4 represents N or CR a-4 B1 is N or CH; B2 is N or CR b-2 B3 is N or CR b-3 B4 is N or CR b-4 B6 is CH2; B7 is O, S, or NR. b-7’ C4 is O, S, or NR. c-4’ C5 is a linker; C6 is CH2; t is 0, 1, or 2;

[0568] R a-2 R a-3 R a-4 R b-2 R b-3 and R b-4 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;

[0569] R b-5’ R b-7’ and R c-4’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace at any position; R b-5’ R b-7’ and R c-4’ Each is independently preferred to be hydrogen or C 1-6 alkyl;

[0570] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0571] In some embodiments, in the compound represented by formula (III),

[0572] X is either N or CH;

[0573] Y is N;

[0574] U is either O or S;

[0575] V is either O or NH;

[0576] Z is CH2 or C(O);

[0577] L 1-1 For -(CR1R2) x -; x is 1 or 2;

[0578] w is 0, 1, or 2 (preferably 1 or 2);

[0579] L2 is -(CR3R4) y -; y is 0, 1, 2, or 3;

[0580] L3 is -L-(W) m -; m is 0, 1, or 2;

[0581] L stands for connector or O;

[0582] W is C 3-8 Monocyclic cycloalkylene or 4-8 membered monocyclic heterocyclic cycloalkylene; the C 3-8 The monocyclic cycloalkyl group and the 4-8 membered monocyclic heterocyclic cycloalkyl group are each independently and optionally substituted by one or more R5s at any position;

[0583] R represents hydrogen, C represents... 1-6 Alkyl or C 3-8 cycloalkyl;

[0584] R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0585] R5 represents deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0586] M is selected from the following groups:

[0587] (For example )or

[0588] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring;

[0589] Rings B and C are each independently a benzene ring, a 5-6 membered heteroaromatic ring, or a 4-8 membered monocyclic heterocycle;

[0590] R a R b and R c Each can be independently selected as C 1-6 Alkyl, C1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen (e.g., F or Cl), cyano, oxo, or -C(O)N(R) e )2; C is the preferred choice. 1-6 Alkyl, C 1-6 Alkyl group, halogen (e.g., F or Cl), cyano group, oxo group or -C(O)N(R) e )2;

[0591] R e Each is independently hydrogen or C 1-6 alkyl;

[0592] n, v, and u can each be independently chosen as 0, 1, 2, 3, or 4.

[0593] In some embodiments, the compounds shown in formulas (III-1) and (III-2),

[0594] X is either N or CH;

[0595] Y is N;

[0596] U is either O or S;

[0597] V is either O or NH;

[0598] Z is CH2 or C(O);

[0599] L 1-1 For -(CR1R2) x -;

[0600] x is 1, w is 1; or x is 2, w is 2;

[0601] L2 is -(CR3R4) y -; y is 0, 1, 2, or 3;

[0602] L3 is -L-(W) m -; m is 0, 1, or 2;

[0603] L stands for connector or O;

[0604] W is C 3-8 Monocyclic cycloalkylene or 4-8 membered monocyclic heterocyclic cycloalkylene; the C 3-8 The monocyclic cycloalkyl group and the 4-8 membered monocyclic heterocyclic cycloalkyl group are each independently and optionally substituted by one or more R5s at any position;

[0605] R represents hydrogen, C represents... 1-6 Alkyl or C 3-8 cycloalkyl;

[0606] R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0607] R5 represents deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 alkyl;

[0608] M is selected from the following groups:

[0609] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring;

[0610] Rings B and C are each independently a benzene ring, a 5-6 membered heteroaromatic ring, or a 4-8 membered monocyclic heterocycle;

[0611] R a R b and R c Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen (e.g., F or Cl), cyano, oxo, or -C(O)N(R) e )2; C is the preferred choice. 1-6 Alkyl, C 1-6 Alkyl group, halogen (e.g., F or Cl), cyano group, oxo group or -C(O)N(R) e )2;

[0612] R e Each is independently hydrogen or C 1-6 alkyl;

[0613] n, v, and u can each be independently chosen as 0, 1, 2, 3, or 4.

[0614] In some embodiments, the compounds represented by formula (III) (e.g., formula (III-1) or formula (III-2))

[0615] X is N or CH, preferably N;

[0616] Y is N;

[0617] U can be O or S, preferably O;

[0618] V is either O or NH, preferably NH;

[0619] Z is CH2 or C(O), preferably C(O);

[0620] L1-1 For -(CR1R2) x -; x is 1;

[0621] w is 1;

[0622] L2 is -(CR3R4) y -; y is 0, 1, or 2;

[0623] L3 is -L-(W) m -; m is 0 or 1;

[0624] L stands for a connecting key or O, preferably a connecting key;

[0625] W is C 3-8 Monocyclic cycloalkylene, preferably C 3-4 Monocyclic cycloalkylene;

[0626] R1, R2, R3 and R4 are each independently hydrogen or halogen (e.g. F or Cl), preferably hydrogen;

[0627] M is Preferred

[0628] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring, preferably a benzene ring;

[0629] Ring B is a benzene ring, a 5-6 membered heteroaromatic ring, or a 4-8 membered monocyclic heterocycle, preferably a 4-8 membered monocyclic heterocycle;

[0630] The C ring is a 4-8 membered heterocyclic ring;

[0631] R a C 1-6 Alkyl, halogen or cyano, preferably halogen (e.g. F);

[0632] R b C 1-6 Alkyl, halogen (e.g., F or Cl), cyano or oxo group, preferably C 1-6 Alkyl or oxo group; for example, R b It consists of methyl and oxo groups;

[0633] n can be 0, 1, or 2, preferably 1;

[0634] v can be 0, 1, 2 or 3, preferably 2;

[0635] u can be 0, 1, or 2, preferably 0.

[0636] In some embodiments, the compounds represented by formula (III) (e.g., formula (III-1) or formula (III-2))

[0637] X is N or CH, preferably N;

[0638] Y is N;

[0639] U can be O or S, preferably O;

[0640] V is either O or NH, preferably NH;

[0641] Z is CH2 or C(O), preferably C(O);

[0642] L 1-1 For -(CR1R2) x -; x is 1;

[0643] w is 1;

[0644] L2 is -(CR3R4) y -; y is 0, 1, or 2;

[0645] L3 is -L-(W) m -; m is 0 or 1;

[0646] W is C 3-6 Monocyclic cycloalkylene, preferably C 3-4 Monocyclic cycloalkylene;

[0647] L stands for a connecting key or O, preferably a connecting key;

[0648] R is hydrogen;

[0649] R1, R2, R3 and R4 are each independently hydrogen or halogen (e.g. F or Cl), preferably hydrogen;

[0650] M is

[0651] A1 is N or CH; A2 is N or CR a-2 A3 is N or CR a-3 A4 represents N or CR a-4 B1 is N or CH; B2 is N or CR b-2 B3 is N or CR b-3 B4 is N or CR b-4 B6 is CH2; B7 is O, S, or NR. b-7’ C4 is O, S, or NR. c-4’ C5 is the connecting key, O, S, C(R) c-5 )2 or NR c-5’ ; q and t are each independently 0, 1 or 2;

[0652] R a-2 R a-3 R a-4 R b-2 R b-3 Rb-4 and R c-5 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;

[0653] R b-5’ R b-7’ R c-4’ and R c-5’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace in any position;

[0654] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0655] In some embodiments, the compounds represented by formula (III) (e.g., formula (III-1) or formula (III-2))

[0656] X is N or CH, preferably N;

[0657] Y is N;

[0658] U can be O or S, preferably O;

[0659] V is NH;

[0660] Z is C(O);

[0661] L 1-1 For -(CR1R2) x -; x is 1;

[0662] w is 1;

[0663] L2 is -(CR3R4) y -; y is 0, 1, or 2, preferably 1;

[0664] L3 is -L-;

[0665] L stands for connection key;

[0666] R is hydrogen;

[0667] R1, R2, R3 and R4 are each independently hydrogen or halogen (e.g. F or Cl), preferably hydrogen;

[0668] M is Preferred More preferably

[0669] A1 is N or CH; A2 is N or CR a-2 A4 represents N or CR a-4 B1 is N or CH; B2 is N or CR b-2 B3 is N or CR b-3 B4 is N or CR b-4 B6 is CH2; B7 is O, S, or NR. b-7’ C4 is O, S, or NR. c-4’ C5 is a linker; C6 is CH2; t is 0, 1, or 2;

[0670] R a-2 R a-3 R a-4 R b-2 R b-3 and R b-4 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R) e )2;

[0671] R b-5’ R b-7’ and R c-4’ Each independently is hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl C 1-6 Alkyl or 3-8 membered heterocyclic C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace at any position; R b-5’ R b-7’ and R c-4’ Each is independently preferred to be hydrogen or C 1-6 alkyl;

[0672] R d Each independently constitutes deuterium, -N(R) e )2、-OR e or -SO2R e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0673] In some embodiments, the compounds represented by formula (III) (e.g., formula (III-1) or formula (III-2))

[0674] X is N or CH, preferably N;

[0675] Y is N;

[0676] U is either O or S;

[0677] V is either O or NH, preferably NH;

[0678] Z is CH2 or C(O), preferably C(O);

[0679] L 1-1 For -(CR1R2) x -; x is 1;

[0680] w is 1;

[0681] L2 is -(CR3R4) y -; y is 0, 1 or 2, preferably 1 or 2; more preferably 1;

[0682] L3 is -L-(W) m -; m is 0 or 1, preferably 0;

[0683] W is C 3-6 Monocyclic cycloalkylene, preferably C 3-4 Monocyclic cycloalkylene;

[0684] L stands for connection key;

[0685] R is hydrogen;

[0686] R1, R2, R3 and R4 are each independently hydrogen or halogen (e.g. F or Cl), preferably hydrogen;

[0687] M is Preferred Further preferred More preferably

[0688] A1 is N or CH; A2 is N or CR a-2 A3 is N or CR a-3 A4 represents N or CR a-4 B1 is N or CH; B2 is N or CR b-2 B3 is N or CR b-3 B4 is N or CR b-4 B6 is O or CH2; B7 is O, S, or NR. b-7’ C4 is O, S, or NR. c- 4’ C5 is a linker; C6 is CH2; q and t are each independently 0, 1, or 2;

[0689] R a-2 R a-3 R a-4 R b-2 R b-3 and R b-4 Each is independently hydrogen, halogen (e.g., F or Cl), cyano, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl or halogenated C 1-6 Alkoxy;

[0690] R b-5’ R b-7’ and R c-4’ Each is independently hydrogen or C 1-6 Alkyl; wherein, the C 1-6 Alkyl groups are optionally surrounded by 1 to 3 R groups. d Replace at any position; R b-5’ R b-7’ and R c-4’ Each is independently preferred to be hydrogen or C 1-6 alkyl;

[0691] R d Each independently is either deuterium or -OR e ;R e Each is independently hydrogen or C 1-6 alkyl.

[0692] In some embodiments, the compounds represented by formula (III) (e.g., formula (III-1) or formula (III-2))

[0693] X is N or CH; preferably N;

[0694] Y is N;

[0695] U is either O or S;

[0696] V is NH;

[0697] Z is C(O);

[0698] L 1-1 For -(CR1R2) x -; x is 1;

[0699] w is 1;

[0700] L2 is -(CR3R4) y -; y is 1 or 2, preferably 1;

[0701] L3 is -L-;

[0702] L stands for connection key;

[0703] R is hydrogen;

[0704] R1, R2, R3, and R4 are each independently hydrogen;

[0705] M is Preferred

[0706] A2 is N or CR a-2 A4 represents N or CR a-4 B1 is N or CH; B4 is N or CR b-4 ;

[0707] R a-2 R a-3 R a-4 R b-2 R b-3 and R b-4 Each is independently hydrogen, halogen (e.g., F or Cl), C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl or halogenated C 1-6 Alkoxy;

[0708] R b-5’ It is hydrogen or C 1-6 Alkyl (e.g., C10) 1-3 alkyl).

[0709] In some embodiments, in the compound represented by formula (IV),

[0710] X is either N or CH;

[0711] Y is N;

[0712] U is either O or S;

[0713] V is either O or NH;

[0714] Z is CH2 or C(O);

[0715] L1 is -(CR1R2) x -; x is 1 or 2;

[0716] L2 is -(CR3R4) y -; y is 0, 1, 2, or 3;

[0717] z is 1 or 2;

[0718] L stands for connector or O;

[0719] R represents hydrogen, C represents... 1-6 Alkyl or C 3-8 cycloalkyl;

[0720] R', R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen, hydroxyl, amino, or C. 1-6 alkyl;

[0721] M is selected from the following groups:

[0722] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring;

[0723] The B ring is a benzene ring, a 5-6 membered heteroaromatic ring, or a 4-8 membered monocyclic heterocycle;

[0724] R a R b and R c Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, cyano, oxo, or -C(O)N(R) e )2; C is the preferred choice. 1-6 Alkyl, C 1-6 Alkyl, halogen, cyano, oxo, or -C(O)N(R) e )2;

[0725] R e Each is independently hydrogen or C 1-6 alkyl;

[0726] n, v, and u can each be independently chosen as 0, 1, 2, 3, or 4.

[0727] In some embodiments, in the compound represented by formula (IV),

[0728] X is N or CH, preferably N;

[0729] Y is N;

[0730] U can be O or S, preferably O;

[0731] V is either O or NH, preferably NH;

[0732] Z is CH2 or C(O), preferably C(O);

[0733] L1 is -(CR1R2) x -; x is 1;

[0734] L2 is -(CR3R4) y -; y is 1;

[0735] z is 1;

[0736] L stands for a connecting key or O, preferably a connecting key;

[0737] R represents hydrogen, C represents... 1-6 Alkyl or C 3-8 Cycloalkyl groups, preferably hydrogen-based;

[0738] R', R1, R2, R3 and R4 are each independently hydrogen or halogen (e.g. F or Cl), preferably hydrogen;

[0739] M is

[0740] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring, preferably a benzene ring;

[0741] Ring B is a 5-6 membered heteroaromatic ring or a 4-8 membered monocyclic heterocyclic ring, preferably a 4-8 membered monocyclic heterocyclic ring;

[0742] R a It is halogen or cyano, preferably halogen (e.g., F);

[0743] R b C 1-6 Alkyl, halogen (e.g., F or Cl), or oxo group, preferably C 1-6 Alkyl or oxo group, such as R b It consists of methyl and oxo groups;

[0744] n can be 0, 1, or 2, preferably 0 or 1;

[0745] v can be 0, 1, 2 or 3, preferably 2.

[0746] In some embodiments, in the compound represented by formula (V),

[0747] U can be O or S, preferably O;

[0748] V is either O or NH, preferably NH;

[0749] Z is CH2 or C(O), preferably C(O);

[0750] L1 is -(CR1R2) x -; x is 1 or 2, preferably 1;

[0751] L2 is -(CR3R4) y -; y is 0, 1, or 2, preferably 1;

[0752] z is 1 or 2, preferably 1;

[0753] L stands for a connecting key or O, preferably a connecting key;

[0754] R represents hydrogen, C represents... 1-6 Alkyl or C 3-8 Cycloalkyl groups, preferably hydrogen-based;

[0755] R', R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 Alkyl groups, preferably hydrogen;

[0756] M is

[0757] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring, preferably a benzene ring;

[0758] Ring B is a benzene ring, a 5-6 membered heteroaromatic ring, or a 4-8 membered heterocycle, preferably a 4-8 membered heterocycle;

[0759] R a and R b Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2- 6-Alkyne, halogen, cyano, oxo, or -C(O)N(R) e )2, C is the preferred choice 1-6 Alkyl, C 1-6 Alkyl, halogen, cyano, oxo, or -C(O)N(R) e )2;R e Each is independently hydrogen or C 1-6 alkyl;

[0760] Preferably, R a Halogens (e.g., F); R b C 1-6 Alkyl or oxo group, such as methyl and oxo group;

[0761] n is 0, 1, or 2; preferably 1;

[0762] v can be 0, 1, 2 or 3; preferably 2.

[0763] In some embodiments, in the compound represented by formula (VI),

[0764] U can be O or S, preferably O;

[0765] V is either O or NH, preferably NH;

[0766] Z is CH2 or C(O), preferably C(O);

[0767] L1 is -(CR1R2) x -; x is 1 or 2, preferably 1;

[0768] L 2-1 For -(CR3R4) y -; y is 0, 1, or 2, preferably 1;

[0769] z is 1 or 2, preferably 1;

[0770] L3 is -L-(W) m -; m is 0 or 1;

[0771] L stands for a connecting key or O, preferably a connecting key;

[0772] W is C 3-8 Cycloalkylene, preferably C 3-4 Cycloalkylene;

[0773] R', R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen (e.g., F or Cl), hydroxyl, amino, or C. 1-6 Alkyl groups, preferably hydrogen;

[0774] M is

[0775] Ring A is a benzene ring or a 5-6 membered heteroaromatic ring, preferably a benzene ring;

[0776] Ring B is a benzene ring, a 5-6 membered heteroaromatic ring, or a 4-8 membered heterocycle, preferably a 4-8 membered heterocycle;

[0777] R a and R b Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2- 6-Alkyne, halogen, cyano, oxo, or -C(O)N(R) e )2, C is the preferred choice 1-6 Alkyl, C 1-6Alkyl, halogen, cyano, oxo, or -C(O)N(R) e )2;R e Each is independently hydrogen or C 1-6 alkyl;

[0778] Preferably, R a Halogens (e.g., F); R b C 1-6 Alkyl or oxo groups, such as methyl and oxo groups;

[0779] n can be 0, 1, or 2, preferably 1;

[0780] v can be 0, 1, 2 or 3, preferably 2.

[0781] The compound shown in formula (I) may have any of the following structures:

[0782] (For example ), (For example ), (For example ), (For example ),

[0783] The compound shown in formula (I) may have any of the following structures:

[0784] The compound shown in formula (I) may have any of the following structures:

[0785] The compound shown in formula (I) may have any of the following structures:

[0786] (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now )or (Right now ).

[0787] The compound shown in formula (I) may have any of the following structures:

[0788] (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now ), (Right now )or (Right now ).

[0789] The compound shown in formula (I) may have any of the following structures:

[0790] The compound shown in formula (I) may have any of the following structures:

[0791] The compound shown in formula (I) may have any of the following structures:

[0792] (Right now ), (Right now ), (Right now )or (Right now ).

[0793] The compound shown in formula (I) can be any of the following compounds:

[0794] (1) Stereoisomers of the following compound,

[0795] The stereoisomers were prepared under the following conditions, with the peak eluting first (retention time approximately 16.8 min): the chromatographic column was a Nucifera C18 20×250 mm, 10 μm; the mobile phase was water and acetonitrile, the elution gradient was 5%–75% acetonitrile aqueous solution, and the elution time was 20 min.

[0796] (2) Stereoisomers of the following compounds,

[0797] The stereoisomer eluted later under the following preparation conditions (retention time can be about 17.9 min): the chromatographic column was Nucifera C18 20×250 mm, 10 μm; the mobile phase was water and acetonitrile, the elution gradient was 5% to 75% acetonitrile aqueous solution, and the elution time was 20 min.

[0798] (3) Stereoisomers of the following compounds,

[0799] The stereoisomers were prepared under the following conditions, with the peak eluting first (retention time approximately 17.2 min): the chromatographic column was a Nucifera C18 20×250 mm, 10 μm; the mobile phase was water and acetonitrile, the elution gradient was 5%–60% acetonitrile aqueous solution, and the elution time was 30 min.

[0800] (4) Stereoisomers of the following compounds,

[0801] The stereoisomer eluted later under the following preparation conditions (retention time can be about 19.5 min): the chromatographic column was Nucifera C18 20×250 mm, 10 μm; the mobile phase was water and acetonitrile, the elution gradient was 5% to 60% acetonitrile aqueous solution, and the elution time was 30 min.

[0802] (5) Stereoisomers of the following compounds,

[0803] The stereoisomers were prepared under the following conditions, with the peak eluting first (retention time approximately 16.2 min): the chromatographic column was a Nucifera C18 20×250 mm, 10 μm; the mobile phase was water and acetonitrile, the elution gradient was 5%–75% aqueous acetonitrile solution, and the elution time was 20 min.

[0804] (6) Stereoisomers of the following compounds,

[0805] The stereoisomer eluted later under the following preparation conditions (retention time can be about 17.5 min): the chromatographic column was a Nucifera C18 20×250 mm, 10 μm; the mobile phase was water and acetonitrile, the elution gradient was 5% to 75% acetonitrile aqueous solution, and the elution time was 20 min.

[0806] (7) Stereoisomers of the following compounds,

[0807] The stereoisomers were prepared under the following conditions, with the peak eluting first (retention time approximately 16.5 min): the chromatographic column was a Nucifera C18 20×250 mm, 10 μm; the mobile phase was water and acetonitrile, the elution gradient was 5%–75% acetonitrile aqueous solution, and the elution time was 20 min.

[0808] (8) Stereoisomers of the following compounds,

[0809] The stereoisomer eluted later under the following preparation conditions (retention time can be about 17.2 min): the chromatographic column was Nucifera C18 20×250 mm, 10 μm; the mobile phase was water and acetonitrile, the elution gradient was 5% to 75% acetonitrile aqueous solution, and the elution time was 20 min.

[0810] (9) Stereoisomers of the following compounds,

[0811] The stereoisomer is a compound with a short retention time under the following HPLC analysis conditions: column: YMC-Triart C18, 4.6 mm × 150 mm, 3 μm; mobile phase A: 10 mM ammonium acetate solution; mobile phase B: methanol. Preferably, the high-performance liquid chromatograph is a Waters HClass 2998 / 2489, the flow rate is 0.6 mL / min, the column temperature is 40 °C, the injection volume is 2 μL, and the detection wavelength is 190–400 nm. More preferably, the retention time of the compound with the short retention time is 23.8–24.4 min, for example, about 24.097 min.

[0812] (10) Stereoisomers of the following compounds,

[0813] The stereoisomer is a compound with a long retention time under the following HPLC analysis conditions: column: YMC-Triart C18, 4.6 mm × 150 mm, 3 μm; mobile phase A: 10 mM ammonium acetate solution; mobile phase B: methanol. Preferably, the high-performance liquid chromatograph is a Waters HClass 2998 / 2489, the flow rate is 0.6 mL / min, the column temperature is 40 °C, the injection volume is 2 μL, and the detection wavelength is 190–400 nm. More preferably, the retention time of the compound with a long retention time is 24.5–25.1 min, for example, about 24.824 min.

[0814] The present invention also provides a pharmaceutical composition comprising (i) a compound represented by formula (I) above or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable excipient.

[0815] The present invention also provides the use of a compound represented by the above formula (I) or a pharmaceutically acceptable salt thereof, or the above pharmaceutical composition, as a medicine.

[0816] The present invention also provides a compound of formula (I) above, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use as a medicament.

[0817] The present invention also provides a compound represented by formula (I) above or a pharmaceutically acceptable salt thereof, or the use of the above pharmaceutical composition in the preparation of a medicament.

[0818] The present invention also provides a compound of formula (I) above or a pharmaceutically acceptable salt thereof, or the above pharmaceutical composition for the prevention and / or treatment of microbial infections.

[0819] The present invention also provides a compound of formula (I) above, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for the prevention and / or treatment of microbial infections.

[0820] The present invention also provides the use of a compound of formula (I) above or a pharmaceutically acceptable salt thereof, or the above pharmaceutical composition, in the preparation of a medicament for the prevention and / or treatment of microbial infections.

[0821] In some implementations, the microbial infection is a bacterial infection, such as Gram-positive bacteria, Gram-negative bacteria, or mycoplasma infection.

[0822] In some implementations, the microbial infection is a bacterial infection, such as a streptococcal, Haemophilus, or staphylococcal infection.

[0823] The present invention also provides a method for preventing and / or treating microbial infections, comprising administering to a subject requiring such treatment a compound of formula (I) above or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0824] In some implementations, the microbial infection is a bacterial infection, such as Gram-positive bacteria, Gram-negative bacteria, or mycoplasma infection.

[0825] In some implementations, the microbial infection is a bacterial infection, such as a streptococcal, Haemophilus, or staphylococcal infection.

[0826] In some implementations, the mycoplasma is Mycoplasma pneumoniae.

[0827] In some implementations, the Gram-positive bacterium is Streptococcus pneumoniae.

[0828] In some embodiments, the Gram-positive bacteria are Staphylococcus aureus, Streptococcus pyogenes, or Staphylococcus epidermidis.

[0829] In some implementations, the Gram-negative bacterium is Haemophilus influenzae.

[0830] The present invention also provides a method for preparing the compound of formula (I) or a pharmaceutically acceptable salt thereof, comprising one or more of the following methods:

[0831] In general formula 1, X1, X, Y, U, V, Z, R', R, L1, L2, L3, and M are defined as previously stated. The compound shown in formula (IA) and the compound shown in formula (IB) are obtained by reductive amination to the compound shown in formula (I).

[0832] In some embodiments, when y is 0 in L2, the compound shown in formula (IB) is

[0833] In general formula 2, Lev is a leaving group (preferably a halogen, -OTs, or -OMs); X1, X, Y, U, V, Z, R', R, L1, L2, L3, and M are defined as previously stated. The compound shown in formula (IC) and the compound shown in formula (ID) are obtained by nucleophilic substitution reaction to the compound shown in formula (I).

[0834] The present invention also provides the compound of formula (IA) or a pharmaceutically acceptable salt thereof;

[0835] The definitions of X1, X, Y, U, V, Z, R', R, and L1 are as described above.

[0836] The present invention also provides any of the following compounds:

[0837] (For example (Right now )or (Right now )) ( (Right now )or (Right now )) ( (Right now )or (Right now )).

[0838] The compound may be any of the following compounds:

[0839] (1) Stereoisomers of the following compound,

[0840] The stereoisomer is a compound with a short retention time under the following HPLC analysis conditions: column: YMC-Triart C18, 4.6 mm × 150 mm, 3 μm; mobile phase A: 10 mM ammonium acetate solution; mobile phase B: methanol. Preferably, the high-performance liquid chromatograph is a Waters HClass 2998 / 2489, the flow rate is 0.6 mL / min, the column temperature is 40 °C, the injection volume is 2 μL, and the detection wavelength is 190–400 nm. More preferably, the retention time of the compound with the short retention time is 9.2–9.6 min, for example, about 9.478 min.

[0841] (2) Stereoisomers of the following compounds,

[0842] The stereoisomer is a compound with a long retention time under the following HPLC analysis conditions: column: YMC-TriartC18, 4.6 mm × 150 mm, 3 μm; mobile phase A: 10 mM ammonium acetate solution; mobile phase B: methanol. Preferably, the high-performance liquid chromatograph is a Waters HClass 2998 / 2489, the flow rate is 0.6 mL / min, the column temperature is 40 °C, the injection volume is 2 μL, and the detection wavelength is 190–400 nm. More preferably, the retention time of the compound with a long retention time is 9.7–10.0 min, for example, about 9.803 min.

[0843] The present invention also provides the compound shown in formula (IB) or a pharmaceutically acceptable salt thereof;

[0844] The definitions of L1, L2, and M are as described above.

[0845] The present invention also provides any of the following compounds:

[0846] The present invention also provides the compound shown in formula (ID) or a pharmaceutically acceptable salt thereof;

[0847] The definitions of R, L2, L3, and M are as described above.

[0848] The present invention also provides any of the following compounds:

[0849] Terminology Definition

[0850] Unless otherwise stated, the terms used in this invention have the following definitions, and the definitions of terms not referred to below are as commonly understood by those skilled in the art.

[0851] In this invention, the term "pharmaceutically acceptable salt" refers to a salt prepared from a compound with a relatively non-toxic, pharmaceutically acceptable acid or base. When a compound contains a relatively acidic functional group, a base addition salt can be obtained by contacting the neutral form of such a compound with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent. When a compound of this invention contains a relatively basic functional group, an acid addition salt can be obtained by contacting the neutral form of such a compound with a sufficient amount of a pharmaceutically acceptable acid in a pure solution or a suitable inert solvent. When a compound contains both relatively acidic and relatively basic functional groups, it can be converted into a base addition salt or an acid addition salt.

[0852] In this invention, the term "halogen" refers to fluorine, chlorine, bromine, or iodine.

[0853] In this invention, the term "alkyl" refers to a straight-chain or branched saturated hydrocarbon group having a specified number of carbon atoms. In some embodiments, the alkyl group is C64-C ... 1-6 Alkyl groups (C1, C2, C3, C4, C5, C6), for example, C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl, C 1-2 Alkyl groups, etc. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl and similar alkyl groups.

[0854] In this invention, the term "alkylene" refers to a divalent hydrocarbon group obtained by removing one hydrogen atom from an alkyl group as defined above; including but not limited to methylene (-CH2-), ethylene (including -CH2CH2-, -CH(CH3)-), propylene (including -CH(CH3)CH2-, -CH2CH(CH3)- or -C(CH3)2-), etc.

[0855] In this invention, the term "alkenyl" refers to a straight-chain or branched hydrocarbon group containing at least one carbon-carbon double bond. It may contain 1-3 carbon-carbon double bonds, preferably 1 carbon-carbon double bond. The term "C"... 2-4 "Alkenyl" refers to an alkenyl group having 2-4 carbon atoms; the term "C" is used to indicate this. 2-6 "Alkenyl" refers to alkenyl groups with 2-6 carbon atoms, including vinyl, propenyl, butenyl, and 2-methylbutenyl.

[0856] In this invention, the term "alkenyl" refers to a divalent group obtained by removing one hydrogen atom from an alkenyl group as defined above.

[0857] In this invention, the term "alkynyl" refers to a straight-chain or branched hydrocarbon group containing at least one carbon-carbon triple bond. It may contain 1-3 carbon-carbon triple bonds, preferably 1. The term "C"... 2-6 "Alynyl" refers to an alkynyl group with 2-6 carbon atoms, including ethynyl, propynyl, butynyl, and 3-methylbutynyl, etc.

[0858] In this invention, the term "ethynyl" refers to a divalent group obtained by removing one hydrogen atom from an ethynyl group as defined above.

[0859] In this invention, the term "cycloalkyl" refers to a saturated or partially unsaturated cyclic hydrocarbon group, which can be monocyclic or polycyclic (preferably monocyclic). Examples include monocyclic cycloalkyl, spirocyclic alkyl, fused cycloalkyl, and bridged cycloalkyl. For example, the term "C..." 3-6 "Cycloalkyl" refers to cycloalkyl groups having 3 to 6 ring carbon atoms, including monocyclic cycloalkyl, spirocyclic cycloalkyl, fused cycloalkyl, and bridged cycloalkyl.

[0860] In this invention, the term "cycloalkylene" refers to a divalent group obtained by removing one hydrogen atom from a cycloalkyl group as defined above.

[0861] In this invention, the term "heterocyclic group" refers to a stable, saturated or partially unsaturated, non-aromatic cyclic group composed of a carbon atom and 1, 2, 3, 4, 5, or 6 heteroatoms or heterogroups selected from N, NH, O, and S, etc. This cyclic group can be monocyclic or polycyclic (preferably monocyclic). Polycyclic heterocyclic groups include fused rings, bridged rings, and spirocyclic heterocyclic groups. For example, a heterocyclic group contains 1-3 heteroatoms or heterogroups selected from N, NH, O, and S, etc. (e.g., containing one N atom).

[0862] In this invention, the term "heterocyclic alkyl" refers to a divalent group obtained by removing one hydrogen atom from a heterocyclic group as defined above.

[0863] In this invention, the term "aryl" refers to an aromatic group consisting of carbon atoms in a conjugated hydrocarbon ring system that satisfies the 4n+2 rule, where each ring is aromatic. Examples of aryl groups include, but are not limited to, phenyl or naphthyl groups.

[0864] In this invention, the term "heteroaryl" refers to an aromatic group with a conjugated π-electron system, consisting of a single-ring or fused polycyclic aromatic ring composed of a carbon atom and at least one heteroatom selected from N, O, and S. For example, a heteroaryl contains 1-3 heteroatoms or heteroatom groups selected from N, NH, O, and S.

[0865] In this invention, the term "carbocyclic ring" refers to a saturated or partially unsaturated non-aromatic carbocyclic group with a certain number of atoms. This cyclic group can be monocyclic or polycyclic (e.g., saturated monocyclic). Monocyclic carbocyclic groups include, but are not limited to, groups such as cyclopropane, cyclobutane, cyclopentane, cyclohexane, or cyclohexene; polycyclic carbocyclic groups include spirocyclic, fused (fused) ring, and bridged ring carbocyclic groups.

[0866] In this invention, the term "heterocyclic" refers to a saturated or partially unsaturated non-aromatic cyclic group composed of carbon atoms and heteroatoms selected from nitrogen, oxygen, sulfur, or boron, etc. This cyclic group can be monocyclic or polycyclic (e.g., a saturated monocyclic). Polycyclic heterocyclic groups include fused rings, bridged rings, and spirocyclic heterocyclic groups. For example, a heterocycle contains 1-3 heteroatoms or heteroatomic groups, wherein the heteroatoms or heteroatoms are selected from N, NH, O, and S, etc., preferably containing at least one N atom.

[0867] In this invention, the term "arylalkyl" refers to an alkyl group that is substituted with one or more aryl groups, with the aryl group connected to the parent structure via an alkyl group. Thus, "arylalkyl" encompasses the definitions of alkyl and aryl groups described above.

[0868] In this invention, the term "heteroarylalkyl" refers to an alkyl group that is substituted with one or more heteroaryl groups, with the heteroaryl group connected to the parent structure via an alkyl group. Thus, "heteroarylalkyl" encompasses the definitions of alkyl and heteroaryl groups described above.

[0869] In this invention, the term "alkoxy" refers to the group -O-alkyl, wherein alkyl is defined as described above.

[0870] In this invention, the term "amino" refers to -NH2.

[0871] In this invention, the term "thiol" refers to -SH.

[0872] In this invention, the term "oxo" refers to the =O group, such as the =O portion in carbonyl (-CO-), nitrosyl (-N=O), sulfinyl (-SO-), or sulfonyl (-SO2-).

[0873] In this invention, the term "cyano" refers to -CN.

[0874] In this invention, the term "hydroxyl group" refers to -OH.

[0875] In this invention, the term "haloalkoxy" refers to an alkoxy group that is substituted with one or more halogens. Thus, "haloalkoxy" encompasses the definitions of halogens and alkoxy groups above. For example, alkoxy groups substituted with 1 to 6 halogens, preferably alkoxy groups substituted with 1 to 3 halogens.

[0876] In this invention, the term "haloalkyl" refers to an alkyl group that has been substituted with one or more halogens. Thus, "haloalkyl" encompasses the definitions of halogens and alkyl groups as described above. For example, alkyl groups substituted with 1 to 6 halogens, preferably alkyl groups substituted with 1 to 3 halogens.

[0877] In this invention, the term "hydroxyalkyl" refers to an alkyl group that is substituted with one or more hydroxyl groups. Thus, "hydroxyalkyl" encompasses the definitions of hydroxyl and alkyl groups above. For example, alkyl groups substituted with 1 to 6 hydroxyl groups, preferably alkyl groups substituted with 1 to 3 hydroxyl groups.

[0878] In this invention, the term "alkylamino" refers to an amino group in which at least one hydrogen atom is replaced by an alkyl group, including "monoalkylamino" and "dialkylamino," examples of which include, but are not limited to: -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH2CH3)2, -N(CH2CH2CH3)2, -N(CH3)(CH2CH3), and -N(CH3)(CH2CH2CH3). The term "aminoalkyl" refers to an alkyl group in which any one hydrogen atom is replaced by an amino group, examples of which include, but are not limited to: -CH2NH2 and -CH2CH2NH2. Thus, "aminoalkyl" and "alkylamino" encompass the definitions of alkyl and amino groups described above.

[0879] In this invention, the term "cycloalkylalkyl" refers to an alkyl group that is substituted by one or more cycloalkyl groups, with the cycloalkyl group linked to the parent core structure via an alkyl group. Thus, "cycloalkylalkyl" encompasses the definitions of alkyl and cycloalkyl groups described above. For example, an alkyl group substituted by 1-6 cycloalkyl groups, preferably an alkyl group substituted by 1-3 cycloalkyl groups.

[0880] In this invention, the term "heterocyclic alkyl" refers to a heterocyclic group that is connected to the parent structure via an alkyl group. Thus, "heterocyclic alkyl" encompasses the definitions of alkyl and heterocyclic groups described above.

[0881] In this invention, the term "optionally replaced by..." means either "replaced by..." or "not replaced".

[0882] In this invention, the portion containing a pyridinyl (ring) or pyrazinyl (ring) can be interconverted into a pyridinone or pyrazinone when the N-ortho position of the pyridinyl (ring) or pyrazinyl (ring) is substituted with a hydroxyl group. For example, the group containing the 2-position (ortho) substitution of the pyridinyl group with a hydroxyl group is represented by the following structure:

[0883] In this invention, the structural segments This refers to the structural segment being connected to the rest of the molecule via this bond. For example, This refers to the cyclopropyl group being linked to the rest of the molecule through this bond.

[0884] In this invention, when the chemical bond is non-directional and a hydrogen atom is present at the bondable site, the number of H atoms at that site decreases accordingly with the number of bonds being bonded, transforming into groups of the corresponding valence (i.e., replacing the H atom at that site with a bond). For example, in this invention... This indicates that the connection site is not fixed; any connectable site on ring A can be linked to other groups via a single chemical bond. For example... This indicates that any connectable site on rings A and B can be linked to other groups by a single chemical bond.

[0885] In this invention, the "-" at the end of a group indicates that the group is connected to the rest of the molecule through that site.

[0886] In this invention, the "*" in the structural segment represents a chiral center.

[0887] In this invention, unless otherwise specified, wedge-shaped solid line keys are used. and wedge-shaped dashed key Represents the absolute configuration of the center of a solid. Uses straight solid lines as keys. and straight dashed key or wedge-shaped solid line key and wedge-shaped dashed key Represents the relative configuration of the center of a solid; for example Indicates the same segment; and Indicates the same segment; Fragment of the compound shown They have the same spatial arrangement; They refer to the same substance.

[0888] Generally, the term "substituted" indicates that one or more hydrogen atoms in a given structure are substituted by a specific substituent. Further, when the group is substituted by more than one of the substituents, the substituents are independent of each other; that is, the more than one substituent can be different or the same. Unless otherwise explicitly stated, a substituent can be substituted at each substituted position of the substituted group. When more than one position in a given structural formula can be substituted by one or more substituents selected from a specific group, the substituents can be substituted at the same or different positions.

[0889] Furthermore, it should be noted that, unless otherwise explicitly stated, the descriptive phrase "...each independently is" used in this application should be interpreted broadly, meaning that the described entities are independent of each other and can independently be the same or different specific functional groups. More specifically, the descriptive phrase "...independently is" can mean either that the specific options expressed by the same symbol in different functional groups do not affect each other, or that the specific options expressed by the same symbol in the same functional group do not affect each other.

[0890] In this invention, the term "pharmaceuticalally acceptable excipients" refers to excipients and additives used in the production of pharmaceuticals and the dispensing of prescriptions; these are all substances contained in pharmaceutical preparations, excluding the active ingredient. See the Pharmacopoeia of the People's Republic of China (2020 Edition), Part IV, or the Handbook of Pharmaceutical Excipients (Raymond C. Rowe, 2009 Sixth Edition).

[0891] In this invention, the term “treatment” refers to a therapeutic approach. When a specific condition is involved, treatment means: (1) alleviating one or more biological manifestations of the disease or condition; (2) interfering with (a) one or more points in a biological cascade that causes or induces the condition or (b) one or more biological manifestations of the condition; (3) improving one or more symptoms, effects or side effects associated with the condition, or one or more symptoms, effects or side effects associated with the condition or its treatment; or (4) slowing the development of the condition or one or more biological manifestations of the condition.

[0892] In this invention, the term "prevention" refers to a reduction in the risk of acquiring or developing a disease or disorder.

[0893] Based on common knowledge in the field, the above-mentioned preferred conditions / implementations can be combined arbitrarily to obtain various preferred embodiments of the present invention.

[0894] The reagents and raw materials used in this invention are all commercially available.

[0895] The positive and progressive effects of the present invention are that the compounds of the present invention have one or more of the following effects: (1) novel structure; (2) good inhibitory activity against Mycoplasma pneumoniae; (3) good inhibitory activity against Gram-positive bacteria (e.g., Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes and Staphylococcus epidermidis); (4) good inhibitory activity against Gram-negative bacteria (e.g., Haemophilus influenzae); (5) good stability of human liver microsomal metabolism; (6) low inhibitory effect on human cardiac potassium ion channels and high cardiac safety; (7) good in vivo antibacterial efficacy; (8) weak inhibition of acetylcholinesterase and good selectivity. Detailed Implementation

[0896] The present invention will be described in detail below with reference to embodiments, but this does not imply any adverse limitation on the invention. The present invention has been described in detail, and specific embodiments thereof have been disclosed. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present invention without departing from the concept and scope of the invention.

[0897] The structures of all compounds in this invention can be determined by nuclear magnetic resonance (NMR). 1 Identification by 1H NMR and / or mass spectrometry (MS).

[0898] 1 10 H NMR chemical shifts (δ) were recorded in pPM (10 -6 NMR was performed using a Bruker AVANCE-400 spectrometer. Suitable solvents were deuterated chloroform (CDCl3), deuterated methanol (CD3OD), and deuterated dimethyl sulfoxide (DMSO-d6), with tetramethylsilane as an internal standard (TMS).

[0899] Liquid chromatography-mass spectrometry (LC-MS) was performed using a Shimadzu LCMS-2020 mass spectrometer with an Ultimate C18 column (3.0 × 50 mm, 3 μm) at 40 °C. Shimadzu gradient elution was used: 95-5% solvent A1 and 5-95% solvent B1 (0-2.0 min), followed by 95% solvent B1 and 5% solvent A1 (hold for 2 min). Percentages represent the volume percentage of a specific solvent in the total solvent volume. Solvent A1: 0.01% aqueous solution of trifluoroacetic acid (TFA); Solvent B1: 0.01% acetonitrile solution of trifluoroacetic acid; percentages represent the volume percentage of the solute in the solution.

[0900] All compounds of this invention can be separated by preparative high performance liquid chromatography, silica gel column chromatography, or rapid silica gel column chromatography.

[0901] Preparative high-performance liquid chromatography (prep-HPLC) was performed using a Hanbon-NP7000C preparative HPLC system. The chromatographic column was a Nucifera C18 20×250mm, 10μm. Separation conditions: mobile phase A: water, mobile phase B: acetonitrile. Detection wavelengths: 214nm & 254nm; flow rate: 18.0mL / min.

[0902] The rapid silica column chromatography (Flash system) used was Biotage's Isolera assist, and the matching normal phase separation column was Sante's SEPA Flash Irregular Silica Column (4g, 25g, 40g, 80g, 120g or 330g). The elution system was ethyl acetate / petroleum ether or dichloromethane / methanol.

[0903] The compounds of this invention can be analyzed using high-performance liquid chromatography.

[0904] High-performance liquid chromatography (HPLC) was performed using a Waters HClass 2998 / 2489 system. The column was a YMC-Triart C18, 4.6 mm × 150 mm, 3 μm. Elution conditions: Mobile phase A: 10 mM ammonium acetate solution; Mobile phase B: methanol. Detection wavelength: 190–400 nm; Flow rate: 0.6 mL / min; Column temperature: 40 °C; Injection volume: 2 μL. Elution gradient:

[0905] Microwave reaction is used in the embodiments of the present invention. Initiator+Microwave System EU(356006) type microwave reactor.

[0906] The configuration of the compounds of this invention can be confirmed by single-crystal diffraction experiments. Single-crystal diffraction was performed using a SMART APEX-II single-crystal X-ray diffractometer to collect diffraction intensity data, determined according to Method 1 of General Chapter 451 in the 2025 edition of the Chinese Pharmacopoeia. Test conditions: CuKα radiation. Scanning. The single-crystal diffraction experiment collected a total of 35,944 diffraction points, with 4,219 independent diffraction points, and the number of observable points (|F|). 2 ≥2σ|F| 2 The number is 3291.

[0907] Unless otherwise specified in the embodiments of the present invention, all reactions can be carried out under a nitrogen atmosphere; in all post-reaction processing, the organic phase after extraction can be dried using anhydrous sodium sulfate or anhydrous magnesium sulfate.

[0908] Unless otherwise specified, the abbreviations used in the embodiments of this invention have the following meanings: DMF: N,N-dimethylformamide; DMSO: dimethyl sulfoxide; NaBH3CN: sodium cyanoborohydride; Pd(PPh3)4: tetrakis(triphenylphosphine)palladium; DMP: Dys-Martin oxidant; NaOtBu: sodium tert-butoxide; LAH: lithium aluminum hydride; Me3SOI: trimethyl iodosulfur oxide; BINAP: 1,1'-binaphthyl-2,2'-bis(diphenylphosphine); DCM: dichloromethane; KHMDS: potassium bis(trimethylsilyl)amino; Selectfluor: 1-chloromethyl-4-fluoro-1,4-diazabicyclo[2.2.2]octane di(tetrafluoroborate) salt (selective fluorine reagent). tBuXPhos-Pd-G3: Methanesulfonic acid (2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (CAS: 1447963-75-8) DMAP: 4-Dimethylaminopyridine Ruphos Pd G3: Methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (CAS: 1445085-77-7)

[0909] Example 1: Synthesis of 6-(8-(2-(7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)ethyl)-2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-3-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-1)

[0910] Compound 1-2 (50 mg, 0.16 mmol, synthetic reference WO2021190727A1) was added to a mixed solution of compound 1-1 (35 mg, 0.16 mmol, synthetic reference WO2018225097A1) in dichloromethane (2.5 mL) and methanol (2.5 mL). The reaction mixture was stirred at room temperature for 10 min, and then NaBH3CN (30 mg, 0.48 mmol) was added. After stirring at room temperature for another 3 hours, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol / dichloromethane = 0–10%) to obtain the crude product, which was then purified by prep-HPLC (elution conditions: 5%–75% acetonitrile aqueous solution, elution time 20 min) to give compound T-1 (7 mg, yield: 9%) as a white solid. m / z [M+H] + =509; 1 H NMR (400MHz, DMSO-d6): δ11.63(s,1H),8.40(s,1H),7.90(d,J=9.3Hz,1H),7.73(s,1H),7.27(d,J=36.4Hz,1H),6.59(d,J=9.4Hz,1H),4.88 (s,2H),3.89(d,J=29.1Hz,2H),3.75(s,3H),3.44–3.39(m,2H),3.27– 3.24(m,2H),2.54–2.50(m,2H),2.40–2.33(m,2H),2.09–1.91(m,4H).

[0911] Example 2: Synthesis of 6-(2-(2-(7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-2)

[0912] Compound T-2, a white solid, was prepared from compounds 1-1 and 2-1 (synthesis reference WO2021190727A1) using the same method as in Example 1. m / z[M+H] + =481; 1H NMR (400MHz, DMSO-d6): δ11.67(s,1H),8.34(s,1H),7.88(d,J=9.5Hz,1H),7.69–7.65(m,1H),7.23–7.13(m,1H),6.57(d,J=9.4Hz,1H ), 4.86 (s, 2H), 4.21 (s, 2H), 3.74 (s, 3H), 3.51 (d, J = 8.5Hz, 2H), 3.37 (d, J = 11.2Hz, 2H), 3.05 (t, J = 6.3Hz, 2H), 2.75 (t, J = 7.1Hz, 2H).

[0913] Example 3: Synthesis of 6-(2-(2-((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-3)

[0914] Compound T-3, a white solid, was prepared from compounds 3-1 (synthesis reference WO2019106693A1) and 2-1 using the same method as in Example 1. m / z[M+H] + =497; 1 H NMR (400MHz, DMSO-d6): δ11.66(s,1H),8.33(s,1H),7.87(d,J=9.5Hz,1H),7.54–7.50(m,1H),7.26–7.21(m 1H),6.58(d,J=9.4Hz,1H),4.86(s,2H),4.22(s,2H),3.99(t,J=5.2Hz,2H),3. 86 (s, 3H), 3.57 (d, J = 9.1Hz, 2H), 3.46 (d, J = 9.0Hz, 2H), 2.88 (t, J = 5.2Hz, 2H).

[0915] Example 4: Synthesis of 6-(2-((2-(7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)ethyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-4)

[0916] Compound T-4 was prepared as a white solid using compounds 1-1 and 4-1 (synthesis reference WO2023041757A1) as starting materials, following the same method as in Example 1. m / z[M+H] +=495; 1 H NMR (400MHz, DMSO-d6): δ11.63(s,1H),8.34(d,J=4.5Hz,1H),7.87(d,J=9.5Hz,1H),7.70–7.61(m,1H),7.22–7.12(m,1H),6.56(d,J=9. 2Hz,1H),4.86(s,2H),4.10-4.06(m,2H),3.75–3.73(m,3H),3.17-3.08(m,4H),2.76-2.70(m,2H),2.64–2.60(m,2H),2.29–2.17(m,2H).

[0917] Example 5: Synthesis of 6-((2s,4s)-2-(((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-5 or T-6) and 6-((2r,4r)-2-(((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-5 or T-6)

[0918] Step 1: Compound 5-1 (1 g, 3.91 mmol, synthesis reference WO2018225097A1) was dissolved in DMF (14 mL), followed by the addition of tributylvinyltin (1.49 g, 4.69 mmol) and Pd(PPh3)4 (452 ​​mg, 0.39 mmol). The reaction mixture was purged with nitrogen and stirred at 100 °C for 2 hours. The mixture was then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 5-2 (470 mg, yield: 59%) as a pale yellow solid. m / z [M+H] + =204.

[0919] Step 2: At -78°C, ozone was bubbled into a mixed solution of compound 5-2 (470 mg, 2.32 mmol) in dichloromethane (10 mL) and methanol (10 mL). After 10 minutes, nitrogen was bubbled to replace the ozone. Then, dimethyl sulfide (431 mg, 6.95 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours, then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 5-3 (262 mg, yield: 55%). m / z[M+H] + =206.

[0920] Step 3: Using compounds 5-3 and 4-1 as raw materials, compounds T-5 (first eluting isomer, elution time: 16.8 min) and T-6 (second eluting isomer, elution time: 17.9 min) were prepared using the same method as in Example 1 (prep-HPLC elution gradient of 5% to 75% acetonitrile aqueous solution, elution time: 20 min), both of which were white solids.

[0921] Compound T-5: m / z [M+H] + =481; 1 H NMR (400MHz, DMSO-d6): δ11.60(s,1H),8.36(s,1H),7.90(d,J=9.5Hz,1H),7.77-7.70(m,1H),7.22-7.15(m,1H),6.59(d,J=9 .4Hz,1H),4.86(s,2H),4.08(s,2H),4.02(s,3H),3.89-3.85(m,2H),2.65-2.60(m,2H),2.22-2.18(m,2H),2.05-1.91(m,2H).

[0922] Compound T-6: m / z [M+H] + =481; 1 H NMR (400MHz, DMSO-d6): δ11.63(s,1H),8.33(s,1H),7.88(d,J=9.4Hz,1H),7.74-7.66(m,1H),7.21-7.12(m,1H),6.57(d,J=9 .3Hz,1H),4.86(s,2H),4.11(s,2H),3.99(s,3H),3.90-3.86(m,2H),2.65-2.63(m,2H),2.32-2.28(m,2H),2.05-1.95(m,2H).

[0923] Example 6: Synthesis of 6-(2-(2-((4-methyl-3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-6-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3,4]oct-7-yl)-2H-pyrazin[2,3-b][1,4]oxazin-3(4H)-one (T-7)

[0924] Compound T-7, a white solid, was prepared from compounds 6-1 (synthesis reference WO2023017549A1) and 2-1 using the same method as in Example 1. m / z[M+H] + =481; 1H NMR (400MHz, DMSO-d6): δ11.64(s,1H),8.33(s,1H),8.18–8.10(m,2H),6.84(d,J=8.6Hz,1H),4.86(s,2 H), 4.44 (t, J = 5.3Hz, 2H), 4.23 (s, 2H), 3.62–3.60 (m, 5H), 3.49 (d, J = 9.0Hz, 2H), 2.91 (t, J = 5.3Hz, 2H).

[0925] Example 7: Synthesis of 6-(2-(2-((4-methyl-3-oxo-1,2,3,4-tetrahydropyridano[2,3-b]pyrazin-6-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3,4]oct-7-yl)-2H-pyrazin[2,3-b][1,4]oxazin-3(4H)-one (T-8)

[0926] To a methanol (2 mL) solution of compound T-7 (30 mg, 0.06 mmol), NaBH3CN (15 mg, 0.24 mmol) and two drops of acetic acid were added. The reaction mixture was stirred at 40 °C for 6 hours and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol / dichloromethane = 0–10%) to obtain the crude product, which was then purified by prep-HPLC (elution conditions: 5%–75% acetonitrile aqueous solution, elution time 20 min) to obtain compound T-8 (6.5 mg, yield: 22%) as a white solid. m / z [M+H] + =483; 1 H NMR (400MHz, DMSO-d6): δ11.67(s,1H),8.33(s,1H),7.08(d,J=8.2Hz,1H),6.32(d,J=8.2Hz,1H),5.7 8(s,1H),4.86(s,2H),4.23(s,2H),4.18(s,2H),3.78(s,2H),3.62(m,4H),3.28(s,3H),2.83(m,2H).

[0927] Example 8: Synthesis of 6-((5S)-5-(((2-((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)oxo)cyclobutyl)amino)methyl)-2-oxooxazolidin-3-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-9)

[0928] Step 1: Add 2-bromocyclobutanone (185 mg, 1.24 mmol) and potassium carbonate (142 mg, 1.03 mmol) sequentially to a 5 mL DMF solution of compound 8-1 (200 mg, 1.04 mmol, synthetic method referred to WO2010045987A1). After purging the reaction system with nitrogen, stir at 80 °C for 2 hours, then quench the reaction with saturated ammonium chloride aqueous solution. Extract the aqueous phase with ethyl acetate, combine the organic phases, and concentrate under reduced pressure. Purify the residue by silica gel column chromatography to obtain compound 8-2 (280 mg, crude product) as an oil. m / z [M+H] + =262.

[0929] Step 2: Using compounds 8-2 and 8-3 (synthetic method referred to WO2019106693A1) as raw materials, compound T-9 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =511; 1 H NMR (400MHz, DMSO-d6): δ11.61(s,1H),8.43–8.31(m,1H),7.83(m,1H),7.46( m,1H),7.28–7.12(m,1H),6.63–6.48(m,1H),4.87(m,2H),4.68(m,2H),4.31– 4.10(m,1H),4.07–3.86(m,1H),3.80(m,3H),3.77–3.56(m,1H),2.93(m,1H), 2.83–2.58(m,1H),2.38(m,1H),2.17(m,1H),2.05–1.96(m,1H),1.80(m,1H).

[0930] Example 9: Synthesis of 6-(2-(2-((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)oxo)cyclobutyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-10 or T-11)

[0931] "*" indicates a chiral center.

[0932] Using compounds 8-2 and 2-1 as raw materials, the same synthesis method as in Example 1 was employed (prep-HPLC elution gradient of 5%–60% acetonitrile aqueous solution, elution time 30 min) to obtain white solids T-10 (first eluting isomer, peak time: 17.2 min) and T-11 (second eluting isomer, peak time: 19.5 min).

[0933] Compound T-10: m / z [M+H] + =523; 1 H NMR (400MHz, DMSO-d6): δ11.66(s,1H),8.32(s,1H),7.88(d,J=9.4Hz,1H),7.52(dd,J=8.6,6.1Hz,1H),7.25(dd,J=10.3,8.8Hz,1H),6.59(d, J=9.4Hz,1H),4.87(s,2H),4.29(m,1H),4.16(s,2H),3.84(s,3H),3.37 -3.27(m,5H),2.09–1.96(m,1H),1.84–1.68(m,2H),1.37–1.27(m,1H).

[0934] Compound T-11: m / z [M+H] + =523; 1 H NMR (400MHz, DMSO-d6): δ11.65(s,1H),8.35(s,1H),7.86(d,J=9.5Hz,1H),7.49(dd,J=8.6,6.0Hz,1H),7.30–7.05(m,1H),6.58(d,J=9.4Hz, 1H),4.87(s,2H),4.43(m,1H),4.27(m,2H),3.88(s,3H),3.65(m,1H), 3.55(m,2H),3.43(m,2H),2.48–2.36(m,1H),2.08(m,1H),1.47(m,2H).

[0935] Example 10: Synthesis of 6-((5S)-5-((((2-(7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)cyclopropyl)methyl)amino)methyl)-2-oxooxazolidin-3-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-12)

[0936] Step 1: Add methoxyformylmethylenetriphenylphosphine (636 mg, 1.9 mmol) to a toluene (10 mL) solution of compound 5-3 (220 mg, 1.07 mmol). Stir the reaction mixture at 90 °C for 4 hours. Concentrate under reduced pressure, and purify the residue by silica gel column chromatography to give compound 10-1 (380 mg, crude) as a white solid. m / z [M+H] + =262.

[0937] Step 2: Add sodium hydroxide (87.4 mg, 2.18 mmol, 60%) to a DMSO (5 mL) solution of Me3SOI (480 mg, 2.18 mmol). After stirring the reaction mixture at room temperature for 2 minutes, add a DMSO (5 mL) solution of compound 10⁻¹ (380 mg, crude). After stirring the reaction system at room temperature for 2 hours, quench the reaction with a saturated ammonium chloride aqueous solution. Extract the aqueous phase with ethyl acetate, combine the organic phases, and concentrate under reduced pressure. Purify the residue by silica gel column chromatography to obtain compound 10⁻² (241 mg) as a white solid. m / z [M+H] + =276.

[0938] Step 3: Under ice bath conditions, LAH (14 mg, 0.36 mmol) was added to a tetrahydrofuran (4 mL) solution of compound 10⁻² (100 mg, 0.36 mmol). The reaction mixture was stirred at 0 °C for 2 hours, and the reaction was quenched with saturated ammonium chloride aqueous solution. The aqueous phase was extracted with ethyl acetate, the organic phases were combined and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 10⁻³ (50 mg, yield: 56%) as a white solid. m / z [M+H] + =248.

[0939] Step 4: Under ice bath conditions, DMP (129 mg, 0.3 mmol) was added to a solution of compound 10⁻³ (50 mg, 0.2 mmol) in dichloromethane (4 mL). The reaction mixture was stirred at 0 °C for 4 hours. The reaction was quenched with saturated sodium bicarbonate solution, the aqueous phase was extracted with ethyl acetate, the organic phases were combined and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 10⁻⁴ (32 mg, yield: 65%). m / z [M+H] + =246.

[0940] Step 5: Using compounds 10-4 and 8-3 as raw materials, compound T-12 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =495; 1H NMR (400MHz, DMSO-d6): δ11.59(s,1H),8.82(s,1H),8.30(s,1H),7.77(d,J=9. 4Hz,1H),7.61–7.51(m,1H),7.06(t,J=9.1Hz,1H),6.46(d,J=9.4Hz,1H),4.97 (m,1H),4.79(s,2H),4.15(m,1H),3.79–3.70(m,1H),3.68(s,3H),3.37(m,2H) ,2.94–2.74(m,1H),2.22(m,1H),1.13(m,2H),0.73(s,1H),0.48–0.26(m,1H).

[0941] Example 11: Synthesis of 6-(2-((2-(7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)cyclopropyl)methyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-13)

[0942] Compound T-13, a white solid, was prepared from compounds 10-4 and 2-1 using the same method as in Example 1. (m / z[M+H]) + =507; 1 H NMR (400MHz, DMSO-d6): δ11.62(s,1H),8.28(s,1H),7.77(d,J=9.5Hz,1H), 7.57(dd,J=8.5,6.5Hz,1H),7.11–6.95(m,1H),6.46(d,J=9.4Hz,1H),4.80 (s,2H),4.46(m,2H),4.19(m,2H),3.68(s,3H),3.50(m,1H),2.45(s,1H),2 .24(m,1H),1.66(s,1H),1.18–0.95(m,2H),0.69(m,1H),0.49–0.28(m,1H).

[0943] Example 12: Synthesis of (S)-6-(5-((3-((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)oxo)azacyclobutane-1-yl)methyl)-2-oxooxazolidin-3-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-14)

[0944] Step 1: To a DMF (3 mL) solution of compound 8-1 (100 mg, 0.52 mmol), add 1-(tert-butoxycarbonyl)-3-(methanesulfonyloxy)azabutane (260 mg, 1.04 mmol) and cesium carbonate (337 mg, 1.04 mmol). Purge the reaction mixture with nitrogen and stir overnight at 80 °C. Quench the reaction with saturated ammonium chloride solution, and extract the aqueous phase with ethyl acetate. Combine the organic phases and concentrate under reduced pressure. Purify the residue by rapid silica gel column chromatography to obtain 150 mg of solid. Dissolve the solid in dichloromethane (2 mL), then add trifluoroacetic acid (0.4 mL), stir at room temperature for 2 hours, and concentrate under reduced pressure to obtain compound 12-1 (crude product). m / z [M+H] + =249.

[0945] Step 2: Compound 12-2 (69.4 mg, 0.2 mmol, synthetic method referred to WO2019106693A1), triethylamine (40.7 mg, 0.4 mmol), and sodium iodide (60.5 mg, 0.4 mmol) were added sequentially to a 3 mL solution of acetonitrile (50 mg, 0.2 mmol) containing compound 12-1. The reaction system was purged with nitrogen, microwave-heated for 18 hours, and the reaction was quenched with saturated ammonium chloride aqueous solution. The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol / dichloromethane = 0–10%) to obtain the crude product, which was then purified by prep-HPLC (elution conditions: 5%–75% acetonitrile aqueous solution, elution time 20 min) to obtain compound T-14 (1.6 mg, yield: 2%) as a white solid. m / z [M+H] + =497; 1 H NMR (400MHz, CD3OD): δ8.45(s,1H),7.81(d,J=9.5Hz,1H),7.43(dd,J=8.7,5.9Hz,1 H),7.14(dd,J=10.6,8.7Hz,1H),6.58(d,J=9.4Hz,1H),4.91(s,2H),4.83–4.76(m, 2H),4.25–4.17(m,1H),3.97(dd,J=10.0,6.4Hz,1H),3.93(s,3H),3.79(m,2H),3.5 0(dd,J=9.1,4.3Hz,2H), 2.96(dd,J=13.4,3.6Hz,1H), 2.87(dd,J=13.4,5.5Hz,1H).

[0946] Example 13: Synthesis of 6-(5-(1-(2-(7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)ethyl)azacyclobutane-3-yl)-2-oxooxazolidin-3-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-15)

[0947] Compound T-15 was prepared as a white solid using compounds 1-1 and 13-1 (synthesis reference WO2021190727A1) as starting materials, following the same method as in Example 1. m / z[M+H] + =495; 1 H NMR (400MHz, DMSO-d6): δ11.63(s,1H),8.38(s,1H),7.87(d,J=9.5Hz,1H),7.68–7.64(m,1H),7.20–7.09(m,1H),6.55(d,J= 9.3Hz,1H),4.92-4.86(m,3H),4.26-4.06(m,2H),3.78-3.62(m,4H),3.17(d,J=5.2Hz,2H),3.05(br,3H),2.79-2.67(m,3H).

[0948] Example 14: Synthesis of (S)-6-(5-(((1-(7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)azacyclobut-3-yl)amino)methyl)-2-oxooxazolidin-3-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-16)

[0949] Step 1: To a solution of compound 5-1 (800 mg, 3.13 mmol) in 1,4-dioxane (20 mL), add aziridine-3-ol hydrochloride (1.7 g, 15.6 mmol), cesium carbonate (6.12 g, 18.8 mmol), BINAP (488 mg, 0.78 mmol), and palladium dichloride (69 mg, 0.389 mmol) sequentially. After purging the reaction system with nitrogen, stir overnight at 85 °C. Quench the reaction with saturated ammonium chloride solution, and extract the aqueous phase with ethyl acetate. Combine the organic phases and concentrate under reduced pressure. Purify the residue by rapid silica gel column chromatography to give compound 14-1 (110 mg, yield: 14%) as a yellow solid. m / z [M+H] + =249.

[0950] Step 2: DMP (376 mg, 0.88 mmol) was added to a dichloromethane (4 mL) solution of compound 14-1 (110 mg, 0.44 mmol), and the reaction mixture was stirred at room temperature for 3 hours. The solution was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate. The organic phase was washed with water. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 80) to give compound 14-2 (55 mg, yield: 50%) as a white solid. m / z [M+H] + =247.

[0951] Step 3: Using compounds 14-2 and 8-3 as raw materials, compound T-16 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =496; 1 H NMR (400MHz, DMSO-d6): δ11.64(s,1H),8.39(s,1H),7.80(d,J=9.5Hz,1H),7.45–7.37(m,1H),7.17-7.12(m,1H),6.5 1(d,J=9.4Hz,1H),4.86(s,2H),4.80(br,1H),4.15-4.06(m,3H),3.85-3.81(m,2H),3.77–3.65(m,5H),2.93(br,2H).

[0952] Example 15: 6-(2-(2-((4-methyl-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazin[2,3-b][1,4]oxazin-3(4H)-one (T-17)

[0953] Step 1: Potassium carbonate (7.92 g, 57.3 mmol) was added to a dimethyl sulfoxide (DMSO) solution of compound 15-1 (5 g, 28.6 mmol). The reaction system was purged with nitrogen three times. Methyl bromoacetate (6.57 g, 43.0 mmol) was added with stirring. After the addition was complete, the reaction system was stirred at 60 °C for 3 hours. After cooling to room temperature, the mixture was filtered through diatomaceous earth. The filter cake was washed with ethyl acetate. Water and ethyl acetate were added to the filtrate. The organic phase was separated and concentrated under reduced pressure to obtain compound 15-2 (6.94 g) as an oil. m / z[M+H] + =247.

[0954] Step 2: Reduced iron powder (8.02 g, 0.14 mol) was added to a 50 mL solution of compound 15-2 (6.94 g, crude) in acetic acid. The reaction system was purged with nitrogen three times, stirred at 100 °C for 4 hours, cooled to room temperature, diluted with dichloromethane, filtered through diatomaceous earth, and the filter cake was washed with dichloromethane. Water was added to the filtrate, and the aqueous phase was extracted with dichloromethane. The organic phases were combined and concentrated under reduced pressure to obtain compound 15-3 (1.5 g) as an oily substance. m / z[M+H] + =185.

[0955] Step 3: Cesium carbonate (1.77 g, 5.42 mmol) and methyl iodide (1.54 g, 10.8 mmol) were added sequentially to a DMF (15 mL) solution of compound 15-3 (1.5 g, 8.13 mmol). After the addition was complete, the mixture was stirred at room temperature for 4 hours. The reaction was quenched with water. The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 15-4 (1.05 g, three-step yield: 19%) as an off-white solid. m / z [M+H] + =199.

[0956] Step 4: To a solution of compound 15-4 (0.90 g, 4.53 mmol) in 1,4-dioxane (14 mL), cesium carbonate (2.95 g, 9.06 mmol), glycolate diethanol (0.96 g, 9.06 mmol), palladium acetate (0.21 g, 0.906 mmol), and Johnphos (0.41 g, 1.36 mmol) were added sequentially. The reaction system was purged with nitrogen three times, stirred at 100 °C for 4 hours, cooled to room temperature, filtered with diatomaceous earth, the filter cake was washed with ethyl acetate, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 15-5 (1.07 g, yield: 88%) as an off-white solid. m / z [M+H] + =269.

[0957] Step 5: Under ice bath conditions, trifluoroacetic acid (5.5 mL) was added dropwise to a solution of compound 15-5 (1.07 g, 3.99 mmol) in dichloromethane (30 mL). After the addition was complete, the mixture was heated to room temperature and stirred overnight. The reaction solution was concentrated under reduced pressure. Dichloromethane and saturated sodium bicarbonate aqueous solution were added to the residue to adjust the pH to 7-8. The aqueous phase was extracted with dichloromethane. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 15-6 (0.27 g, yield: 31%) as an off-white solid. m / z[M+H] + =223.

[0958] Step Six: Using compounds 15-6 and 2-1 as raw materials, compound T-17 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =484; 1 H NMR (400MHz, DMSO-d6): δ11.65(s,1H),8.34(s,1H),7.38(d,J=8.5Hz,1H),6.42(d,J=8.5Hz,1H),4.86(s,2H),4. 67 (s, 2H), 4.22 (d, J = 6.3Hz, 4H), 3.59 (d, J = 9.1Hz, 2H), 3.46 (d, J = 9.0Hz, 2H), 3.31 (s, 3H), 2.84 (t, J = 5.4Hz, 2H).

[0959] Example 16: Synthesis of 6-(2-((1-((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)oxo)cyclopropyl)methyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-18)

[0960] Step 1: Potassium carbonate (107 mg, 0.78 mmol) and ethyl 2,4-dibromobutyrate (156 mg, 0.57 mmol) were added sequentially to a DMF (2 mL) solution of compound 8-1 (100 mg, 0.52 mmol). The reaction mixture was purged with nitrogen and stirred at room temperature for 4 hours. The reaction solution was then poured into water, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was directly dissolved in tetrahydrofuran (3 mL), and then NaOtBu (75 mg, 0.78 mmol) was added. The reaction mixture was stirred overnight at room temperature. The reaction solution was directly concentrated under reduced pressure, and the residue was purified by rapid silica gel column chromatography to give compound 16-1 (84 mg, yield: 54%) as a yellow solid. m / z [M+H] + =306.

[0961] Step 2: At -20 to -30°C, LAH (15 mg, 0.39 mmol) was added to a tetrahydrofuran (2 mL) solution of compound 16-1 (80 mg, 0.26 mmol). The reaction mixture was stirred at this temperature for 2 hours. The reaction was quenched by adding saturated ammonium chloride aqueous solution. The aqueous phase was extracted with ethyl acetate, and the organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 16-2 (68 mg, yield: 98%) as a white solid. m / z [M+H] + =264.

[0962] Step 3: Under ice bath conditions, DMP (165 mg, 0.39 mmol) was added to a dichloromethane (4 mL) solution of compound 16-2 (68 mg, 0.26 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction was quenched with saturated sodium bicarbonate aqueous solution, and the aqueous phase was extracted with dichloromethane. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 16-3 (30 mg, yield: 45%) as a yellow oil. m / z [M+H] + =262.

[0963] Step 4: Using compounds 16-3 and 2-1 as raw materials, compound T-18 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =523; 1 H NMR (400MHz, DMSO-d6): δ11.65(s,1H),8.32(s,1H),7.88(d,J=9.5Hz,1H),7.53(dd,J=8.7,6.0Hz,1H),7.21(dd,J=10.3,8.7Hz,1H),6.59(d,J=9.4 Hz,1H),4.88(s,2H),4.15(s,2H),3.86(s,3H),3.46(d,J=8.8Hz,2H),3.4 2–3.36(m,2H),2.77(s,2H),0.73(t,J=6.3Hz,2H),0.66(t,J=6.7Hz,2H).

[0964] Example 17: 1-Methyl-9-((6-oxo-7-(3-oxo-3,4-dihydro-2H-pyrazino[2,3-b][1,4]oxazin-6-yl)-5-oxa-2,7-diazaspiro[3,4]oct-2-yl)methyl)-8,9-dihydrofurano[2,3-h]quinoline-2(1H)-one (T-19)

[0965] Step 1: Iodomethane (7.82 g, 55 mmol) was added to a 50 mL solution of compound 19-1 (5.0 g, 34.4 mmol) in acetonitrile (50 mL). The reaction mixture was stirred at 80 °C for 16 hours. The reaction mixture was then cooled to room temperature, concentrated under reduced pressure to remove most of the solvent, filtered as a solid, and the filter cake was dried to obtain compound 19-2 (6.3 g, yield: 64%) as a yellow solid.

[0966] Step 2: Under ice bath conditions, N-bromosuccinimide (4.29 g, 24.1 mmol) was added in portions to a DMF (60 mL) solution of compound 19-2 (6.3 g, 21.9 mmol). The reaction system was stirred at 0 °C for 4 hours. The reaction was quenched by adding saturated ammonium chloride aqueous solution (200 mL), the aqueous phase was extracted with dichloromethane, the combined organic phases were washed with saturated brine, and the organic phase was concentrated under reduced pressure to give compound 19-3 (6.2 g, yield: 78%) as a yellow solid.

[0967] Step 3: Under ice bath conditions, sodium hydroxide (4.05 g, 101 mmol) and potassium ferricyanide (22.2 g, 67.6 mmol) were added in portions to a mixed solution of compound 19-3 (6.2 g, 16.9 mmol) in acetonitrile (60 mL) and water (60 mL). The reaction system was stirred at 20 °C for 20 hours. The reaction was quenched by adding saturated ammonium chloride aqueous solution (300 mL). The aqueous phase was extracted with dichloromethane, the organic phases were combined and washed with saturated brine, the organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 19-4 (2.8 g, yield: 65%) as a white solid. m / z [M+H] + =254.

[0968] Step 4: Potassium hydroxide (1.23 g, 22 mmol) and oxetane-2-ylmethyl-4-methylbenzenesulfonate (3.77 g, 16.5 mmol) were added sequentially to a DMF (30 mL) solution of compound 19-4 (2.8 g, 11 mmol). The reaction system was stirred at 85 °C for 16 hours. The reaction was quenched by adding saturated ammonium chloride aqueous solution (100 mL), the aqueous phase was extracted with dichloromethane, the combined organic phases were washed with saturated brine, the organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 19-5 (2.3 g, yield: 67%) as a white solid. m / z [M+H] + =310.

[0969] Step 5: Under a nitrogen atmosphere, at -78°C, phenyllithium (14.8 mL, 1 M) was added dropwise to an anhydrous tetrahydrofuran (30 mL) solution of compound 19-5 (2.3 g, 7.44 mmol). After the addition was complete, the reaction mixture was stirred at this temperature for 2 hours. The reaction was quenched by adding saturated ammonium chloride aqueous solution (50 mL). The aqueous phase was extracted with dichloromethane, and the combined organic phases were washed with saturated brine. The organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 19-6 (1.2 g, yield: 70%) as a white solid. m / z[M+H] + =232.

[0970] Step Six: Add DMP (200 mg, 0.47 mmol) to a solution of compound 19-6 (100 mg, 0.43 mmol) in dichloromethane (5 mL). Stir the reaction mixture overnight at room temperature, dilute with ethyl acetate, and filter. Concentrate the filtrate under reduced pressure, and purify the residue by rapid silica gel column chromatography to give compound 19-7 (50 mg, yield: 50%) as a white solid. m / z [M+H] + =230.

[0971] Step 7: Using compounds 19-7 and 2-1 as raw materials, compound T-19 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =491; 1 H NMR (400MHz, DMSO-d6): δ11.63(s,1H),8.32(s,1H),7.79(d,J=9.4Hz,1H),7.54(d ,J=8.4Hz,1H),6.80(d,J=8.3Hz,1H),6.40(d,J=9.4Hz,1H),4.86(s,2H),4.63(d,J =8.6Hz,1H),4.49(t,J=7.9Hz,1H),4.22-4.08(m,2H),4.01-3.97(m,1H),3.81(s,3 H), 3.47 (d, J = 8.1Hz, 1H), 3.40-3.36 (m, 3H), 2.65-2.61 (m, 1H), 2.48-2.47 (m, 1H).

[0972] Example 18: 2-((6-oxo-7-(3-oxo-3,4-dihydro-2H-pyrazino[2,3-b][1,4]oxazin-6-yl)-5-oxa-2,7-diazaspiro[3,4]oct-2-yl)methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthene-3,8-dione (T-20)

[0973] Step 1: Add 20-2 (synthesis reference WO2021190727A1) (80 mg, 0.196 mmol) and potassium carbonate (50 mg, 0.362 mmol) to a 2 mL DMF solution of compound 20-1 (synthesis reference WO2008128942A1) (50 mg, 0.168 mmol). After purging the reaction system with nitrogen, stir at 90 °C for 48 hours. Cool to room temperature, add water, and extract with ethyl acetate. Concentrate the organic phase under reduced pressure. Purify the residue by rapid silica gel column chromatography to obtain compound 20-3 (20 mg, yield: 20%) as a yellow oil. m / z [M+H] + =609.

[0974] Step 2: Add 1 mL of trifluoroacetic acid to a 1 mL solution of compound 20-3 (20 mg, 0.033 mmol) in DCM. Stir the reaction mixture at room temperature for 1 hour, then concentrate under reduced pressure. The residue was purified by rapid silica gel column chromatography to give compound T-20 (2.2 mg, yield: 14%) as a white solid. m / z [M+H] + =479; 1 H NMR (400MHz, DMSO-d6): δ11.60(s,1H),8.30(s,1H),7.87(d,J=9.5Hz,1H),7.75(s,1H),6.28(d,J=9.6Hz,1H),4.97-4.94(m,1H),4.85(s,2H) ,4.37-4.29(m,1H),4.23-4.19(m,1H),4.16-4.09(m,2H),3.54(d,J=8 .3Hz,1H),3.44(d,J=8.4Hz,1H),3.24-3.19(m,2H),3.04-3.00(m,2H).

[0975] Example 19: 6-(2-(2-(imidazo[1,2-a]pyridin-7-yloxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3,4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-21)

[0976] Step 1: To a DMF (1.5 mL) solution of compound 21-1 (27 mg, 0.20 mmol), add bromoacetaldehyde diethanolate (78 mg, 0.40 mmol) and potassium carbonate (55 mg, 0.40 mmol). After purging the reaction system with nitrogen, stir at 80 °C for 8 hours. Cool to room temperature, add water, and extract with ethyl acetate. Concentrate the organic phase under reduced pressure. Purify the residue by rapid silica gel column chromatography to obtain compound 21-2 (40 mg, yield: 80%) as a yellow oil. m / z [M+H] + =251.

[0977] Step 2: Add 1 mL of trifluoroacetic acid to a solution of compound 21-2 (40 mg, 0.16 mmol) in dichloromethane (0.5 mL). Stir the reaction mixture at room temperature for 1 hour, then concentrate under reduced pressure to obtain 21-3 (17 mg, yield: 61%) as a yellow oil. m / z [M+H] + =177.

[0978] Step 3: Using compounds 21-3 and 2-1 as raw materials, compound T-21 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =438; 1 H NMR (400MHz, DMSO-d6): δ11.60(s,1H),8.39(d,J=7.4Hz,1H),8.34(s,1H),7.74(s,1H),7.38(s,1H),6.91(s,1H),6.59(dd,J=7.4 ,2.3Hz,1H),4.86(s,2H),4.24(s,2H),4.04(t,J=5.3Hz,2H),3.61(d,J=9.0Hz,2H),3.49(d,J=9.1Hz,2H),2.88(t,J=5.2Hz,2H).

[0979] Example 20: 6-(6-oxo-2-(2-(quinolin-7-yloxy)ethyl)-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-22)

[0980] Steps one through three: Using compound 22-1 as a starting material, compound T-22 was prepared using the same method as compound T-21 in Example 19. The resulting compound T-22 was a white solid. m / z[M+H] + =449; 1 H NMR (400MHz, DMSO-d6): δ11.66(s,1H),8.81(dd,J=4.3,1.7Hz,1H),8.34(s,1H),8.27(dd,J=8.2,1.4Hz,1H),7.89(d,J=9.0Hz,1H),7.41–7.33(m,2 H),7.26(dd,J=8.9,2.5Hz,1H),4.86(s,2H),4.25(s,2H),4.16(t,J=5.2H z, 2H), 3.65 (d, J = 8.7Hz, 2H), 3.53 (d, J = 8.7Hz, 2H), 2.94 (t, J = 5.0Hz, 2H).

[0981] Example 21: 6-(2-(2-((1-methyl-2-oxo-1,2-dihydroquinolin-7-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-23)

[0982] Step 1: Under ice bath conditions, sodium hydroxide (835 mg, 20.9 mmol) and potassium ferricyanide (4.58 g, 13.9 mmol) were added in portions to a mixed solution of compound 19-2 (1 g, 3.48 mmol) in acetonitrile (10 mL) and water (10 mL). The reaction system was stirred at 20 °C for 4 hours. The reaction was quenched by adding saturated ammonium chloride aqueous solution (20 mL), the aqueous phase was extracted with dichloromethane, the combined organic phases were washed with saturated brine, the organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 23-1 (310 mg, yield: 51%) as a white solid. m / z [M+H] + =176.

[0983] Steps two through four: Using compound 23-1 as a starting material, compound T-23 was prepared using the same method as compound T-21 in Example 19. The resulting compound T-23 was a white solid. m / z[M+H] + =479; 1 H NMR (400MHz, DMSO-d6): δ11.66(s,1H),8.32(s,1H),7.82(d,J=9.5Hz,1H),7.64(d,J=8.5Hz,1H),6.94(s,1H),6.92–6.87(m,1H),6.43(d,J= 9.4Hz, 1H), 4.85 (s, 2H), 4.24 (s, 2H), 4.15 (t, J = 5.3Hz, 2H), 3.63 (d, J = 9.2Hz, 2H), 3.59 (s, 3H), 3.51 (d, J = 9.0Hz, 2H), 2.90 (t, J = 5.3Hz, 2H).

[0984] Example 22: 6-(6-oxo-2-(2-((6-oxo-5,6-dihydropyridano[2,3-b]pyrazin-3-yl)oxy)ethyl)-5-oxa-2,7-diazaspiro[3,4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-24)

[0985] Step 1: Add 2 mL of trifluoroacetic acid to a 1 mL solution of compound 24-1 (68 mg, 0.24 mmol) in dichloromethane (synthesis reference WO2019186590A1). Stir the reaction mixture at room temperature for 1 hour, concentrate under reduced pressure, neutralize the residue with an aqueous sodium bicarbonate solution, extract the aqueous phase with ethyl acetate, combine the organic phases, and concentrate under reduced pressure to obtain compound 24-2 (50 mg, yield: 100%) as a yellow oil. m / z [M+H] + =206.

[0986] Step 2: Using compounds 24-2 and 2-1 as raw materials, compound T-24 was prepared as a pale yellow solid using the same method as in Example 1. m / z[M+H] + =467; 1 H NMR (400MHz, DMSO-d6): δ11.66(s,2H),8.33(s,1H),7.92-7.91(m,2H),6.52(s,1H),4.86(s,2H ), 4.24 (t, J = 6.3Hz, 2H), 4.17 (s, 2H), 3.57 (d, J = 9.1Hz, 2H), 3.42 (s, 2H), 2.78 (t, J = 6.4Hz, 2H).

[0987] Example 23: 6-(2-(2-((6-methoxypyridano[2,3-b]pyrazin-3-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3,4]oct-7-yl)-2H-pyrazinano[2,3-b][1,4]oxazin-3(4H)-one (T-25)

[0988] Step 1: Under ice bath conditions, sodium hydroxide (10 mg, 0.25 mmol, 60%) was added to a mixed solution of compound 24-1 (50 mg, 0.18 mmol) and sodium bromide (12 mg, 0.12 mmol) in DMF (1 mL) and ethylene glycol dimethyl ether (1 mL). The reaction system was stirred at 0 °C for 0.5 h, then iodomethane (25 mg, 0.18 mmol) was added, and stirring was continued for 1 h. The reaction was quenched with water, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by rapid silica gel column chromatography to obtain compound 25-1 (40 mg, yield: 76%) as a yellow oil. 1 H NMR (400MHz, DMSO-d6): δ8.15(t,J=4.3Hz,2H),6.86(d,J=8.6Hz,1H),5.07(t,J=5.7Hz,1H),4.44 (d,J=5.7Hz,2H),4.01(d,J=8.1Hz,3H),3.72–3.60(m,2H),3.54–3.40(m,2H),1.09–0.91(m,6H).

[0989] Step 2: Add 2 mL of trifluoroacetic acid to a 1 mL solution of compound 25-1 (30 mg, 0.10 mmol) in dichloromethane. Stir the reaction mixture at room temperature for 2 hours, concentrate under reduced pressure, neutralize the residue with a small amount of sodium bicarbonate solution, extract the aqueous phase with ethyl acetate, combine the organic phases, and concentrate under reduced pressure to obtain compound 25-2 (18 mg, yield: 80%) as a yellow oil. m / z [M+H]+ =220.

[0990] Step 3: Using compounds 25-2 and 2-1 as raw materials, compound T-25 was prepared as a pale yellow solid using the same method as in Example 1. m / z[M+H] + =481; 1 H NMR (400MHz, DMSO-d6): δ11.64(s,1H),8.33(s,1H),8.18–8.08(m,2H),6.87(d,J=8.6Hz,1H),4.85(s,2H),4.32 (t,J=6.6Hz,2H),4.19(s,2H),4.02(s,3H),3.57(d,J=9.1Hz,2H),3.45(d,J=9.1Hz,2H),2.85(t,J=6.7Hz,2H).

[0991] Example 24: 6-(2-(2-(benzo[d]isoxazol-6-yloxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-26)

[0992] Steps one through three: Using compound 26-1 as a starting material, compound T-26 was prepared using the same method as compound T-21 in Example 19. The resulting compound T-26 was a white solid. m / z[M+H] + =439; 1 H NMR (400MHz, DMSO-d6): δ8.33(s,1H),7.47(d,J=8.2Hz,1H),6.50-6.35(m,3H),4.85(s, 2H), 4.24 (s, 2H), 4.06 (s, 2H), 3.63 (d, J = 9.2Hz, 2H), 3.51 (s, 2H), 2.88 (t, J = 5.0Hz, 2H).

[0993] Example 25: 6-(2-(2-((7-chloro-4-methyl-3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-6-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3,4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-27)

[0994] Compound T-27 was prepared as a white solid using compound 27-1 (preparation method as described in WO2019186590A1) and compound 2-1 as raw materials, following the same method as in Example 1. m / z[M+H]+ =515; 1 H NMR (400MHz, DMSO-d6): δ11.65(s,1H),8.40(s,1H),8.34(s,1H),8.17(s,1H),4.86(s,2H),4.53(t,J=5 .0Hz, 2H), 4.24 (s, 2H), 3.66 (d, J = 8.9Hz, 2H), 3.61 (s, 3H), 3.54 (d, J = 9.0Hz, 2H), 2.96 (t, J = 5.0Hz, 2H).

[0995] Example 26: 6-(2-(2-((7-fluoro-4-methyl-3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-6-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3,4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-28)

[0996] Compound T-28 was prepared as a white solid using compound 28-1 (preparation method as described in WO2019186590A1) and compound 2-1 as raw materials, following the same method as in Example 1. m / z[M+H] + =499; 1 H NMR (400MHz, DMSO-d6): δ8.29(s,1H),8.25(d,J=10.0Hz,1H),8.19(s,1H),4.83(s,2H),4. 54(t,2H),4.23(s,2H),3.63(s,3H),3.62–3.59(m,2H),3.50(d,J=8.4Hz,2H),2.95(t,2H).

[0997] Example 27: 6-(2-(((6,7-difluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-29)

[0998] Step 1: Under ice bath conditions, KHMDS (15 mL, 15.0 mmol) was slowly added to a tetrahydrofuran (10 mL) solution of compound 29-1 (2.08 g, 10.0 mmol) and methyl 3,3-dimethoxypropionate (1.78 g, 12.0 mmol). After the addition was complete, the mixture was allowed to react at room temperature for 4 hours. The reaction solution was cooled to 0 °C, and water and ethyl acetate were added. The aqueous phase was extracted with ethyl acetate, and the combined organic phases were washed with water and saturated brine. The organic phase was concentrated under reduced pressure to obtain compound 29-2 (3.24 g) as a solid.

[0999] Step 2: Concentrated sulfuric acid (4 mL) was added to compound 29-2 (3.24 g, 10.0 mmol), and the mixture was stirred at room temperature for 4 hours. The reaction solution was then cooled to 0 °C, and water and ethyl acetate were added. The mixture was stirred and separated. The aqueous phase was extracted again with ethyl acetate. The combined organic phases were washed with water and saturated brine. The organic phase was concentrated under reduced pressure to obtain compound 29-3 (2.52 g) as a solid. m / z[M+H] + =260.0.

[1000] Step 3: Under ice bath conditions, sodium hydride (0.12 g, 3.00 mmol, 60%) was slowly added to a mixed solution of compound 29-3 (0.52 g, 2.0 mmol) in DMF (0.8 mL) and ethylene glycol dimethyl ether (8 mL). After stirring for 10 minutes, lithium bromide (0.26 g, 3.0 mmol) was added. The reaction system was stirred at room temperature for another 20 minutes. Iodomethane (0.57 g, 4.0 mmol) was added, and the mixture was heated to 40 °C and reacted overnight. Ethyl acetate and water were added, and the aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with water and saturated brine. The organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 29-4 (0.16 g) as a solid. m / z[M+H] + =274.0.

[1001] Step 4: The mixture of compound 29-4 (0.10 g, 0.365 mmol), tributylvinyltin (0.23 g, 0.730 mmol), Pd(PPh3)4 (0.08 g, 0.073 mmol), and DMF (2 mL) was purged three times with nitrogen. The mixture was heated to 100 °C and stirred for 4 hours. The reaction system was cooled to room temperature, and water was added to quench the reaction. The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 29-5 (0.05 g) as a solid. m / z[M+H] + =222.1.

[1002] Step 5: The mixture of compound 29-5 (50 mg, 0.226 mmol), potassium osmium tetroxide dihydrate (16.8 mg, 0.054 mmol), sodium periodate (193 mg, 0.904 mmol), 2,6-dimethylpyridine (48 mg, 0.452 mmol), 1,4-dioxane (3 mL), and water (1 mL) was purged three times with nitrogen and stirred overnight at room temperature under nitrogen protection. The reaction was quenched with water, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 29-6 (20 mg) as a solid. m / z [M+H] + =224.2.

[1003] Step Six: Using compounds 29-6 and 4-1 as raw materials, compound T-29 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =499; 1 H NMR (400MHz, DMSO-d6): δ11.60(s,1H),8.35-8.33(m,1H),7.87–7.77(m,1H),7.68-7.66(m,1H),6.69–6.55(m,1H),4. 86(s,2H),4.12-4.06(m,2H),4.03-3.88(m,3H),3.83(s,2H),3.08-3.04(m,2H),2.75-2.58(m,2H),2.33-2.26(m,2H).

[1004] Example 28: 6-((2r,4r)-2-(((6,7-difluoro-2-methoxyquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-30 or T-31) and 6-((2s,4s)-2-(((6,7-difluoro-2-methoxyquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-30 or T-31)

[1005] Step 1: Under ice bath conditions, sodium hydride (0.12 g, 3.00 mmol, 60%) was slowly added to a DMF (5.2 mL) solution of compound 29-3 (0.52 g, 2.0 mmol). The reaction mixture was stirred at 0 °C for 30 minutes. Iodomethane (0.57 g, 4.0 mmol) was then added, and the reaction mixture was stirred at room temperature for another 4 hours. Ethyl acetate and water were added, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give 30-1 (0.33 g) as a solid. m / z [M+H] + =274.2.

[1006] Step 2: The mixture of compound 30-1 (0.10 g, 0.37 mmol), tributylvinyltin (0.23 g, 0.73 mmol), Pd(PPh3)4 (0.08 g, 0.073 mmol), and DMF (2 mL) was purged three times with nitrogen. The reaction system was heated to 100 °C and stirred for 4 hours. After cooling to room temperature, water was added to quench the reaction. The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 30-2 (0.08 g) as a solid. m / z [M+H] + =222.2.

[1007] Step 3: A mixture of compound 30-2 (80 mg, 0.36 mmol), potassium osmium tetroxide dihydrate (3.1 mg, 0.01 mmol), sodium periodate (308 mg, 1.44 mmol), 2,6-dimethylpyridine (77 mg, 0.72 mmol), 1,4-dioxane (3 mL), and water (1 mL) was purged three times with nitrogen. The mixture was stirred overnight at room temperature under nitrogen protection. The reaction was quenched with water. The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 30-3 (47 mg) as a solid. m / z [M+H] + =224.2.

[1008] Step four uses compounds 30-3 and 4-1 as raw materials and prepares them using the same method as in Example 1 (prep-HPLC elution gradient of 5% to 75% acetonitrile aqueous solution, elution time 20 minutes) to obtain compounds T-30 (first eluting isomer, peak time: 16.2 minutes) and T-31 (second eluting isomer, peak time: 17.5 minutes), both of which are white solids.

[1009] Compound T-30: m / z [M+H] + =499; 1H NMR (400MHz, DMSO-d6): δ11.61(s,1H),8.30(s,1H),8.25(d,J=8.9Hz,1H),7.94–7.85(m,1H),7.10(d,J=8 .9Hz,1H),4.85(s,2H),4.18(s,2H),4.06(s,4H),3.09–2.99(m,2H),2.53-2.51(m,3H),2.22–2.10(m,2H).

[1010] Compound T-31: m / z [M+H] + =499; 1 H NMR (400MHz, DMSO-d6): δ11.61(s,1H),8.34(s,1H),8.25(d,J=8.9Hz,1H),7.95–7.86(m,1H),7.09(d,J=8.9Hz,1H),4.85(s,2 H),4.20(s,2H),4.10(s,1H),4.06(s,1H),4.03(s,2H),3.31-3.29(m,2H),3.05(s,1H),2.54-2.52(m,2H),2.18-2.14(m,2H).

[1011] Example 29: 6-((2r,4r)-2-(((7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-32 or T-33) and 6-((2s,4s)-2-(((7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-32 or T-33)

[1012] Steps 1 & 2: A tetrahydrofuran (32 mL) solution of compound 32-1 (4.50 g, 22.3 mmol) and methyl 3,3-dimethoxypropionate (3.63 g, 24.5 mmol) was purged three times with nitrogen. Under nitrogen protection, KHMDS (33.5 mL, 33.5 mmol) was slowly added at 0 °C. After the addition was complete, the reaction system was stirred at room temperature for 2 hours, then cooled to 0 °C for later use. Sodium hydroxide (2.25 g, 55.7 mmol, 60%) was slowly added to the above reaction solution containing compound 32-2. The reaction system was stirred at 0 °C for 30 minutes, and then iodomethane (9.52 g, 66.8 mmol) was added. The reaction system was stirred overnight at room temperature. The temperature was then lowered back to 0 °C, and ethyl acetate and water were added. The aqueous phase was extracted with ethyl acetate, the organic phases were combined and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 32-3 (5.0 g) as a solid.

[1013] Step 3: Concentrated sulfuric acid (12.5 mL) was added dropwise to a solution of compound 32-3 (5.00 g, 15.1 mmol) in dichloromethane (10 mL). After the addition was complete, the reaction mixture was stirred at room temperature for 3 hours. The temperature was lowered to 0 °C, and water and dichloromethane were added. The aqueous phase was extracted with dichloromethane, the organic phases were combined and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 32-4 (1.70 g) as a solid. m / z[M+H] + =268.0.

[1014] Step 4: The mixture of compound 32-4 (0.30 g, 1.12 mmol), tributylvinyltin (0.71 g, 2.24 mmol), Pd(PPh3)4 (0.21 g, 0.224 mmol), and DMF (5 mL) was purged three times with nitrogen, and the mixture was heated to 100 °C and stirred for 4 hours. The reaction mixture was cooled to room temperature, and the reaction was quenched with water. The aqueous phase was extracted with ethyl acetate, the organic phases were combined and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 32-5 (0.25 g) as a solid. m / z [M+H] + =216.2.

[1015] Step 5: The mixture of compound 32-5 (50 mg, 0.232 mmol), potassium osmium tetroxide dihydrate (16.8 mg, 0.054 mmol), sodium periodate (198 mg, 0.928 mmol), 2,6-dimethylpyridine (50 mg, 0.464 mmol), 1,4-dioxane (3 mL), and water (1 mL) was purged three times with nitrogen and stirred overnight at room temperature under nitrogen protection. The reaction was quenched with water, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 32-6 (43 mg) as a solid. m / z [M+H] + =218.1.

[1016] Step 6: Using compounds 32-6 and 4-1 as raw materials, compounds T-32 (first eluting isomer, elution time: 16.5 min) and T-33 (second eluting isomer, elution time: 17.2 min) were prepared using the same method as in Example 1 (prep-HPLC elution gradient of 5% to 75% acetonitrile aqueous solution, elution time: 20 min), both of which were white solids.

[1017] Compound T-32: m / z [M+H] + =493; 1 H NMR (400MHz, DMSO-d6): δ11.66(s,1H),8.35(s,1H),7.79(d,J=9.4Hz,1H),7.63(s,1H),7.06(d,J=8.6Hz,1H),6.41(d,J=9.2Hz ,1H),4.85(s,2H),4.13(s,2H),3.93(s,3H),3.89(s,3H),3.76(s,2H),3.09-3.05(m,2H),2.69-2.67(m,2H),2.34-2.32(m,2H).

[1018] Compound T-33: m / z [M+H] + =493; 1 H NMR (400MHz, DMSO-d6): 11.59(s,1H),8.37(s,1H),7.80(d,J=9.4Hz,1H),7.65(d,J=8.7Hz,1H),7.07(d,J=8.7Hz,1H),6.42(d,J=9 .3Hz,1H),4.87-4.85(m,2H),4.13(s,2H),3.95-3.92(m,6H),3.73(s,2H),3.44-3.42(m,1H),2.66-2.61(m,2H),2.27-2.22(m,2H).

[1019] Example 30: 6-(2-(((3,7-difluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-34)

[1020] Step 1: Selectfluor (2.78 g, 7.81 mmol) was added to a 10 mL solution of compound 5-1 (1.0 g, 3.91 mmol) in acetonitrile (10 mL). The reaction mixture was stirred at 80 °C for 60 hours. After cooling to room temperature, the reaction was quenched with water. The aqueous phase was extracted with ethyl acetate, the organic phases were combined and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 34-1 (0.2 g) as a solid. m / z [M+H] + =274.1.

[1021] Step 2: A mixture of compound 34-1 (0.1 g, 0.37 mmol), tributylvinyltin (0.23 g, 0.730 mmol), Pd(PPh3)4 (0.08 g, 0.073 mmol), and DMF (2 mL) was purged three times with nitrogen. The reaction mixture was stirred at 100 °C for 4 hours, cooled to room temperature, and quenched with water. The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 34-2 (0.06 g) as a solid. m / z[M+H] + =222.2.

[1022] Step 3: A mixture of compound 34-2 (50 mg, 0.226 mmol), potassium osmium tetroxide dihydrate (16.8 mg, 0.054 mmol), sodium periodate (193 mg, 0.904 mmol), 2,6-dimethylpyridine (48 mg, 0.452 mmol), 1,4-dioxane (3 mL), and water (1 mL) was purged three times with nitrogen and stirred overnight at room temperature under nitrogen protection. The reaction was quenched with water, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 34-3 (40 mg) as a solid. m / z [M+H] + =224.0.

[1023] Step 4: Using compounds 34-3 and 4-1 as raw materials, compound T-34 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =499; 1 H NMR (400MHz, DMSO-d6): δ11.57(s,1H),8.34(s,1H),7.90(d,J=9.8Hz,1H),7.72(dd,J=8.6,6.5Hz,1H),7.25(t,J=9.1 Hz,1H),4.86(s,2H),4.11(s,2H),4.06(s,3H),3.90(s,2H),3.05-3.03(m,1H),2.69-2.60(m,3H),2.34-2.26(m,2H).

[1024] Example 31: 6-((2r,4r)-2-(((1,7-dimethyl-2-oxo-1,2-dihydroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one or 6-((2s,4s)-2-(((1,7-dimethyl-2-oxo-1,2-dihydroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-35)

[1025] Step 1: Under ice bath conditions and a nitrogen atmosphere, potassium tert-butoxide (63 g, 561 mmol) was added to a solution of methyltriphenylphosphine bromide (185 g, 518 mmol) in tetrahydrofuran (1.6 L). The reaction system was stirred at 25 °C for 1 hour. Then, the temperature was lowered to 0 °C, and 400 mL of tetrahydrofuran containing compound 35-1 (80 g, 432 mmol) was added. After the addition was complete, the reaction system was stirred at 25 °C for another 12 hours. The reaction was quenched with a saturated ammonium chloride solution (3 L). The aqueous phase was extracted with ethyl acetate, the organic phases were combined, and the mixture was washed with water and saturated brine, then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to give compound 35-2 (48 g, yield: 61%) as a white solid. m / z [M+H-56+41] + =169.

[1026] Step 2: Under ice bath conditions, m-chloroperoxybenzoic acid (47.5 g, 275 mmol) was added to a dichloromethane (1 L) solution of compound 35-2 (48 g, 262 mmol). The reaction mixture was stirred at 25 °C for 3 hours. The reaction was quenched with a saturated sodium bicarbonate aqueous solution (1 L). The organic phase was washed with water and saturated brine and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to give compound 35-3 (25 g, yield: 48%) as a white solid. m / z [M+H-56] + =144; 1 H NMR (400MHz, CDCl3): δ4.82-4.70(m,1H), 4.28-4.02(m,1H), 2.80-2.69(m,4H), 2.43-2.36(m,2H), 1.45(s,9H).

[1027] Step 3: Under ice bath conditions, a solution of sodium azide (24.5 g, 376 mmol) and ammonium chloride (26.9 g, 502 mmol) in water (25 mL) was added to a DMF (300 mL) solution of compound 35-3 (25 g, 125 mmol). The reaction system was stirred at 25 °C for 6 hours. The reaction was quenched with a saturated sodium bicarbonate aqueous solution (600 mL). The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure to obtain compound 35-4 (25 g) as a yellow oil. 1 H NMR (400MHz, CDCl3): δ4.89-4.70(m,1H),4.30-4.20(m,0.5H),3.76-3.65(m,0.5H),3.38( s,1H),3.35(s,1H),2.63-2.55(m,1H),2.48-2.38(m,1H),2.10-1.80(m,3H),1.44(s,9H).

[1028] Step 4: Add Pd / C (10%, 5g) to a methanol (500mL) solution of compound 35-4 (25g, 103mmol). The reaction system is purged with hydrogen three times and stirred at 50°C for 15 hours. Filter with diatomaceous earth, wash with methanol, and concentrate the filtrate under reduced pressure to obtain compound 35-5 (20g) as an off-white solid.

[1029] Step 5: Under a nitrogen atmosphere, N,N'-carbonyldiimidazole (15 g, 92.5 mmol) was added to a tetrahydrofuran (600 mL) solution of compound 35-5 (20 g, 92.5 mmol). The reaction system was stirred at 25 °C for 5 hours. The reaction was quenched with water (300 mL), and most of the tetrahydrofuran was removed by concentration. The mixture was filtered, and the filter cake was collected. The filter cake was slurried with ethyl acetate (300 mL) overnight. Filtration yielded 35-6-P1 (9 g, 40% yield) as a white solid. After extraction of the filtrate, the mixture was concentrated under reduced pressure and purified by silica gel column chromatography. The purified filtrate was then slurried with methyl tert-butyl ether and filtered to yield 35-6-P2 (9 g, 40% yield) as an off-white solid. 35-6-P1: 1 H NMR (400MHz, DMSO-d6): δ7.51 (s, 1H), 7.23 (d, J = 7.3Hz, 1H), 3.69-3.63 (m, 1H), 3.49 (s, 2H), 2.48-2.45 (m, 2H), 2.33-2.25 (m, 2H), 1.37 (s, 9H). 35-6-P2: 1H NMR (400MHz, DMSO-d6): δ7.45(s,1H),7.22-7.20(m,1H),4.00-3.95(m,1H),3.44(s,2H),2.61-2.52(m,2H),2.21-2.16(m,2H),1.37(s,9H).

[1030] Step Six: Compounds 35-6-P1 (4 g, 16.5 mmol), 35-7 (5.95 g, 16.5 mmol), cuprous iodide (1.57 g, 8.26 mmol), potassium carbonate (6.85 g, 49.5 mmol), and N,N'-dimethyl-1,2-cyclohexanediamine (2.35 g, 16.5 mmol) were dissolved in 1,4-dioxane (160 mL), purged with nitrogen, and the reaction mixture was stirred at 100 °C for 2 hours. The reaction was quenched with saturated ammonium chloride aqueous solution (200 mL), and the aqueous phase was extracted with ethyl acetate. The organic phase was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to give compound 35-8 (7 g, yield: 81%) as an off-white solid. m / z [M+H] + =522.

[1031] Step 7: Add 35 mL of trifluoroacetic acid to a dichloromethane (700 mL) solution of compound 35-8 (7 g, 13.4 mmol), and stir the reaction mixture at 25 °C for 1 hour. Concentrate under reduced pressure, dissolve the residue in methanol (20 mL) and ammonia (20 mL), and continue stirring at 25 °C for 2 hours. Concentrate under reduced pressure, slurry the residue with ethyl acetate (30 mL) and water (30 mL), filter, wash the filter cake with ethyl acetate, collect the filter cake, and dry it to give compound 35-9 (2.5 g, yield: 64%) as a white solid. HPLC retention time: 9.478 min; m / z [M+H] + =292; 1 H NMR (400MHz, DMSO-d6): δ8.32(s,1H),5.57-5.25(m,2H),4.85(s,2H),4.07(s,2 H),3.51-3.23(m,1H),3.11-3.03(m,1H),2.62-2.57(m,2H),2.20-2.15(m,2H).

[1032] Using the same synthetic method as 35-9, compound 35-9-2 was obtained as a white solid by reacting 35-7 and 35-6-P2. HPLC retention time: 9.803 min; m / z [M+H] + =292; 1H NMR (400MHz, DMSO-d6): δ8.34(s,1H),5.60-5.21(m,2H),4.85(s,2H),4.11(s,2 H),3.58-3.51(m,1H),3.45-3.18(m,1H),2.62-2.57(m,2H),2.10-2.06(m,2H).

[1033] Steps 8-9: A solution of compound 35-10 (5 g, 26.9 mmol) and methyl 3,3-dimethoxypropionate (4.18 g, 28.2 mmol) in tetrahydrofuran (50 mL) was purged three times with nitrogen. Under nitrogen protection, KHMDS (40.3 mL, 40.3 mmol, 1 mol / L) was slowly added at 0 °C. After the addition was complete, the mixture was stirred at room temperature for 2 hours and then cooled to 0 °C for later use. Sodium hydroxide (1.3 g, 32.2 mmol, 60%) was slowly added to the above reaction solution containing compound 35-11. The mixture was stirred for 30 minutes, and then iodomethane (5.72 g, 40.3 mmol) was added. The reaction system was stirred at room temperature for 1.5 hours, then cooled back to 0 °C. Ethyl acetate and water were added, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure to obtain compound 35-12 (8.91 g, crude product) as a solid.

[1034] Step 10: Under ice bath conditions, a solution of compound 35-12 (8.91 g, 28.2 mmol) in dichloromethane (8.9 mL) was added dropwise to concentrated sulfuric acid (17.8 mL). After the addition was complete, the reaction mixture was stirred at room temperature for 3 hours, cooled to 0 °C, and water and ethyl acetate were added. The aqueous phase was extracted with ethyl acetate, the organic phases were combined and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 35-13 (3.7 g) as a solid. m / z[M+H] + =252.

[1035] Step 11: The mixture of compound 35-13 (0.50 g, 1.98 mmol), tributylvinyltin (1.26 g, 3.97 mmol), Pd(PPh3)4 (0.46 g, 0.397 mmol), and DMF (8 mL) was purged three times with nitrogen. The mixture was heated to 100 °C and stirred for 4 hours. The reaction system was cooled to room temperature, and water was added to quench the reaction. The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 35-14 (0.36 g) as a solid. m / z[M+H] + =200.

[1036] Step 12: A mixture of compound 35-14 (0.30 g, 1.51 mmol), potassium osmium tetroxide dihydrate (0.11 g, 0.35 mmol), sodium periodate (1.29 g, 6.02 mmol), 2,6-dimethylpyridine (0.33 g, 3.01 mmol), 1,4-dioxane (9 mL), and water (3 mL) was purged three times with nitrogen and stirred overnight at room temperature under nitrogen protection. The reaction was quenched with water, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 35-15 (81 mg) as a solid. m / z [M+H] + =202.

[1037] Step Thirteen: Using compounds 35-15 and 35-9 as raw materials, compound T-35 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =477; 1 H NMR (400MHz, DMSO-d6): δ11.66(s,1H),8.33(s,1H),7.87(s,1H),7.68(s,1H),7.27(s,1H),6.54(s,1H),4.86 (s,2H),4.60–4.55(m,2H),4.15(s,2H),3.70-3.65(m,3H),3.21-3.15(m,2H),2.77-2.73(m,4H),2.57(s,3H).

[1038] Example 32: 6-((2r,4r)-2-(((7-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one or 6-((2s,4s)-2-(((7-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-36)

[1039] Steps one through six: Using compound 36-1 as a starting material, compound T-36 was prepared as a white solid using the same method as compound T-35 in Example 31. m / z[M+H] + =497; 1H NMR (400MHz, DMSO-d6): δ11.64(s,1H),8.28(s,1H),7.89(d,J=9.4Hz,1H),7.66(d,J=8.4Hz,1H),7.38(d,J=8.3Hz,1H),6.63( d,J=9.4Hz,1H),4.82(s,2H),4.12(s,2H),3.96(s,3H),3.92(s,2H),3.11-3.09(m,2H),2.69-2.65(m,2H),2.39-3.37(m,2H).

[1040] Example 32: 6-((2r,4r)-2-(((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrido[2,3-b][1,4]oxazine-3(4H)-one or 6-((2s,4s)-2-(((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrido[2,3-b][1,4]oxazine-3(4H)-one (T-37)

[1041] Step 1: Sodium tert-butoxide (60 mg, 0.62 mmol) and t-BuXphos Pd G3 (17 mg, 0.02 mmol) were added to a 1,4-dioxane (2 mL) solution of compounds 35-6-P1 (100 mg, 0.41 mmol) and 37-2 (95 mg, 0.41 mmol) (synthetic reference WO2013169864A2). The reaction mixture was stirred at 100 °C for 2 hours. After cooling to room temperature, the mixture was concentrated under reduced pressure. Water was added to the residue, and the mixture was filtered. The filter cake was washed with dichloromethane and methanol and dried to give compound 37-3 (52 mg, yield: 32%) as a grayish-white solid. m / z [M+H] + =391.

[1042] Step 2: A mixture of compound 37-3 (52 mg, 0.13 mmol) in dichloromethane (4 mL) and trifluoroacetic acid (2 mL) was stirred at room temperature for 1.5 hours. The solution was then concentrated under reduced pressure to give compound 37-4 (38 mg) as a white solid. m / z [M+H] + =291.

[1043] Step 3: Using compounds 37-4 and 5-3 as raw materials, compound T-37 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =480;1 H NMR (400MHz, DMSO-d6): δ11.22(s,1H),7.92(d,J=9.1Hz,1H),7.81(s,1H),7.55(d,J=8.7Hz,1H),7.44(d,J=8.7Hz,1H),7. 25(s,1H),6.61(d,J=9.2Hz,1H),4.62(s,2H),4.16(s,2H),3.88(s,3H),3.55(s,3H),3.27-3.22(m,2H),2.72-2.67(m,3H).

[1044] Example 33: 6-(2-(2-((4-methyl-3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-6-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3,4]oct-7-yl)-2H-pyrido[2,3-b][1,4]oxazin-3(4H)-one (T-38)

[1045] Compound 38-1 (40 mg, 0.14 mmol) (synthetic reference WO2021190727A1) and sodium triacetoxyborohydride (116 mg, 0.54 mmol) were added to a dichloromethane (20 mL) solution of compound 6-1 (30 mg, 0.14 mmol). The reaction mixture was stirred at room temperature for 1 hour, concentrated under reduced pressure, and the residue was purified by prep-HPLC (elution conditions: 5%–75% acetonitrile aqueous solution, elution time: 20 min) to give compound T-38 (15 mg, yield: 23%) as a white solid. m / z [M+H] + =480; 1 H NMR (400MHz, DMSO-d6): δ11.22(s,1H),8.15-8.12(m,2H),7.56-7.53(m,1H),7.44-7.41(m,1H),6.85-6.82(m,1 H), 4.62 (s, 2H), 4.43 (t, J = 5.2Hz, 2H), 4.26 (s, 2H), 3.62-3.59 (m, 5H), 3.48-3.45 (m, 2H), 2.91 (t, J = 5.4Hz, 2H).

[1046] Example 34: 6-((2r,4r)-2-(((7-fluoro-2-methylquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one or 6-((2s,4s)-2-(((7-fluoro-2-methylquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-39)

[1047] Step 1: Add (2E)-but-2-enal (738 mg, 10.5 mmol) to a hydrochloric acid (25 mL, 6N) solution of compound 39-1 (1 g, 5.26 mmol). After purging the reaction system with nitrogen, stir at 100 °C for 1 hour. Cool the reaction solution to room temperature, quench the reaction with a saturated sodium bicarbonate solution, and extract the aqueous phase with ethyl acetate. Combine the organic phases and concentrate under reduced pressure. Purify the residue by silica gel column chromatography to give compound 39-2 (647 mg, yield: 51%) as a white solid. m / z [M+H] + =240.

[1048] Step 2: Sodium carbonate (318 mg, 3 mmol) and Pd(PPh3)4 (60 mg, 0.05 mmol) were added to a mixed solution of compound 39-2 (200 mg, 0.84 mmol) and pinacol vinylborate (230 mg, 1.49 mmol) in 1,4-dioxane (4 mL) and water (1 mL). The reaction mixture was purged with nitrogen and stirred at 100 °C for 10 hours. The mixture was then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 39-3 (105 mg, yield: 67%) as a yellow oil. m / z [M+H] + =188.

[1049] Step 3: Sodium periodate (260 mg, 1.2 mmol) and potassium osmium tetroxide dihydrate (20 mg, 0.06 mmol) were added to a mixed solution of compound 39-3 (56 mg, 0.3 mmol) in acetone (2 mL) and water (2 mL). The reaction mixture was stirred at room temperature for 1.5 hours, then water was added to quench the reaction. The aqueous phase was extracted with ethyl acetate, and the organic phase was separated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 39-4 (38 mg, yield: 67%). m / z [M+H] + =190.

[1050] Step 4: Using compounds 39-4 and 35-9 as raw materials, compound T-39 was prepared as a white solid using the same method as in Example 1. m / z[M+H]+ =465; 1 H NMR (400MHz, DMSO-d6): δ11.63(s,1H),8.39–8.34(m,1H),8.33(s,1H),8.09–8.02(m,1H),7.55-7.50(m,2H), 4.87(s,2H),4.40(s,2H),4.11(s,2H),3.41-3.36(m,2H),2.75(s,3H),2.71-2.67(m,2H),2.46–2.37(m,2H).

[1051] Example 35: 6-(2-(2-((6-methoxy-1,5-naphthidin-3-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-40)

[1052] Step 1: Add sodium hydride (33.7 mg, 0.84 mmol, 60%) to a DMF (1 mL) solution of 2,2-diethoxyethanol (1.5 g, 11.23 mmol). After stirring at room temperature for 5 minutes, add compound 40-1 (100 mg, 0.56 mmol). After stirring at room temperature for 1 hour, add sodium hydride (130 mg), continue stirring for 4 hours, quench the reaction with saturated ammonium chloride aqueous solution, and extract the aqueous phase with ethyl acetate. Combine the organic phases and concentrate under reduced pressure. Purify the residue by silica gel column chromatography to give compound 40-2 (182 mg, crude product) as a white solid. m / z [M+H] + =293.

[1053] Step 2: Add 1 mL of trifluoroacetic acid to a 2 mL solution of compound 40-2 (100 mg, 0.34 mmol) in dichloromethane. Stir at room temperature for 18 hours, concentrate under reduced pressure, neutralize the residue with a small amount of sodium bicarbonate aqueous solution, extract the aqueous phase with ethyl acetate, combine the organic phases, and concentrate under reduced pressure to obtain compound 40-3 (54 mg) as a white solid. m / z[M+H] + =219.

[1054] Step 3: Using compounds 40-3 and 2-1 as raw materials, compound T-40 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =480; 1H NMR (400MHz, DMSO-d6): δ11.59(s,1H),8.53(d,J=2.8Hz,1H),8.34(s,1H),8.19(d,J=8.8Hz,1H),7.59(d,J=2.5Hz,1H),7.07(d,J=9 .0Hz,1H),4.86(s,2H),4.25(s,2H),4.20(t,J=6.3Hz,2H),4.00(s,3H),3.64(d,J=8.8Hz,2H),3.53-3.51(m,2H),2.96–2.89(m,2H).

[1055] Example 36: 6-(2-(2-((3-methoxyquinoxalin-6-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-41)

[1056] Step 1: Add aluminum chloride (421 mg, 3.16 mmol) to a toluene (5 mL) solution of compound 41-1 (250 mg, 1.28 mmol). After purging the reaction system with nitrogen, stir at 80 °C for 4 hours. Quench the reaction with a saturated aqueous solution of ammonium chloride. Extract the aqueous phase with ethyl acetate. Combine the organic phases and concentrate under reduced pressure to obtain compound 41-2 (crude product). m / z [M+H] + =181.

[1057] Step 2: Dissolve compound 41-2 obtained in the previous step in methanol (6 mL), then add sodium methoxide (98 mg, 1.82 mmol). After purging the reaction system with nitrogen, stir at 60 °C for 4 hours. Quench the reaction with saturated ammonium chloride aqueous solution, and extract the aqueous phase with ethyl acetate. Combine the organic phases and concentrate under reduced pressure. Purify the residue by silica gel column chromatography to obtain compound 41-3 (220 mg, two-step yield: 97%). m / z [M+H] + =177.

[1058] Step 3: Add 2-bromo-1,1-diethoxyethane (369 mg, 1.88 mmol) and potassium carbonate (518 mg, 3.75 mmol) to a DMF (6 mL) solution of compound 41-3 (220 mg, 1.25 mmol). After purging the reaction system with nitrogen, stir overnight at 90 °C. Quench the reaction with a saturated aqueous solution of ammonium chloride. Extract the aqueous phase with ethyl acetate. Combine the organic phases and concentrate under reduced pressure. Purify the residue by silica gel column chromatography to give compound 41-4 (176 mg, 48% yield). m / z [M+H] + =293.

[1059] Step 4: A mixture of compound 41-4 (176 mg, 0.60 mmol) in dichloromethane (2 mL) and trifluoroacetic acid (1 mL) was stirred at room temperature for 5 hours, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 41-5 (98 mg, 75% yield) as a yellow solid. m / z [M+H] + =219.

[1060] Step 5: Using compounds 41-5 and 2-1 as raw materials, compound T-41 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =480; 1 H NMR (400MHz, DMSO-d6): δ11.68(s,1H),8.42(s,1H),8.32(s,1H),7.90(d,J=9.2Hz,1H),7.28 -7.23(m,2H),4.85(s,2H),4.25(s,2H),4.17(t,J=5.2Hz,2H),4.02(s,3H),3.64(d,J=9.3Hz,2H),3.52(d,J=9.2Hz,2H),2.92(t,J=5.1Hz,2H).

[1061] Example 37: 6-(2-(2-((7-methoxy-1,5-naphthidin-2-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-42)

[1062] Step 1: Sodium methoxide (1.2 g, 22.5 mmol) was added to a methanol (20 mL) solution of compound 42-1 (400 mg, 2.25 mmol). The reaction system was purged with nitrogen and stirred at 60 °C for 2 days. The reaction was quenched with water, and the aqueous phase was extracted with ethyl acetate. The combined organic phases were concentrated under reduced pressure to obtain compound 42-2 (418 mg, 98% yield) as a white solid. m / z [M+H] + =191.

[1063] Step 2: The dilute hydrochloric acid (10 mL, 6N) solution of compound 42-2 (418 mg, 2.2 mmol) was purged with nitrogen and stirred at 110 °C for 2 hours. The pH was then adjusted to weakly alkaline with a saturated sodium bicarbonate aqueous solution. The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure to obtain compound 42-3 (380 mg). m / z[M+H] + =177.

[1064] Step 3: Potassium carbonate (1.18 g, 8.53 mmol) and 2-bromo-1,1-diethoxyethane (1.68 g, 8.53 mmol) were added to a 10 mL DMF solution of compound 42-3 (380 mg, 2.13 mmol). The reaction mixture was purged with nitrogen and stirred at 90 °C for 4 hours. The reaction was then quenched with a saturated ammonium chloride solution. The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compounds 42-4 (120 mg) and 42-5 (200 mg). m / z[M+H] + =293.

[1065] Step 4: A mixed solution of compound 42-4 (100 mg, 0.34 mmol) in dichloromethane (2 mL) and trifluoroacetic acid (2 mL) was stirred at room temperature for 2 hours, concentrated under reduced pressure, neutralized with sodium bicarbonate aqueous solution, extracted with ethyl acetate, concentrated the organic phase under reduced pressure, and purified the residue by silica gel column chromatography to obtain compound 42-6 (62 mg, 83% yield) as a yellow solid. m / z [M+H] + =219.

[1066] Step 5: Using compounds 42-6 and 2-1 as raw materials, compound T-42 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =480; 1 H NMR (400MHz, DMSO-d6): δ11.68(s,1H),8.57(s,1H),8.35(s,1H),8.26(s,1H),7.57(d,J=2.8Hz,1H),7.09( d,J=8.8Hz,1H),4.88(s,2H),4.63(s,2H),4.25(s,2H),3.96(s,3H),3.85–3.51(m,4H),3.05–2.83(m,2H).

[1067] Example 38: 6-(2-(2-(7-methoxy-2-oxo-1,5-naphthidin-1(2H)-yl)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-43)

[1068] Step 1: A mixed solution of compound 42-5 (200 mg, 0.68 mmol) in dichloromethane (2 mL) and trifluoroacetic acid (2 mL) was stirred at room temperature for 18 hours, concentrated under reduced pressure, neutralized with a small amount of sodium bicarbonate aqueous solution, extracted with ethyl acetate, concentrated the organic phase under reduced pressure, and purified the residue by silica gel column chromatography to obtain compound 43-1 (149 mg, yield: 100%) as a yellow solid. m / z [M+H] + =219.

[1069] Step 2: Using compounds 43-1 and 2-1 as raw materials, compound T-43 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =480; 1 H NMR (400MHz, DMSO-d6): δ11.68(s,1H),8.36-8.35(m,2H),7.94(d,J=9.7Hz,1H),7.45(s,1H),6.75(s ,1H),4.88(s,2H),4.55(s,4H),4.46-4.40(m,2H),4.28-4.21(m,2H),4.01(s,3H),3.72-3.67(m,2H).

[1070] Example 39: 6-((2r,4r)-2-(((2-chloro-7-fluoroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one or 6-((2s,4s)-2-(((2-chloro-7-fluoroquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-44)

[1071] Step 1: Pd(PPh3)4 (716 mg, 0.62 mmol) and tributylvinyltin (2.95 g, 9.3 mmol) were added to a DMF (30 mL) solution of compound 44-1 (synthesis reference: Organic Process Research & Development, 2017, 21(7):1003-1011) (1.5 g, 6.2 mmol). The reaction system was purged with nitrogen and stirred overnight at 100 °C. The reaction was then quenched with a saturated potassium fluoride aqueous solution. The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 44-2 (900 mg, yield 77%). m / z[M+H] + =190.

[1072] Step 2: Compound 44-2 (300 mg, 1.59 mmol) was dissolved in phosphorus oxychloride (3 mL) and stirred at 110 °C for 40 minutes. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 44-3 (298 mg, 91% yield). m / z [M+H] + =208.

[1073] Step 3: Sodium periodate (417 mg, 1.93 mmol) and potassium osmium tetroxide dihydrate (15 mg, 0.048 mmol) were added to a mixed solution of compound 44-3 (100 mg, 0.48 mmol) in acetone (3 mL) and water (3 mL). The reaction mixture was stirred at room temperature for 40 minutes, then water and ethyl acetate were added, and the organic phase was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 44-4 (65 mg, yield: 64%). m / z [M+H] + =210.

[1074] Step 4: Using compounds 44-4 and 35-9 as raw materials, compound T-44 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =485; 1 H NMR (400MHz, DMSO-d6): δ11.63(s,1H),8.56(d,J=8.6Hz,1H),8.33(s,1H),8.19(s,1H),7.68(t,J=9 .0Hz,2H),4.87(s,2H),4.36(s,2H),4.11(s,2H),3.39-3.37(m,2H),2.68(s,2H),2.48-2.36(m,2H).

[1075] Example 40: 7-fluoro-8-((((2r,4r)-6-oxo-7-(3-oxo-3,4-dihydro-2H-pyrazino[2,3-b][1,4]oxazin-6-yl)-5-oxa-7-azaspiro[3.4]oct-2-yl)amino)methyl)quinoline-2-carboxylonitrile or 7-fluoro-8-((((2s,4s)-6-oxo-7-(3-oxo-3,4-dihydro-2H-pyrazino[2,3-b][1,4]oxazin-6-yl)-5-oxa-7-azaspiro[3.4]oct-2-yl)amino)methyl)quinoline-2-carboxylonitrile (T-45)

[1076] Step 1: Zinc cyanide (24 mg, 0.2 mmol), bis(diphenylphosphine)ferrocene (7 mg, 0.014 mmol), and Pd2(dba)3 (13 mg, 0.014 mmol) were added to a 2 mL DMF solution of compound 44-4 (30 mg, 0.14 mmol). The reaction mixture was purged with nitrogen, stirred at 80 °C for 2 hours, cooled to room temperature, and the reaction was quenched with water. The aqueous phase was extracted with ethyl acetate, and the organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 45-1 (28 mg, 98% yield). m / z [M+H] + =201.

[1077] Step 2: Using compounds 45-1 and 35-9 as raw materials, compound T-45 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =476; 1 H NMR (400MHz, DMSO-d6): δ11.64(s,1H),8.83(d,J=8.4Hz,1H),8.42–8.30(m,2H),8.20(d,J=8.4Hz,1H),7.90(t ,J=9.2Hz,1H),4.87(s,2H),4.56(s,2H),4.14(s,2H),3.67-3.54(m,2H),2.82-2.76(m,2H),2.64-2.59(m,2H).

[1078] Example 41: 6-(2-(2-((4-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-46)

[1079] Step 1: Potassium carbonate (235 mg, 1.7 mmol) and methyl iodide (302 mg, 2.13 mmol) were added to a DMF (7 mL) solution of compound 46-1 (250 mg, 1.42 mmol). The reaction mixture was stirred at room temperature for 3 hours, then quenched with a saturated aqueous solution of ammonium chloride. The aqueous phase was extracted with ethyl acetate, and the organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 46-2 (202 mg, 75% yield). m / z [M+H] + =191. 1H NMR (400MHz, CDCl3): δ8.15 (s, 1H), 7.80 (d, J = 8.9 Hz, 1H), 6.94 (dd, J = 8.9, 2.5 Hz, 1H), 6.74 (d, J = 2.5 Hz, 1H), 3.94 (s, 3H), 3.66 (s, 3H).

[1080] Step 2: Boron tribromide (0.4 mL) was added to a dichloromethane (4 mL) solution of compound 46-2 (170 mg, 0.89 mmol). The reaction mixture was stirred at room temperature for 24 hours, then ethanol (5 mL) was added to quench the reaction, followed by the addition of water. The aqueous phase was extracted with ethyl acetate, and the organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 46-3 (106 mg, 68% yield). m / z [M+H] + =177.

[1081] Step 3: Bromoacetaldehyde diethanolamide (78 mg, 0.40 mmol) and potassium carbonate (55 mg, 0.40 mmol) were added to a DMF (3 mL) solution of compound 46-3 (106 mg, 0.60 mmol). The reaction mixture was stirred at 90 °C for 6 hours and then cooled to room temperature. The reaction was quenched with water (10 mL), and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 46-4 (119 mg, 68% yield). m / z [M+H] + =293.

[1082] Step 4: A mixed solution of compound 46-4 (119 mg, 0.40 mmol) in dichloromethane (2 mL) and trifluoroacetic acid (2 mL) was stirred at room temperature for 2 hours, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 46-5 (88 mg, 99% yield) as a yellow solid. m / z [M+H] + =219.

[1083] Step 5: Using compounds 46-5 and 2-1 as raw materials, compound T-46 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =480; 1H NMR (400MHz, DMSO-d6): δ11.64(s,1H),8.34(s,1H),8.05(s,1H),7.78–7.67(m,1H),7.00-6.99(m,2H),4.86(s,2H), 4.24 (s, 2H), 4.17 (t, J = 5.0Hz, 2H), 3.63 (d, J = 8.8Hz, 2H), 3.59 (s, 3H), 3.51 (d, J = 8.7Hz, 2H), 2.91 (t, J = 5.0Hz, 2H).

[1084] Example 42: 6-((2r,4r)-2-(((7-fluoro-2-methoxyquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one or 6-((2s,4s)-2-(((7-fluoro-2-methoxyquinoline-8-yl)methyl)amino)-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-47)

[1085] Step 1: Sodium hydroxide (57 mg, 1.42 mmol, 60%) and methyl iodide (149 mg, 1.05 mmol) were added to a DMF (3 mL) solution of compound 44-1 (172 mg, 0.71 mmol). The reaction mixture was stirred at room temperature for 3 hours, then quenched with a saturated aqueous solution of ammonium chloride. The aqueous phase was extracted with ethyl acetate, and the organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 47-1 (140 mg, 77% yield). m / z [M+H] + =256. 1 H NMR (400MHz, CDCl3): δ7.97 (d, J = 8.8 Hz, 1H), 7.66 (dd, J = 8.8, 5.9 Hz, 1H), 7.21 (t, J = 8.5 Hz, 1H), 6.91 (d, J = 8.8 Hz, 1H), 4.16 (s, 3H).

[1086] Steps 2-3: Using 47-1 as the raw material, compound 47-3 is obtained by performing the same operations as in steps 2 and 3 of T-39.

[1087] Step 4: Using compounds 47-3 and 35-9 as raw materials, compound T-47 was prepared using the same method as in Example 1. m / z[M+H] + =481. 1H NMR (400MHz, DMSO-d6): δ11.63(s,1H),8.34-8.31(m,2H),7.99(s,1H),7.43-7.38(m,1H),7.08(d,J=8.7Hz,1H),4.86(s ,2H),4.34(s,2H),4.11(s,2H),4.09(s,3H),3.65-3.54(m,1H),2.96–2.89(m,1H),2.70-2.64(m,2H),2.45-2.37(m,2H).

[1088] Example 43: (2s,4s)-2-(((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)methyl)amino)-7-(3-oxo-3,4-dihydro-2H-pyrazino[2,3-b][1,4]thiazin-6-yl)-5-oxa-7-azaspiro[3.4]oct-6-one or (2r,4r)-2-(((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)methyl)amino)-7-(3-oxo-3,4-dihydro-2H-pyrazino[2,3-b][1,4]thiazin-6-yl)-5-oxa-7-azaspiro[3.4]oct-6-one (T-48)

[1089] Step 1: A solution of 3-bromo-6-chloropyrazine-2-amine (5 g, 24.0 mmol) in 1,4-dioxane (75 mL) was purged three times with nitrogen. Sodium tert-butoxide (6.92 g, 72.0 mmol) was added in portions under nitrogen protection. The mixture was stirred at room temperature for half an hour, followed by dropwise addition of ethyl mercaptoacetate (4.61 g, 38.4 mmol). Stirring continued at 100 °C for 3 hours. After cooling to room temperature, the reaction solution was concentrated under reduced pressure. Water (75 mL) was added, and the pH was adjusted to neutral with hydrochloric acid (1.5 M). A large amount of solid precipitated. The solid was filtered, and the filter cake was dried under vacuum to obtain compound 48-1 (3.18 g) as a solid. m / z[M+H] + 202.

[1090] Step 2: Tert-butyl (6-oxo-5-oxa-7-azaspiro[3.4]oct-2-yl)carbamate (121 mg, 0.5 mmol), compound 48-1 (100 mg, 0.496 mmol), potassium tert-butoxide (70 mg, 0.62 mmol), and tBuXPhos-Pd-G3 (20 mg, 20% w / wt) were sequentially added to 1,4-dioxane (3 mL). The mixture was purged with nitrogen three times. Under nitrogen protection, the mixture was stirred at 100 °C for 6 hours. The reaction system was cooled to room temperature, concentrated under reduced pressure, and methyl tert-butyl ether (3 mL) and water (1 mL) were added to the residue. The mixture was stirred and slurried at room temperature for half an hour, filtered, and the filter cake was dried under vacuum to obtain compound 48-2 (140 mg) as a solid. m / z[M+H] + 408.

[1091] Step 3: Dissolve compound 48-2 (140 mg) in HCl-1,4-dioxane (3 mL, 4 mol / L), stir at room temperature for 2 hours, then evaporate to dryness. The resulting solid is used directly in the next step. m / z[M+H] + 308.

[1092] Step 4: A solution of compound 5-3 (112 mg, 0.55 mmol) and the solid obtained in Step 3 (126 mg, 0.41 mmol) in dichloromethane (2 mL) and methanol (2 mL) was stirred at room temperature for 20 minutes. Sodium cyanoborohydride (65 mg, 1.03 mmol) was added in portions. After stirring the reaction mixture at room temperature for 4 hours, it was directly concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound T-48 (80 mg) as a solid. m / z[M+H] + 497. 1 H NMR (400MHz, DMSO-d6): δ11.23(s,1H),8.77(s,1H),7.89(d,J=9.5Hz,1H),7.73(dd,J=8.6,6.6Hz,1H),7.23–7.11(m,1H),6.58(d,J=9.4Hz,1 H),4.05(d,J=8.9Hz,2H),4.01(s,3H),3.88(s,2H),3.77(s,2H),3.43 -3.42(m,1H),2.70-2.68(m,1H),2.66-2.58(m,2H),2.19-2.14(m,2H).

[1093] Example 44: 1-Methyl-8-(2-(6-oxo-7-(3-oxo-3,4-dihydro-2H-pyrazino[2,3-b][1,4]oxazin-6-yl)-5-oxa-2,7-diazaspiro[3,4]oct-2-yl)ethyl)-1,8-naphthidium-2,7(1H,8H)-dione (T-49)

[1094] Step 1: At 0°C, concentrated sulfuric acid (250 mL) was added dropwise to pyridine-2,6-diamine (50.0 g, 458 mmol) and malic acid (67.6 g, 504 mmol). After the addition was complete, the reaction mixture was stirred at 100°C for 6 hours. The mixture was then cooled to room temperature, and the reaction mixture was added dropwise to ice water. After the addition was complete, sodium hydroxide was slowly added to adjust the pH to neutral, resulting in the precipitation of a large amount of solid. This solid was filtered, and the solid was mixed with water (30 mL) and methanol (270 mL) to form a slurry. The mixture was then filtered again, and the filter cake was dried under vacuum to obtain compound 49-1 (69.1 g) as a solid. m / z[M+H] + =162.

[1095] Step 2: Dichloromethane (300 mL) was added to compound 49-1 (30.0 g, 185 mmol) and benzyltriethylammonium chloride (189.6 g, 833 mmol). The reaction system was purged with nitrogen three times, and the temperature was lowered to below 0 °C under nitrogen protection. Tert-butyl nitrite (191 g, 1.85 mol) was added dropwise. After the addition was complete, the mixture was stirred overnight at room temperature. The reaction system was cooled to 0 °C, and the reaction was quenched with saturated sodium bicarbonate aqueous solution. The mixture was filtered through diatomaceous earth, and the filtrate was separated into layers. The organic phase was separated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 49-2 (5.76 g) as a solid. m / z[M+H] + =181.

[1096] Step 3: Under nitrogen protection at 0°C, sodium hydride (1.33 g, 33.3 mmol, 60%) was added to a solution of compound 49-2 (4.0 g, 22.2 mmol) in DMF (6 mL) and ethylene glycol dimethyl ether (60 mL). The reaction system was stirred for 10 minutes, and then iodomethane (6.3 g, 44.4 mmol) was added. The reaction solution was stirred at 40°C for 2 hours. After cooling, water was added to quench the reaction solution. The aqueous phase was extracted with ethyl acetate, and the organic phases were combined and concentrated under reduced pressure to obtain compound 49-3 (3.89 g) as a solid, m / z [M+H]. + =195.

[1097] Step 4: Under nitrogen protection, a mixture of compound 49-3 (1.0 g, 5.15 mmol), tBuXphos-Pd-G3 (40.8 mg, 0.05 mmol), Pd2(dba)3 (91.6 mg, 0.1 mmol), potassium hydroxide (576 mg, 10.3 mmol), 1,4-dioxane (15 mL), and water (15 mL) was heated to 100 °C and stirred for 1 hour. After cooling the reaction system to room temperature, compound 49-4 (520 mg) was purified by rapid silica gel column chromatography. m / z [M+H] + =177.

[1098] Step 5: To a DMF (2 mL) solution of compound 49-4 (420 mg, 2.37 mmol), add bromoacetaldehyde diethanolate (1.88 g, 9.54 mmol) and potassium carbonate (1.3 g, 9.4 mmol). After purging the reaction system with nitrogen, stir at 90 °C for 8 hours. Cool to room temperature, add water, and extract with ethyl acetate. Concentrate the organic phase under reduced pressure. Purify the residue by rapid silica gel column chromatography to obtain compound 49-5 (370 mg) as a yellow oil. m / z [M+H] + =293.

[1099] Step Six: Add 4 mL of trifluoroacetic acid to a solution of compound 49-5 (350 mg, 1.20 mmol) in dichloromethane (4 mL). Stir the reaction mixture at room temperature for 1 hour, concentrate under reduced pressure, and lyophilize to obtain compound 49-6 (260 mg) as a pale yellow solid. m / z [M+H] + =219.

[1100] Step 7: Using compounds 49-6 and 2-1 as raw materials, compound T-49 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =480; 1 H NMR (400MHz, DMSO-d6): δ11.65(s,1H),8.32(s,1H),8.06(d,J=8.4Hz,1H),7.87(d,J=9.4Hz,1H),6.72(d,J=8.4Hz,1H),6.51(d ,J=9.4Hz,1H),4.85(s,2H),4.42(t,J=5.4Hz,2H),4.23(s,2H),3.69–3.56(m,5H),3.48(d,J=9.1Hz,2H),2.91(t,J=5.4Hz,2H).

[1101] Example 45: 6-(2-(2-((8-methyl-7-oxo-7,8-dihydro-1,8-naphthidin-2-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-50)

[1102] Step 1: A solution of compound 49-3 (0.50 g, 2.57 mmol) in ethylene glycol (0.32 g, 5.14 mol) and DMF (10 mL) was stirred at 70 °C for 7 hours. After cooling to room temperature, the reaction was quenched with water. The aqueous phase was extracted with ethyl acetate, the organic phases were combined and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 50-1 (300 mg) as a solid. m / z [M+H] + =221.

[1103] Step 2: Add Dysmann reagent (1.16 g, 2.72 mmol) and pyridine (0.22 g, 2.72 mmol) to a dichloromethane (5 mL) solution of compound 50-1 (0.30 g, 1.36 mmol). Stir the reaction mixture at room temperature for 4 hours. Quench the reaction mixture with water, extract the aqueous phase with ethyl acetate, combine the organic phases, concentrate under reduced pressure, and purify the residue by silica gel column chromatography to obtain compound 50-2 (30 mg) as a solid. m / z [M+H] + =219.

[1104] Step 3: Using compounds 50-2 and 2-1 as raw materials, compound T-50 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =480; 1 H NMR (400MHz, DMSO-d6): δ8.29 (s, 1H), 8.06 (d, J = 8.4Hz, 1H), 7.87 (d, J = 9.4Hz, 1H), 6.72 (d, J = 8.4Hz, 1H), 6.51 (d, J = 9.4Hz, 1H), 4.82 (s, 2H), 4.42 (t, J = 5.3Hz, 2H), 4.23 (s, 2H), 3.65 (s, 3H), 3.61 (d, J = 8.8Hz, 2H), 3.48 (d, J = 8.9Hz, 2H), 2.91 (t, J = 5.3Hz, 2H).

[1105] Example 46: 6-(2-(2-(7-methoxy-2-oxo-1,8-naphthidin-1(2H)-yl)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-51)

[1106] Step 1: A solution of compound 49-1 (10.0 g, 61.7 mmol), benzyltriethylammonium chloride (63.2 g, 278 mmol) in dichloromethane (300 mL) and methanol (50 mL) was purged three times with nitrogen. Under nitrogen protection, the mixture was cooled to below 10 °C, and tert-butyl nitrite (63.6 g, 617 mmol) was added dropwise. After the addition was complete, the reaction mixture was stirred overnight at room temperature. The mixture was then cooled, and the reaction was quenched with saturated sodium bicarbonate solution. The mixture was filtered through diatomaceous earth. The filtrate was separated into layers, and the organic phase was separated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 51-1 (2.13 g) as a solid. m / z[M+H] + =177.

[1107] Step 2: Cesium carbonate (1.85 g, 5.68 mmol) and 2-bromoethanol (0.70 g, 5.68 mmol) were added to a DMF (5 mL) solution of compound 51-1 (0.5 g, 2.84 mmol). The reaction mixture was stirred at 70 °C for 7 hours. After cooling, the reaction solution was quenched with water. The aqueous phase was extracted with ethyl acetate, the organic phases were combined and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 51-2 (90 mg), m / z [M+H]. + =221; and compound 52-1 (220 mg), m / z [M+H] + =221.

[1108] Step 3: Add Dysmann reagent (232 mg, 0.55 mmol) and pyridine (43 mg, 0.55 mmol) to a dichloromethane (3 mL) solution of compound 51-2 (80 mg, 0.27 mmol). Stir the reaction mixture at room temperature for 4 hours, quench the reaction with water, extract the aqueous phase with ethyl acetate, combine the organic phases, concentrate under reduced pressure, and purify the residue by silica gel column chromatography to obtain compound 51-3 (70 mg) as a solid. m / z [M+H] + =219.

[1109] Step 4: Using compounds 51-3 and 2-1 as raw materials, compound T-51 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =480; 1H NMR (400MHz, DMSO-d6): δ11.66(s,1H),8.34(s,1H),8.07(d,J=8.4Hz,1H),7.88(d,J=9.2Hz,1H),6.76(d,J=8.3Hz,1H),6. 52(d,J=9.3Hz,1H),4.87(s,2H),4.39-4.37(m,2H),4.21(s,2H),4.00(s,3H),3.58(s,2H),3.45(s,2H),2.83-2.77(m,2H).

[1110] Example 47: 6-(2-(2-((7-methoxy-1,8-naphthidin-2-yl)oxy)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-52)

[1111] Step 1: Using compound 52-1 as the starting material, compound 52-2 (150 mg) was obtained using the same method as for 51-3. m / z[M+H] + =219.

[1112] Step 2: Using compounds 52-2 and 2-1 as raw materials, compound T-52 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =480; 1 H NMR (400MHz, DMSO-d6): δ8.25(s,1H),8.06(d,J=8.4Hz,1H),7.87(d,J=9.4Hz,1H),6.75(d,J=8.4Hz,1H),6.51(d,J=9.4Hz,1 H), 4.79 (s, 2H), 4.36 (t, J = 6.8Hz, 2H), 4.20 (s, 2H), 3.99 (s, 3H), 3.59-3.56 (m, 2H), 3.51-3.45 (m, 2H), 2.80 (t, J = 6.7Hz, 2H).

[1113] Example 48: 6-(2-(2-(methyl(8-methyl-7-oxo-7,8-dihydro-1,8-naphthidin-2-yl)amino)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-53)

[1114] Step 1: Compound 49-4 (0.50 g, 2.57 mmol), 2-(methylamino)-acetaldehyde diethanol (0.75 g, 5.14 mmol), and cesium carbonate (1.68 g, 5.16 mmol) in 5 mL of DMF were stirred at 70 °C for 12 hours. After cooling to room temperature, the reaction was quenched with water. The aqueous phase was extracted with ethyl acetate, and the organic phases were combined and washed with water. The organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 53-1 (0.30 g) as a solid, m / z [M+H]. + =306.

[1115] Step 2: Add 2 mL of trifluoroacetic acid to a 2 mL solution of compound 53-1 (100 mg, 0.33 mmol) in dichloromethane. Stir the reaction mixture at room temperature for 1 hour, then concentrate under reduced pressure to obtain compound 53-2 (crude product, 100 mg). m / z [M+H] + =232.

[1116] Step 3: Using compounds 53-2 and 2-1 as raw materials, compound T-53 was prepared as a white solid using the same method as in Example 1. m / z[M+H] + =493; 1 H NMR (400MHz, DMSO-d6): δ11.64(s,1H),8.34(s,1H),7.80(d,J=8.7Hz,1H),7.69(d,J=9.3Hz,1H),6.59(t,J=13.3Hz,1H),6.25(d,J=9.2Hz,1H),4. 87(s,2H),4.22(s,2H),3.65-3.62(m,2H),3.60(s,3H),3.56(d,J=8.7Hz, 2H), 3.43 (d, J = 8.7Hz, 2H), 3.12 (d, J = 15.4Hz, 3H), 2.74 (t, J = 6.3Hz, 2H).

[1117] Example 49: 6-(2-(2-((7-fluoro-1-methyl-2-oxo-1,2-dihydroquinolin-8-yl)amino)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-54)

[1118] Step 1: A solution of compound 5-1 (5.0 g, 19.5 mmol), aminoacetaldehyde diethanolamide (5.19 g, 39 mmol), and sodium tert-butoxide (3.75 g, 39 mmol) in 1,4-dioxane (50 mL) was purged with nitrogen. Ruphos Pd G3 (1.67 g, 2 mmol) was then added under nitrogen protection. The reaction mixture was stirred at 100 °C for 2 hours until complete. The mixture was concentrated under reduced pressure, and the reaction was quenched with ice water. The aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 54-1 (2.86 g) as an oil, m / z [M+H]. + =309.

[1119] Step 2: Add DMAP (40 mg, 0.327 mmol), triethylamine (0.2 mL, 1.44 mmol), and trifluoroacetic anhydride (0.15 mL, 1.06 mmol) to a dichloromethane (3 mL) solution of compound 54-1 (95 mg, 0.308 mmol). Stir the reaction mixture overnight at room temperature, concentrate under reduced pressure, and purify the residue by silica gel column chromatography to obtain compound 54-2 (110 mg) as a yellow viscous substance. m / z [M+H] + =405.

[1120] Step 3: Add 1 mL of trifluoroacetic acid to a solution of compound 54-2 (80 mg, 0.198 mmol) in dichloromethane (1 mL). After stirring the reaction solution at room temperature for 1 hour, concentrate under reduced pressure to obtain compound 54-3 (crude product, 60 mg), m / z [M+H]. + =331.

[1121] Step 4: Compound 2-1 (60 mg, 0.217 mmol) was added to a mixed solution of compound 54-3 (60 mg, 0.182 mmol) in dichloromethane (2 mL) and methanol (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, and then sodium cyanoborohydride (28 mg, 0.44 mmol) was added. The reaction mixture was stirred at room temperature for another 48 hours, then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 54-4 (80 mg) as a yellow oil, m / z [M+H]. + =592.

[1122] Step 5: Potassium carbonate (500 mg, 3.6 mmol) was added to a methanol / water (7 mL / 3 mL) solution of compound 54-4 (80 mg, 0.135 mmol). The reaction mixture was stirred at room temperature for 6 hours. Extraction was performed twice with ethyl acetate, followed by concentration under reduced pressure. The residue was purified by prep-HPLC to give compound T-54 (7.71 mg) as a white solid, m / z [M+H]. +=496. H NMR (400MHz, DMSO-d6): δ11.72(s,1H),10.79(s,1H),8.37(d,J=12.6Hz,1H),7.84(d,J=9.5Hz,1H),7.47–7.34(m,1H),7 .24–7.09(m,1H),6.53(d,J=9.4Hz,1H),4.88(s,2H),4.64(s,2H),4.24(s,2H),3.84(s,3H),3.67–3.38(m,4H),2.94(br 2H).

[1123] Example 50: 6-(2-(2-((8-methyl-7-oxo-7,8-dihydro-1,8-naphthidin-2-yl)amino)ethyl)-6-oxo-5-oxa-2,7-diazaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-55)

[1124] Step 1: A mixture of compound 2-1 (270 mg, 0.97 mmol) and N-Boc-2-aminoacetaldehyde (300 mg, 1.89 mmol) in methanol (1 mL) and dichloromethane (5 mL) was stirred at room temperature for 10 minutes. Sodium cyanoborohydride (185 mg, 2.93 mmol) was added, and the reaction mixture was stirred at room temperature for another 6 hours. The mixture was then concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give compound 55-1 (200 mg) as a white solid, m / z [M+H]. + =421.

[1125] Step 2: Add 2 mL of trifluoroacetic acid to a 200 mg (0.48 mmol) solution of compound 55-1 in dichloromethane (2 mL). Stir the reaction mixture at room temperature for 40 minutes, concentrate under reduced pressure, neutralize the residue with sodium bicarbonate solution, extract with ethyl acetate, combine the organic phases, and concentrate under reduced pressure to obtain compound 55-2 (crude product, 170 mg). m / z [M+H] + =321.

[1126] Step 3: Diisopropylethylamine (0.2 mL, 1.15 mmol) was added to a solution of compounds 55-2 (200 mg, 0.62 mmol) and 49-4 (120 mg, 0.62 mmol) in dimethyl sulfoxide (2.5 mL). The reaction mixture was stirred at 140 °C for 30 minutes under microwave conditions. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The solution was concentrated under reduced pressure with an organic solvent. The residue was purified by silica gel column chromatography and then purified by prep-HPLC to obtain compound T-55 (9.42 mg) as a white solid. m / z [M+H] + =479;1 H NMR (400MHz, DMSO-d6): δ11.67(s,1H),8.35(s,1H),7.71-7.66(m,2H),7.51(s,1H),6.43(d,J=8.5Hz,1H),6. 25(d,J=9.2Hz,1H),4.87(s,2H),4.42(s,2H),4.24(s,2H),3.61(s,3H),3.52-3.44(m,4H),3.16-3.09(m,2H).

[1127] Example 51: 6-(2-(2-((3-fluoro-8-methyl-7-oxo-7,8-dihydro-1,8-naphthidin-2-yl)amino)ethyl)-6-oxo-5-oxa-2,7-azaspiro[3.4]oct-7-yl)-2H-pyrazino[2,3-b][1,4]oxazin-3(4H)-one (T-56)

[1128] Step 1: A methylamine ethanol solution (35 mL, 33% wt) of compound 56-1 (11 g, 52.6 mmol) was stirred at 100 °C for 18 hours in a sealed tube. The reaction solution was concentrated under reduced pressure, and the crude product was used directly for the next step, m / z [M+H]. + =205.

[1129] Step 2: Borane dimethyl sulfide solution (10 mL, 100 mmol) was slowly added to a tetrahydrofuran (30 mL) solution of compound 56-2 (6.6 g, 32.3 mmol). The reaction mixture was stirred at 70 °C for 80 minutes. The mixture was then quenched with methanol slowly at 0 °C, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 56-3 (4.3 g) as a yellow viscous liquid, m / z [M+H]. + =191.

[1130] Step 3: Under ice bath conditions, DMP (19.2 g, 45.3 mmol) was added to a dichloromethane (100 mL) solution of compound 56-3 (4.3 g, 22.6 mmol), and the mixture was stirred at room temperature for 1 hour. The mixture was then quenched with sodium sulfite solution, extracted with dichloromethane, concentrated the organic phase, and purified by silica gel column chromatography to obtain compound 56-4 (1.2 g) as a yellow solid, m / z [M+H]. + =189.

[1131] Steps 4-5: At -78°C, add n-butyllithium (4.5 mL, 11.25 mmol) to a tetrahydrofuran (15 mL) solution of diisopropylamine (1.1 g, 11.2 mmol). Stir for 5 minutes, then slowly add a tetrahydrofuran (10 mL) solution of tert-butyl acetate (1.23 g, 10.6 mmol). Maintain at -78°C and stir for 10 minutes, then slowly add a tetrahydrofuran (10 mL) solution of compound 56-4 (1.0 g, 5.3 mmol). After the addition is complete, bring to room temperature and stir for 1 hour. The reaction was quenched by adding ammonium chloride aqueous solution. The aqueous phase was extracted with ethyl acetate, and the organic phases were combined and concentrated under reduced pressure. The residue was dissolved in 1,4-dioxane (10 mL), and 2N HCl (10 mL) was added. The mixture was stirred at 100 °C for 5 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography to give compound 56-6 (190 mg) as a yellow solid, m / z [M+H]. + =213.

[1132] Step Six: Diisopropylethylamine (0.4 mL, 2.3 mmol) was added to a dimethyl sulfoxide (DMSO) solution of compounds 55-2 (325 mg, 1.02 mmol) and 56-6 (80 mg, 0.38 mmol) (2.5 mL). The reaction mixture was stirred at 140 °C for 40 minutes under microwave conditions. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, followed by prep-HPLC purification to obtain compound T-55 (23.7 mg) as a white solid. m / z [M+H] + =497; 1 H NMR (400MHz, DMSO-d6): δ11.70(s,1H),8.35(s,1H),7.76(d,J=10.9Hz,1H),7.69-7.64(m,2 H), 6.35 (d, J = 9.3Hz, 1H), 4.88 (s, 2H), 4.43-4.07 (m, 6H), 3.51 (br, 5H), 3.42-3.44 (m, 2H).

[1133] Example 52: Synthesis of T-5

[1134] Using 5-3 and 35-9 as raw materials, compound T-5 was obtained as a white solid using the same method as in Example 1. HPLC retention time: 24.097 minutes.

[1135] Example 53: Synthesis of T-6

[1136] Compound T-6 was obtained as a white solid using 5-3 and 35-9-2 as raw materials, following the same method as in Example 1. HPLC retention time: 24.824 min; m / z [M+H] + =481.

[1137] The T-6 crystal structure was subjected to X-ray single-crystal testing. The testing method was as follows:

[1138] 1. Add T-6 (200 mg) to a mixed solution of dichloromethane and methanol (10 mL, volume ratio 1:1), heat to 30 °C and stir until basically dissolved, filter, put the filtrate into a vial, seal with sealing film, let stand, crystals precipitate, collect single crystals for single crystal diffraction test.

[1139] 2. The test parameters are shown in Table 1 below:

[1140] Table 1

[1141] Test results: The configuration of compound T-6 is as follows: (that is, the above) )

[1142] Biological Example:

[1143] Example 1: Minimum inhibitory concentration (MIC) test for Mycoplasma pneumoniae

[1144] The test compound was dissolved in dimethyl sulfoxide to prepare a high-concentration stock solution, which was used on the same day or stored at -20°C. On the day of testing, the stock solution was serially diluted 2-fold to prepare a working solution of the compound at a final test concentration of 100×, and 2 μL was transferred to a 96-well plate to obtain the compound test plate.

[1145] Glyceryl-dehydrated Mycoplasma pneumoniae (ATCC 15531) was inoculated into ATCC Medium 2611 liquid medium and grown until the medium color changed. The culture was then aliquoted and stored at -80°C. CFU counts were performed on the frozen culture using the plate count method to confirm the Mycoplasma pneumoniae concentration. On the day of the experiment, the frozen culture was thawed and diluted to the target bacterial concentration using preheated SP4 test medium (10⁻⁶). 4 -10 5 The inoculum was prepared by aerobic incubation at 37°C for 2 hours (CFU / ml). Then, 198 μL of the inoculum was added to test plates containing 2 μL of a 2-fold serially diluted compound, and the plates were incubated at 37°C for 4 days. The minimum inhibitory concentration (MIC) was determined based on the color change of the culture medium. The results are shown in Table 2.

[1146] Table 2

[1147] The compounds of this invention have good inhibitory activity against Mycoplasma pneumoniae.

[1148] Example 2: Minimum Inhibitory Concentration (MIC) Test for Streptococcus pneumoniae and Haemophilus influenzae

[1149] Dissolve the test compound in dimethyl sulfoxide to prepare a high-concentration stock solution, which can be used on the same day or stored at -20°C. On the day of testing, serially dilute the stock solution of the compound by 2-fold to prepare a working solution of the compound at a final test concentration of 100×, and transfer 1 μL to a 96-well plate. Obtain the compound test plate.

[1150] Cryopreserved bacteria at -80℃ were inoculated onto solid agar plates (Streptococcus pneumoniae ATCC49619: blood agar, Haemophilus influenzae ATCC49247: chocolate agar) and incubated at 35±2℃, 5% CO2 for 20 hours. On the day of testing, single colonies from the plates were picked and dissolved in sterile physiological saline to prepare a 0.5% McFarland bacterial suspension. The bacterial suspension was then diluted 200-fold in the test medium (Streptococcus pneumoniae ATCC49619: MHIIB + 5% lysed horse blood; Haemophilus influenzae ATCC49247: HTM medium) to obtain an inoculum solution (~5×10⁻⁶). 5 (CFU / mL). 99 μL of inoculum was added to the prepared compound test plate. For *Streptococcus pneumoniae*, the test plate was incubated at 35±2℃ for approximately 20 hours; for *Haemophilus influenzae*, the test plate was incubated at 35±2℃ with 5% CO2 for approximately 20 hours. After incubation, the minimum inhibitory concentration (MIC) of the compound was visually determined. The results are shown in Table 3, where A indicates MIC < 0.016 μg / mL, B indicates 0.016 μg / mL ≤ MIC ≤ 0.03 μg / mL, and C indicates MIC > 0.03 μg / mL.

[1151] Table 3

[1152] The compounds of this invention have good inhibitory activity against Gram-positive bacteria (e.g., Streptococcus pneumoniae) and Gram-negative bacteria (e.g., Haemophilus influenzae).

[1153] Example 3: Minimum inhibitory concentration (MIC) test for Staphylococcus aureus, Streptococcus pyogenes, and Staphylococcus epidermidis

[1154] Dissolve the test compound in dimethyl sulfoxide to prepare a high-concentration stock solution, which can be used on the same day or stored at -20°C. On the day of testing, serially dilute the stock solution of the compound by 2-fold to prepare a working solution of the compound at a final test concentration of 100×, and transfer 1 μL to a 96-well plate. Obtain the compound test plate.

[1155] Cryopreserved bacteria at -80℃ were inoculated onto solid agar plates (Staphylococcus aureus ATCC29213 and Staphylococcus epidermidis ATCC35984: Miller-Shinton agar, 35±2℃; Streptococcus pyogenes ATCC700942: blood agar, 35±2℃, 5% CO2) and incubated for 20 hours. On the day of testing, single colonies from the plates were picked and dissolved in sterile physiological saline to prepare a high-concentration bacterial suspension. The bacterial suspension was then diluted to the specified inoculum concentration (~5×10⁻⁶) in the test medium (Staphylococcus aureus ATCC29213 and Staphylococcus epidermidis ATCC35984: calcium-magnesium ion-regulated Miller-Shinton broth; Streptococcus pyogenes ATCC700942: calcium-magnesium ion-regulated Miller-Shinton broth + 5% lysed horse blood). 5 (CFU / mL). Add 99 μL of inoculum to the prepared compound test plate. For Staphylococcus aureus and Staphylococcus epidermidis, incubate the test plate at 35±2℃ for approximately 20 hours; for Streptococcus pyogenes, incubate the test plate at 35±2℃ with 5% CO2 for approximately 20 hours. After incubation, visually read the minimum inhibitory concentration (MIC) of the compound for bacterial growth.

[1156] Table 4

[1157] The compounds of this invention exhibit good inhibitory activity against Gram-positive bacteria (e.g., Staphylococcus aureus, Streptococcus pyogenes, and Staphylococcus epidermidis).

[1158] Example 4: Acetylcholinesterase (AChE) enzyme activity inhibition experiment

[1159] The Absorbance (Abs) method was used to test the inhibitory effect of compounds on AChE enzyme activity. This method uses acetylthiocholine (ATC) as a specific substrate and assesses enzyme activity by utilizing the specific hydrolysis of ATC by AChE: AChE catalyzes the hydrolysis of ATC to generate thiocholine (TCh). TCh then undergoes a characteristic reaction with the chromogenic agent 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) to generate 2-nitro-5-mercaptobenzoic acid (TNB), which has a strong characteristic absorption peak at 405 nm. 2- The catalytic activity of AChE was reflected by monitoring the change in absorbance of the reaction system at 405 nm using an enzyme-linked immunosorbent assay (ELISA) reader, thereby evaluating the inhibitory effect of the test compound on AChE enzyme.

[1160] Solutions of AChE (Acro, Cat: AHE-H52H3), ATC (Sigma, Cat: A5626-1G), and DTNB (Sigma, Cat: D8130-1G) were prepared in reaction buffer (0.1M Sodium Phosphate, 0.05% Brij35, pH 7.5). The final concentrations of AChE, ATC, and DTNB were 0.015 nM, 300 μM, and 100 μM, respectively. The positive control, Donepezil, was prepared at a detection concentration of 10 μM, diluted 3-fold, for 10 doses. The test compounds were vortexed thoroughly to obtain a 100-fold dilution to the detection concentration, followed by a 3-fold serial dilution to obtain 10 different concentrations. This part of the reaction was performed in dilution source plates. 0.1 μL of the compound diluted in 100% DMSO from the Source plate was transferred to a 384-well plate (Corning 3701) using acoustic liquid delivery technology (Echo 655). The plate was centrifuged at 1000 rpm for 1 minute to achieve a final DMSO concentration of 1%. 10 μL of AChE enzyme solution was then transferred to the 384-well plate and centrifuged at 1000 rpm for 1 minute, followed by incubation at 25°C for 15 minutes. 10 μL of a mixed solution of ATC and DTNB was then transferred to the 384-well plate and centrifuged at 1000 rpm for 1 minute, followed by incubation at 25°C for 90 minutes. Finally, the Abs405 signal was read using BMG (CLARIOstar Plus). The IC was obtained using GraphPad Prism software. 50 Values. The results are shown in Table 5.

[1161] Table 5

[1162] The compounds of this invention have very weak inhibitory activity against acetylcholinesterase and exhibit better selectivity.

[1163] Example 5: Liver microsomal metabolic stability test

[1164] The analyte was dissolved in dimethyl sulfoxide to prepare a 10 mM stock solution. 2 μL of the 10 mM stock solution was added to 198 μL of 50% acetonitrile (ACN) to prepare a 0.1 mM secondary stock solution. 200 μL of ACN-IS (acetonitrile solution containing internal standard) was added to the deep-well plate and stored at 2–8 °C for later use. NADPH was dissolved in phosphate buffer (pH = 7.4) to prepare a 5 mM NADPH solution.

[1165] Add 5 μL (20 mg / mL) of human liver microsomes to 153 μL of phosphate buffer to prepare a 0.63 mg / mL liver microsome solution. Take 158 μL of the liver microsome solution and add 2 μL of positive control (Verapamil) or the working solution of the test compound (0.1 mM), and mix thoroughly by inverting. Place the reaction system in a 37°C water bath and incubate with shaking at 100–200 rpm for 5 minutes.

[1166] Sample at 0 min: Add 24 μL of the reaction mixture to the precipitant, then add 6 μL of NADPH solution. Samples at other time points: Directly add 34 μL of NADPH solution to start the reaction and mix well. At 5, 15, 30, and 60 min, add 30 μL of the reaction mixture to 200 μL of ACN-IS to terminate the reaction and vortex mix well.

[1167] The reacted sample was centrifuged at 4℃ and 4000 rpm for 10 minutes. 50 μL of the supernatant was added to 150 μL of an aqueous solution containing 0.1% formic acid, vortexed, and then analyzed by LC-MS / MS. The LC-MS / MS responses of the samples at each time point were obtained, and the residual rate of the original sample at each time point relative to the 0 min time point was calculated. The logarithm of the residual rate was plotted against the incubation time to calculate the elimination half-life T. 1 / 2 The results are shown in Table 6.

[1168] Table 6

[1169] The compounds of this invention exhibit good stability in human liver microsomal metabolism.

[1170] Example 6: Detection of inhibitory activity of human cardiac potassium channels (hERG)

[1171] HEK-293 cell line stably expressing hERG potassium channels was used. hERG potassium channel cells were purchased from Creacell (catalog number: A-0320).

[1172] Cell culture and passage:

[1173] 1) Cell culture: HEK-293 cell line stably expressing hERG potassium channels was cultured in DMEM medium containing 10% fetal bovine serum and 0.8 mg / mL G418 at 37°C and 5% carbon dioxide.

[1174] 2) Cell passage: Remove the old culture medium and wash once with PBS, then add 1 mL TrypLE TMIncubate with Express solution at 37°C for approximately 0.5 min. Once cells detach from the bottom of the dish, add approximately 5 mL of preheated (37°C) complete culture medium. Gently pipette the cell suspension to separate any aggregated cells. Transfer the cell suspension to sterile centrifuge tubes and centrifuge at 1000 rpm for 5 min to collect the cells. For expansion or maintenance culture, seed cells into 6 cm cell culture dishes at a density of 2.5 × 10⁶ cells per dish. 5 Cells (final volume: 5 mL). To maintain the electrophysiological activity of the cells, the cell density must not exceed 80%.

[1175] Compound administration and patch-clamp assay: Cells were separated using TrypLE™ Express before the experiment, and 4 × 10⁶ cells were administered. 3 Cells were seeded onto coverslips and cultured in 24-well plates (final volume: 500 μL). After 18 hours, the cells were tested.

[1176] Once the hERG current recorded in whole cells stabilized, drug administration began. Each drug concentration was administered for 5 minutes (or until the current stabilized) before moving on to the next compound. One concentration was measured for each test compound. A coverslip containing cells was placed in the recording bath of an inverted microscope. The working solution of the test compound and the external solution without the compound were administered sequentially from low to high concentration through the recording bath using gravity perfusion, while a peristaltic pump was used for fluid replacement during recording. The current detected in the external solution without the compound for each cell served as its control group.

[1177] The voltage stimulation protocol for whole-cell patch-clamp recording of hERG potassium currents is as follows: After whole-cell sealing, the cell membrane voltage is clamped at -80 mV. The clamping voltage is depolarized from -80 mV to -50 mV and maintained for 0.5 s (as a leakage current detection), then stepped to 30 mV and maintained for 2.5 s, and then rapidly restored to -50 mV and maintained for 4 s to excite the tail current of the hERG channel. Data is collected every 10 s to observe the effect of the drug on the hERG tail current. A 0.5 s stimulation at -50 mV is used as a leakage current detection.

[1178] Data Analysis: Experimental data were acquired by the EPC 10 amplifier and stored in PatchMaster software.

[1179] First, the peak tail current (Peak tail current compound) and the peak tail current (Peak tail current control) after each drug concentration were normalized (Peak tail current compound / Peak tail current control). Then, the inhibition rate % corresponding to the drug concentration was calculated as (1 - (Peak tail current compound / Peak tail current control) * 100). The results are shown in Table 7.

[1180] Table 7

[1181] The compound of this invention exhibits minimal inhibitory effect on potassium ion channels in the human heart at a concentration of 10 μM, demonstrating high cardiac safety.

[1182] Example 7: In vivo efficacy experiment of Streptococcus pneumoniae in mice

[1183] 1. Experimental objective: To establish a mouse model of pneumonia caused by Streptococcus pneumoniae (Sp) infection and to evaluate the efficacy of the tested compounds.

[1184] 2. Experimental animals: 6-8 week old SPF grade ICR mice (female) were purchased from Shanghai Jihui Biotechnology Co., Ltd.

[1185] 3. Experimental methods:

[1186] 1) Preparation of the test substance:

[1187] Solvent group:

[1188] DMA (dimethylacetamide): PEG400: propylene glycol: pure water = 1:4:4:1 (V:V)

[1189] Test compound:

[1190] Weigh the drug to be tested, add 10% DMA, heat in a 40-50℃ water bath until completely clear, slowly add 40% PEG400 and shake well, then slowly add 40% propylene glycol and shake well, and finally add 10% pure water and shake well.

[1191] 2) Animal grouping

[1192] The experimental animals were randomly divided into four groups according to their body weight: G1-model control 2h group, G2-solvent 48h group, G3-T-7 20mpk group, and G4-T-7 60mpk group, with five animals in each group.

[1193] 3) Establishment and administration of a mouse model of Streptococcus pneumoniae infection

[1194] On the day of the experiment, mice were infected with Streptococcus pneumoniae (Sp) ATCC6301 via nasal drops. The target dose was 5.0E+06 cfu / mouse, and the volume was 50 μL.

[1195] Model control group 2h: Lung tissue was taken 2 hours after infection for bacterial load measurement.

[1196] Other groups: Day 0-1: 2 hours after infection, mice were given solvent or test compound according to the plan in Table 8, with a volume of 10 mL / kg; lung tissue was taken for bacterial load determination 48 hours after infection.

[1197] Table 8 Note: Three times a day (tid), orally (po)

[1198] Experimental data are expressed as mean ± standard error (Mean ± SEM). One-way ANOVA (Dunnett's multiple comparison test) was used for statistical analysis to evaluate the differences between each drug administration group and the model 48h group. **** indicates P < 0.0001.

[1199] 4) Experimental results: As shown in Table 9, T-7 can inhibit the CFU of Streptococcus pneumoniae in mice in a dose-dependent manner.

[1200] Table 9

[1201] Example 8: In vivo efficacy experiment of Streptococcus pneumoniae in rats

[1202] 1. Experimental objective: To establish a rat model of pneumonia caused by Streptococcus pneumoniae (Sp) infection and to evaluate the efficacy of the test compound.

[1203] 2. Experimental animals: 6-8 week old SPF grade male SD rats were purchased from Shanghai Jihui Biotechnology Co., Ltd. and housed in an ABSL-2 grade laboratory with a relative humidity of 40-70% and a temperature of 20-26℃. The room was kept under alternating light and dark conditions for 12 hours. All animals had free access to food and water. The experiment began after 1 week of acclimatization.

[1204] 3. Test methods:

[1205] 1) Preparation of the test substance:

[1206] Weigh 60 mg of the compound, add 30 ml of 40% SBECD (pH = 1.5), heat and stir until the compound is completely dissolved, then add 90 ml of ddH2O, and adjust the pH to 4.3 with 1 M NaOH. The final drug concentration is 0.5 mg / ml.

[1207] Preparation of 0.5% CMC-Na solution: Weigh 0.5g of sodium carboxymethyl cellulose (CMC-Na) powder, add ultrapure water, and allow it to fully swell into a transparent, uniform, bubble-free colloidal solution with a final volume of 100ml.

[1208] Levofloxacin solution (50mg / kg): Take levofloxacin tablets, grind them into powder, add them to 0.5% CMC-Na solution while stirring to ensure thorough and uniform dispersion, and prepare a suspension with a concentration of 5mg / ml. Prepare fresh for use daily.

[1209] 2) Animal grouping

[1210] The experimental animals were randomly divided into 6 groups according to their body weight: G1-model control 2h group, G2-solvent 72h group, G3-positive drug (levofloxacin) group, G4-T-3 group, G5-T-6 group, and G6-T-50 group, with 6 animals in each group, for a total of 36 animals.

[1211] 3) Establishment and administration of a rat model of Streptococcus pneumoniae infection

[1212] Experimental rats were anesthetized with 3%–5% isoflurane inhalation and fixed in a supine position on a multi-functional control panel. 200 μl of Streptococcus pneumoniae (1 × 10⁻⁶) was administered intratracheally. 9 (CFU / ml).

[1213] The experimental rats were given the drug 2 hours after inoculation, and the drug was administered twice a day for 3 consecutive days. For details of the administration regimen, please refer to Table 10.

[1214] Table 10

[1215] During the experiment, the health status of the rats was observed daily, and their weight and survival status before and after modeling were recorded.

[1216] In the model control group (2h), lung tissue was taken 2h after bacterial inoculation. In the other groups, lung tissue was taken 3 days after administration for CFU counting.

[1217] Experimental data are expressed as mean ± standard error (Mean ± SEM). One-way ANOVA (Dunnett's multiple comparison test) was used for statistical analysis to assess the differences between each treatment group and the model group. **** indicates P < 0.0001.

[1218] 4) Test Results

[1219] The experimental results are shown in Table 11. The compound of the present invention at 5 mg / kg can strongly inhibit Streptococcus pneumoniae, and its efficacy is comparable to that of levofloxacin at 50 mg / kg.

[1220] Table 11 Note: Ref. A in the above biological examples refers to compound 15 disclosed in WO2018225097A1. The generic name is BWC0977, and it is currently in Phase I clinical trials.

Claims

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X and Y are each independently N or CH; X1is N or CR7; X, X1and Y are not simultaneously CH; U is CH2, O or S; V is CH2, O or NH; Z is CH2or C(O); L1is -(CR1R2) x -; x is 1, 2, 3 or 4; L2is -(CR3R4) y -; y is 0, 1, 2, 3, or 4; L3is -L-(W) m -; m is 0, 1 or 2; W is C 2-6 alkylene, C 2-6 alkynylene, C 3-8 cycloalkylene or 4-8 membered heterocycloalkylene; each of said C 2-6 alkylene, C 2-6 alkynylene, C 3-8 cycloalkylene and 4-8 membered heterocycloalkylene is independently optionally substituted at any position with one or more R5. L is a bond, O, S or NR6; R and R6are each independently hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, 4-8 membered heterocyclyl, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, C 1-6 alkyl, C 1-6 alkyl or C 1-6 alkoxy; R', R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen, hydroxyl, amino, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogenated C 1-6 alkyl, hydroxyl C 1-6 alkyl, amino C 1-6 alkyl or C 1-6 alkoxy; or, R1and R2together with the carbon atom to which they are both attached form a 4-8 membered heterocyclic ring or C 3-8 carbocycle; or, R and R' together with the atoms between them form a 4-8 membered heterocyclic ring; or, R and one of R1together with the atoms between them form a 4-8 membered heterocyclic ring; or, R' and one of R1together with the atoms between them form a 4-8 membered heterocyclic ring or C 3-8 carbocycle; or, R and one of R3together with the atoms between them form a 4-8 membered heterocyclic ring; said 4-8 membered heterocyclic ring and C 3-8 each R5is independently selected from the group consisting of halo, -OR, -SR, -N(R)2, -CN, -C(O)R, -C(O)OR, -C(O)N(R)2, -S(O)R, -S(O)2R, -S(O)2N(R)2, -N(R)C(O)R, -N(R)S(O)2R, -OC(O)N(R)2, -N(R)C(O)N(R)2, -N(R)C(O)OR, -OC(O)R, -N3, -NO2, -ORa, -SRa, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)N(Ra)2, R5are each independently deuterium, halogen, hydroxyl, amino, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogenated C 1-6 alkyl, hydroxyl C 1- 6alkyl, amino C 1-6 alkyl or C 1-6 alkoxy; R7is hydrogen, halogen or C 1-6 alkyl; M is selected from the group consisting of: A ring is a phenyl ring or a 5-6 membered heteroaromatic ring; B ring and C ring are each independently a phenyl ring, a 5-6 membered heteroaromatic ring, a 4-8 membered heterocyclic ring, C 3-4 carbocyclic or C 6-8 carbocyclic; B' and C' are each independently a phenyl ring, a 5-6 membered heteroaromatic ring, a 4-8 membered heterocyclic ring, or C 3-8 carbocyclic; R a R b and R c Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, hydroxyl, mercapto, amino, cyano, oxo, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, C 6-10 Aryl C 1-6 Alkyl, 5-10-membered heteroaryl C 1-6 Alkyl, -N(R) e )2、-OR e -SO2R e -C(O)R e -C(O)OR e -C(O)N(R) e )2、-OC(O)R e -NR f C(O)R e or -NR f C(O)N(R e )2; wherein, the C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, C 6-10 Aryl C 1-6 Alkyl and 5-10 heteroaryl C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replace in any position; R d each independently is optionally deuterium, halogen, cyano, C 1-6 alkyl, haloC 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, oxo, -N(R e )2, -OR e , -SO2R e , -C(O)R e , -C(O)OR e , -C(O)N(R e )2, -OC(O)R e , -NR f C(O)R e , or -NR f C(O)N(R e )2; R e each independently hydrogen, C 1-6 alkyl, phenyl, 5-6 membered heteroaryl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 3-8 cycloalkyl C 1- 6alkyl or 3-8 membered heterocyclyl C 1-6 alkyl; wherein the C 1-6 alkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 3-8 cycloalkyl C 1-6 alkyl and 3-8 membered heterocyclyl C 1-6 each independently optionally substituted with 1-3 selected from halo, hydroxyl, amino, cyano, carboxyl, oxo, C 1-6 alkyl, halo C 1-6 alkyl, halo C 1-6 alkoxy, C 1-6 alkoxy, C 1-6 alkylamino, hydroxyl C 1-6 alkyl or amino C 1-6 substituted at any position with alkyl; R f each independently is hydrogen or C 1-6 alkyl; n, v and u are each independently optionally 0, 1, 2, 3, 4, 5 or 6; and the compound of formula (I) satisfies any one of the following conditions: 1) R and R' and the atoms therebetween together form a 4-8 membered heterocycle; or R and one of R1 and the atoms therebetween together form a 4-8 membered heterocycle; or R' and one of R1 and the atoms therebetween together form a 4-8 membered heterocycle or a carbocycle; 3-8 the 4-8 membered heterocycle and the carbocycle; 3-8 each R5 is independently selected from the group consisting of halo, -ORa, -CN, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)N(Ra)2, -NRaC(O)Ra, -NRaC(O)N(Ra)2, -NRaC(O)ORa, -OC(O)Ra, -OC(O)N(Ra)2, -SRa, -S(O)Ra, -S(O)2Ra, -S(O)2N(Ra)2, -N(Ra)S(O 2) m is 1, W is C 3-8 cycloalkylene; 3) m is 1, W is 4-8 membered heterocycloalkylene, X is N, Y is N; 4) R and one of R3together with the atoms therebetween form a 4-8 membered heterocyclic ring, X is N, Y is N; said 4-8 membered heterocyclic ring is optionally substituted at any position with one or more R5; 5) R1and R2together with the carbon atom to which they are both attached form a 4-8 membered heterocyclic ring or C 3-8 carbocyclic ring.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein which satisfies one or more of the following conditions: (1) X is N; (2) Y is N; (3) X1is CR7; (4) U is O or S, preferably O; (5) V is O or NH, preferably NH; (6) Z is C(O); (7) L1is -(CR1R2) x -; x is 1, 2 or 3, preferably 1 or 2; (8) L2is -(CR3R4) y -; y is 0, 1, 2 or 3, preferably 0, 1 or 2; (9) L3is -L-(W) m -; m is 0 or 1; (10) W is C 3-8 cycloalkylene or 4-8 membered heterocycloalkylene, preferably C 3-8 monocycloalkylene or 4-8 membered monocycloheteroalkylene, further preferably C 3-6 monocycloalkylene or 4-6 membered monocycloheteroalkylene, more preferably C 3-4 monocycloalkylene or 4-5 membered monocycloheteroalkylene, most preferably C3monocycloalkylene or 4 membered monocycloheteroalkylene; said C 3-8 cycloalkylene (preferably C 3- 8monocycloalkylene, further preferably C 3-6 monocycloalkylene, more preferably C 3-4 monocycloalkylene, most preferably C3monocycloalkylene) and 4-8 membered heterocycloalkylene (preferably 4-8 membered monocycloheteroalkylene, further preferably 4-6 membered monocycloheteroalkylene, more preferably 4-5 membered monocycloheteroalkylene, most preferably 4 membered monocycloheteroalkylene) are each independently optionally substituted at any position with one or more R5; (11) L is a bond, O or NR6, preferably a bond or O, more preferably a bond; (12) R and R6are each independently hydrogen, C 1-6 alkyl or C 3-8 cycloalkyl; (13) R is hydrogen, C 1-6 alkyl or C 3-6 cycloalkyl, preferably hydrogen; (14) R6is hydrogen or C 1-6 alkyl, preferably hydrogen; (15) R', R1, R2, R3and R4are each independently hydrogen, deuterium, halogen, hydroxyl, amino, C 1-6 alkyl, hydroxyl C 1-6 alkyl or amino C 1-6 alkyl, preferably hydrogen, deuterium, halogen, hydroxyl, amino or C 1-6 alkyl; (16) R' is H; (17) R1is hydrogen, deuterium, halogen or C 1-6 alkyl, preferably hydrogen; (18) R2is hydrogen, deuterium, halogen or C 1-6 alkyl, preferably hydrogen; (19) R3is hydrogen, deuterium, halogen or C 1-6 alkyl, preferably hydrogen; (20) R4is hydrogen, deuterium, halogen or C 1-3 alkyl, preferably hydrogen; (21 ) R1and R2, together with the carbon atom to which they are both attached, form a 4-8 membered heterocyclic ring (preferably a 4-8 membered monocyclic heterocyclic ring, further preferably a 4-6 membered monocyclic heterocyclic ring) or C 3-8 carbocyclic ring (preferably a C 3-8 monocyclic carbocyclic ring, further preferably a C 3-6 monocyclic carbocyclic ring); said 4-8 membered heterocyclic ring (preferably a 4-8 membered monocyclic heterocyclic ring, further preferably a 4-6 membered monocyclic heterocyclic ring) comprises 1-2 heteroatoms or heteroatom groups selected from one or more of N, NH, S and O; and said 4-8 membered heterocyclic ring (preferably a 4-8 membered monocyclic heterocyclic ring, further preferably a 4-6 membered monocyclic heterocyclic ring) and C 3-8 carbocyclic ring (preferably a C 3-8 monocyclic carbocyclic ring, further preferably a C 3-6 monocyclic carbocyclic ring) are each independently optionally substituted at any position with one or more R5; (22) R and R' together with the atoms therebetween form a 4-8 membered heterocyclic ring (preferably a 4-8 membered monocyclic heterocyclic ring, more preferably a 4-6 membered monocyclic heterocyclic ring); said 4-8 membered heterocyclic ring (preferably a 4-8 member monocyclic heterocyclic ring, more preferably a 4-6 membered monocyclic heteroaromatic ring) is optionally substituted at any position with one or more R5; (23) R and one of R1together with the atoms therebetween form a 4-8 membered heterocyclic ring (preferabl a 4-8 membered monocyclic heterocyclic ring, more preferably a 4- (24) R' and one of R1and the atoms between them together form a 4-8 membered heterocyclic ring (preferably a 4-8 membered monocyclic heterocyclic ring, further preferably a 4-6 membered monocyclic heterocyclic ring) or C 3-8 carbocyclic (preferably C 3-8 monocyclic carbocyclic, further preferably C 3-6 monocyclic carbocyclic); each of said 4-8 membered heterocyclic ring (preferably a 4-8 membered monocyclic heterocyclic ring, further preferably a 4-6 membered monocyclic heterocyclic ring) and C 3-8 carbocyclic (preferably C 3-8 monocyclic carbocyclic, further preferably C 3-6 monocyclic carbocyclic) is independently optionally substituted at any position with one or more R5. (25) R' and one of R1and the atoms between them together form C 3-8 carbocyclic (preferably C 3-8 monocyclic carbocyclic, further preferably C 3-6 monocyclic carbocyclic); said C 3-8 carbocyclic (preferably C 3-8 monocyclic carbocyclic, further preferably C 3-6 monocyclic carbocyclic) is optionally substituted at any position by one or more R5; (26) R and one of R3together with the atoms therebetween form a 4- 8 membered heterocyclic ring (preferably a 4-8 membered monocyclic (27) R5is deuterium, halogen, hydroxyl, amino, or C 1-6 alkyl; (28) R7is H, F, Cl or -CH3, preferably H or F, for example H; (29) M is selected from the following groups: Preferably (preferably ); (30) A ring is a phenyl ring; (31) B ring and C ring are each independently a phenyl ring, a 5-6 membered heteroaromatic ring or a 4-8 membered heterocyclic ring (preferably a 4-8 (32) each B' ring and C' ring is independently a 4-8 membered heterocycle (preferably a 4-8 membered monocyclic heterocycle) or C 3-8 carbocycle (preferably a C 3-8 monocyclic carbocycle); (33)R a R b and R c Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, hydroxyl, amino, cyano, oxo, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, -N(R) e )2、-OR e -C(O)R e -C(O)OR e or -C(O)N(R) e )2 (preferably each independently is C) 1-6 Alkyl, C 1-6 Alkyl, halogen, hydroxyl, cyano, or oxo group; more preferably, each independently has a C group. 1-6 Alkyl, halogen, hydroxyl or oxo group), wherein the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replacement at any position; preferably, R a R b and R c Each independently is C 1-6 Alkyl, C 1-6 Alkyl, halogen, hydroxyl, cyano, or oxo group; more preferably, R a R b and R c Each independently is C 1- 6. Alkyl, halogen, hydroxyl, or oxo group; (34)R a (35)R b (36)R c , wherein the C 1-6 1-6C-alkyl, C 3-8 3-8C-cycloalkyl, 3-8C-heterocyclyl, C 3-8 3-8C-cycloalkyl-C 1-6 1-6C-alkyl and 3-8C-heterocyclyl-C 1-6 1-6C-alkyl are each independently optionally substituted with 1-3 R d at any position; (35)R a each independently C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 2-6 alkenyl, C 2- alkynyl, halogen, hydroxyl, amino, cyano, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, C 3-8 cycloalkyl, C 1-6 alkyl, 3-8 membered heterocyclyl, C 1-6 alkyl, -N(R e )2, -OR e , -C(O)R e , -C(O)OR e , or -C(O)N(R e )2, preferably each independently C 1-6 alkyl, C 1-6 alkoxy, halogen, or cyano, for example halogen, more preferably each independently C 1-6 alkoxy, wherein said C 1-6 alkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 3-8 cycloalkyl, C 1-6 alkyl, and 3-8 membered heterocyclyl, each independently optionally substituted with one or more R 1-6 at any position; preferably, R d each independently C a alkyl, C 1-6 alkoxy, halogen, or cyano, for example halogen, more preferably each 1-6 independently C 1-6 alkoxy; (36)R b Each can be independently selected as C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, hydroxyl, amino, cyano, oxo, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, -N(R) e )2、-OR e -C(O)R e -C(O)OR e or -C(O)N(R) e )2 (preferably each independently is C) 1-6 Alkyl, C 1-6 Alkyl, halogen, hydroxyl, cyano, or oxo group; more preferably, each independently has a C group. 1-6 Alkyl, hydroxyl or oxo group), wherein the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replacement at any position; preferably, R b Each independently is C 1-6 Alkyl, C 1-6 Alkyl, halogen, hydroxyl, cyano, or oxo group; more preferably, R b Each independently is C 1-6 Alkyl, hydroxyl, or oxo group; (37) R d each independently is optionally deuterium, halogen, cyano, C 1-6 alkyl, oxo, -N(R e )2, -OR e , or -SO2R e ; preferably deuterium, -N(R e )2, -OR e , or -SO2R e ; (38) R e each independently is hydrogen or C 1-6 alkyl; (39) n, v and u are each independently optionally 0, 1, 2, 3 or 4, preferably 0, 1, 2 or 3; (40) n is 0, 1 or 2, preferably 1; (41) v is 0, 1, 2 or 3, preferably 1 or 2; (42) each of said heterocycloalkylene, heterocyclyl and heterocycle independently contains 1, 2 or 3 heteroatoms or heteroatom groups selected from N, NH, O and S, preferably saturated monocyclic; (43) each of said heteroaromatic ring and heteroaryl independently contains 1, 2 or 3 heteroatoms or heteroatom groups selected form N, NH, O and S, preferably monocyclic.

3. The compound of any one of claims 1-2, or a pharmaceutically acceptable salt thereof, wherein, which satisfies one or more of the following conditions: (1) wherein U is CH2, O or S; V is CH2, O or NH; Z is CH2or C(O); X and Y are each independently N or CH; X1is N or CR7; X, X1and Y are not simultaneously CH; and, when U and V are simultaneously O, and Z is CH2, X is N; R7is as defined in claim 1 or 2; (2) wherein U is O or S, V is NH, Z is C(O), X1is N or CR7, X and Y are each independently N or CH; X, X1and Y are not simultaneously CH; R7is as defined in claim 1 or 2; preferably, U is O or S, V is NH, Z is C(O), X1is CR7, X is N; Y is N; (3) wherein U is CH2, O or S, V is CH2, Z is CH2, X1is N or CR7, X and Y are each independently N or CH; X1, X1and Y are not simultaneously CH; R7is as defined in claim 1or 2; (4) wherein U is CH2, O or S, V is CH2or O, Z is CH2, X1is CR7, X is N; Y is N or CH; R7is as defined in claim 1 or 2; (5) For X1is N or CR7, X and Y are each independently N or CH; U is CH2, O or S, V is CH2or O; X, X1and Y are not simultaneously CH; Z and R7are as defined in claim 1 or 2; (6) For X1is N or CR7, X1and Y are each independently N or CH; X, X1and Y are not simultaneously CH; U, V, Z, R7are as defined in claim 1 or 2; (7) For Preferably More preferably (8) in L1, R1is H or deuterium; R2is H or deuterium; (9) L1is -CH2- or -(CH2)2-; (10) in L2, R3is H, deuterium, F, -OH, -NH2or -CH3; R4is H, deuterium, F or -CH3; (11) in L2, R3is H, deuterium or F; R4is H, deuterium or F; (12) L2is -CH2-, -(CH2)2- or -CF2-CH2-, preferably -CH2-; (13) L3is -L-(W) m -; L is a direct bond, O or NR6, preferably a direct bond or O; m is 0 or 1 ; W is C 3-6 cycloalkylene (preferably C 3-6 monocycloalkylene, further preferably C 3-4 monocycloalkylene, further preferably C3monocycloalkylene) or 3-6 membered heterocycloalkylene (preferably 3-6 membered monocycloalkylene, further preferably 4-5 membered monocycloalkylene, more preferably 4 membered monocycloalkylene); said C 3-6 cycloalkylene (preferably C 3-6 monocycloalkylene, further preferably C 3-4 monocycloalkylene, further preferably C3monocycloalkylene)or 3-6 membered heterocycloalkylene (preferably 3-6membered monocycloalkylene, further preferably 4-5 membered monocycloalky lene, more preferably 4 membered monocycloalkylene); each independently optionally substituted at any position by one or more R5; (14) in L3, L is attached to M, (W) m attached to L2; (15) in L3, m is 0; L is O; (16) in L3, m is 0; L is a bond; (17) in L3, m is 1, W is o is 0, 1, 2 or 3; (18) in L3, m is 1, W is (19) in L3, m is 1, W is o is 0, 1, 2 or 3; (20) in L3, m is 1, W is (21) L3 is -O-, -NH-, -NCH3-, (a end connected to M, b end connected to L2), (a end connected to M, b end connected to L2) or (a end is connected to M, b end is connected to L2); (22) in L3, L is a bond, O, NH or N(CH3), and (23) M is selected from the following groups: Preferably, M is selected from the following groups: (preferably )、 (preferably )、 (preferably )、 (preferably )、 (preferably )、 (preferably )、 (preferably )、 (preferably )、 Further preferably, M is selected from the following groups: wherein D ring is phenyl, 5-6 membered heteroaryl or 4-8 membered heterocyclyl; A0is N or C; A1is N or CR a-1 ; A2is N or CR a-2 ; A3is N or CR a-3 ; A4is N or CR a-4 ; A6is N or CR a-6 ; B1is N or CR b-1 ; B2is N or CR b-2 ; B3is N or CR b-3 ; B4is N or CR b-4 ; B5is C(R b-5 )2or NR b-5’ ; B6is a bond, O, S, C(R b-6 )2or NR b-6’ ; B7is C(O), O, S, C(R b-7 )2or NR b-7’ ; C1is N or CR c-1 ; C2is N or CR c-2 ; C3is N or CR c-3 ; C4is O, S or NR c-4’ ; C5is a bond, O, S, C(R c-5 )2or NR c-5’ ; C6is C(R c-6 )2; t is 0, 1 or 2; p is 0, 1, 2, 3 or 4; q is 0, 1 or 2; R a-1 , R a-2 , R a-3 , R a-4 , R a-6 , R b-1 , R b-2 , R b-3 , R b-4 , R b-5 , R b-6 , R b-7 , R c-1 , R c-2 , R c-3 , R c-5 , R c-6 and R c-7 are each independently hydrogen, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, halogen, hydroxyl, thiol, amino, cyano, oxo, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, C 3-8 cycloalkylC 1-6 alkyl, 3-8 membered heterocyclylC 1-6 alkyl, C 6-10 arylC 1-6 alkyl, 5-10 membered heteroarylC 1-6 alkyl, -N(R e )2, -OR e , -SO2R e , -C(O)R e , -C(O)OR e , -C(O)N(R e )2, -OC(O)R e , -NR f C(O)R e , or -NR f C(O)N(R e )2; wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, 5-10 membered heteroaryl, C 6-10 aryl, C 3-8 cycloalkylC 1-6 alkyl, 3-8 membered heterocyclylC 1-6 alkyl, C 6-10 arylC 1-6 alkyl, and 5-10 membered heteroarylC 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replacement at any position; preferably, R a-1 R a-2 R a-3 R a-4 R a-6 R b-1 R b-2 R b-3 R b-4 R b-5 R b-6 R b-7 R c-1 R c-2 R c-3 R c-5 R c-6 and R c-7 Each independently is hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 Alkyne, halogen, hydroxyl, amino, cyano, oxo, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-6 membered heteroaryl, C 3-8 cycloalkyl C 1-6 Alkyl, 3-8 membered heterocyclic C 1-6 Alkyl, -N(R) e )2、-OR e -C(O)R e -C(O)OR e or -C(O)N(R) e )2; wherein, the C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 3-8 cycloalkyl C 1-6 Alkyl and 3-8 membered heterocyclic C 1-6 Each alkyl group is independently and optionally surrounded by one or more R d Replacement at any position; more preferably, R a-1 R a-2 R a-3 R a-4 R a-6 R b-1 R b-2 R b-3 R b-4 R b-5 R b-6 R b-7 R c-1 R c-2 , R c-3 , R c-5 , R c-6 and R c-7 are each independently hydrogen, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, halogen, cyano, oxo, or -C(O)N(R e )2; wherein said C 1-6 alkyl is optionally substituted at any position with one or more R d ; more preferably hydrogen, C 1-6 alkyl, C 1-6 alkoxy, halogen, cyano, oxo, or -C(O)N(R e )2; still more preferably R a-1 , R a-2 , R a-3 and R a- 4 are each independently H, halogen, cyano, C 1-6 alkoxy, C 1-6 alkyl, or hydroxyl, for example H, halogen, or C 1-6 alkoxy; R b-1 , R b-2 , R b-3 , R b-4 , R b-6 and R b-7 are each independently H, C 1-6 alkyl, halogen, hydroxyl, cyano, C 1-6 alkoxy, or oxo, for example H, C 1-6 alkyl, hydroxyl, or oxo; R b-5’ , R b-6’ , R b-7’ , R c-4’ and R c-5’ are each independently hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 3-8 cycloalkyl C 1-6 alkyl or 3-8 membered heterocyclyl C 1-6 alkyl; wherein said C 1-6 alkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 3-8 cycloalkyl C 1-6 alkyl and 3-8 membered heterocyclyl C 1-6 alkyl is optionally substituted with one or more R d at any position; preferably R b-5’ , R b-6’ , R b- 7’ , R c-4’ and R c-5’ are each independently hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl C 1-6 alkyl or 3-8 membered heterocyclyl C 1-6 alkyl; wherein said C 1-6 alkyl is optionally substituted with 1-3 R d at any position, further preferably R b-5’ , R b-6’ , R b-7’ , R c-4’ and R c-5’ are each independently hydrogen or C 1-6 alkyl; more further preferably R b-5’ is C 1-6 alkyl; R b-0 is defined as R a .

4. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-3, wherein M is selected from the following groups: wherein, A1 is N or CH; A2 is N or CR a-2 ; A4 is N or CR a-4 ; B1 is N or CH; B4 is N or CR b-4 ; B6 is a bond, O, S, CH2 or NR b-6’ ; B7 is C(O), O, S, C(R b-7 )2 or NR b-7’ ; R a-2 , R a-3 , R a-4 , R b-2 , R b-3 , R b-4 , and R b-7 are each independently hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, or -C(O)N(R e )2; said C 1-6 alkyl is optionally substituted anywhere with one or more R d ; R b-5’ , R b-6’ , and R b-7’ are each independently hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 3-8 cycloalkyl C 1-6 alkyl, or 3-8 membered heterocyclyl C 1-6 alkyl; wherein said C 1-6 alkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, and C 3-8 cycloalkyl C 1-6 alkyl and 3-8 membered heterocyclyl C 1-6 alkyl are each independently optionally substituted with one or more R d at any position; R d each independently is deuterium, -N(R e )2, -OR e , or -SO2R e ; R e each independently is hydrogen or C 1-6 1-6alkyl; R a-2 , R a-3 , R a-4 , R b-2 , R b-3 and R b-4 are each independently hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R e )2; R b-7 is hydrogen or C 1-6 alkyl; R b-5’ , R b-6’ , and R b-7’ are each independently hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl C 1-6 alkyl, or 3-8 membered heterocyclyl C 1-6 alkyl; wherein said C 1-6 alkyl is optionally substituted with 1-3 R d groups at any position; R d each independently is deuterium, -N(R e )2, -OR e , or -SO2R e ; R e each independently is hydrogen or C 1-6 1-6alkyl; More preferably, A1 is N or CH; A2 is N or CR a-2 ; A4 is N or CR a-4 ; B1 is N or CH; B4 is N or CR b- 4; B6 is CH2; B7 is O, S or NR b-7’ ; R a-2 , R a-3 , R a-4 , R b-2 , R b-3 , and R b-4 are each independently hydrogen, halogen, cyano, C 1-6 1-6alkyl, C 1-6 1-6alkoxy, haloC 1- 1-6alkyl, haloC 1-6 1-6alkoxy, C 2-6 1-6alkenyl, C 2-6 1-6alkynyl, or -C(O)N(R e )2; R b-5’ and R b-7’ each independently is hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl C 1-6 alkyl or 3-8 membered heterocyclyl C 1-6 alkyl; wherein said C 1-6 alkyl is optionally substituted with 1 to 3 R d groups at any position; R d each independently is deuterium, -N(R e )2, -OR e , or -SO2R e ; R e each independently is hydrogen or C 1-6 1-6alkyl; Preferably, M is wherein, wherein A4 is N or CR a-4 ; B4 is N or CR b-4 ; R a-2 , R a-3 , R a-4 , R b-3 , and R b-4 are each independently hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl, or -C(O)N(R e )2; said C 1-6 alkyl is optionally substituted anywhere with one or more R d ; R b-5’ is hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 3-8 cycloalkyl C 1-6 alkyl or 3-8 membered heterocyclyl C 1-6 alkyl; wherein said C 1-6 alkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 3-8 cycloalkyl C 1-6 alkyl and 3-8 membered heterocyclyl C 1-6 each R d is independently optionally substituted at any position with one or more R R d each independently deuterium, -N(R e )2, -OR e , or -SO2R e ; R e each independently hydrogen or C 1-6 1-6alkyl; R a-2 , R a-3 , R a-4 , R b-3 and R b-4 are each independently hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl or -C(O)N(R e )2; R b-5’ is hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl C 1-6 alkyl or 3-8 membered heterocyclyl C 1-6 alkyl; wherein said C 1-6 alkyl is optionally substituted with 1-3 R d substituents at any position; R d each independently is deuterium, -N(R e )2, -OR e , or -SO2R e ; R e each independently is hydrogen or C 1-6 1-4alkyl; More preferably, A4 is N or CR a-4 ; B4 is N or CR b-4 ; R a-2 , R a-3 , R a-4 , R b-3 , and R b-4 are each independently hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, or -C(O)N(R e )2; R b-5’ is hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl C 1-6 alkyl or 3-8 membered heterocyclyl C 1-6 alkyl; wherein said C 1-6 alkyl is optionally substituted with 1-3 R d substituents at any position; R d each independently is deuterium, -N(R e )2, -OR e , or -SO2R e ; R e each independently is hydrogen or C 1-6 1-6alkyl.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein, which satisfies one or more of the following conditions: (1) M is selected from the group consisting of: (2) For (For example )、 wherein L 1-1 is -(CR1R2) x -; x is 1 or 2; L 2-1 is -(CR3R4) y -; y is 0, 1, 2 or 3; w is 0, 1 or 2; z is 1 or 2; L1, L2, L3, L, R, R', R1, R2, R3and R4are as defined in any one of claims 1-4. (3) L2is -(CR3R4) y - y is 0, 1, 2 or 3, L3is -L-(W) m - m is 0, L is a bond, O or NR6; preferably, L2is -(CR3R4) y - y is 1, 2 or 3, L3is -L-(W) m - m is 0, L is a bond; (4) L2is -(CR3R4) y -; y is 0, 1, 2, or 3, and L3is -L-(W) m -; m is 1, and W is C 3-8 cycloalkylene or 4-8 membered heterocycloalkylene, and L is a direct bond or O; (5) L2is -(CR3R4) y -; y is 1, 2 or 3, R and one of R3and the atoms therebetween together form a 4-8 membered heterocyclic ring; L3is -L-(W) m -; m is 0, L is O; (6) L2is -(CR3R4) y - y is 1, 2 or 3, L3is -L-(W) m - m is 0, L is a bond, R' and one of R1and the atoms therebetween together form a 4-8 membered heterocyclic or C 3-8 carbocyclic ring.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein, The compound of Formula (I) is a compound of Formula (II), Formula (III) (e.g., Formula (III-1) or Formula (III-2)), Formula (IV), Formula (V), or Formula (VI), wherein L 1-1 is -(CR1R2) x -; x is 1 or 2; L 2-1 is -(CR3R4) y -; y is 0, 1, 2 or 3; w is 0, 1 or 2; z is 1 or 2; X, Y, U, V, Z, L1, L2, L3, L, M, R, R', R1, R2, R3and R4are as defined in any one of claims 1-5; in the compounds of formula (III-1) and formula (III-2), x is 1 and w is 1; or, x is 2 and w is 2. Preferably, in said compound of formula (II), X is N or CH; Y is N; U is O or S; Y is N; V is O or NH; Z is CH2or C(O); L1is -(CR1R2) x -; x is 1 or 2; w is 1 or 2; L2is -(CR3R4) y -; y is 0, 1, 2, or 3; L3is -L-(W) m -; m is 0, 1 or 2; L is a bond, O, or NR6, R6is hydrogen or C 1-6 alkyl; preferably, L is a bond, O, NH, or N(CH3); more preferably, L is a bond or O; W is C 3-8 monocyclic cycloalkylene or 4-8 membered monocyclic heterocycloalkylene; said C 3-8 monocyclic cycloalkylene and 4-8 membered monocyclic heterocycloalkylene are each independently optionally substituted at any position with one or more R5; R1, R2, R3, and R4are each independently hydrogen, deuterium, halogen, hydroxyl, amino, or C 1-6 alkyl; R5is deuterium, halogen, hydroxyl, amino, or C 1-6 alkyl; M is (preferably )、 A ring is a phenyl ring or a 5-6 membered heteroaromatic ring; B ring, C ring and C' ring are each independently a phenyl ring, a 5-6 membered heteroaromatic ring or a 4-8 membered monocyclic heterocyclic ring; R a , R b , and R c are each independently optionally C 1-6 1-6 alkyl, C 1-6 1-6 alkoxy, haloC 1-6 1-6 alkyl, haloC 1-6 1-6 alkoxy, C 2-6 1-6 alkenyl, C 2-6 1-6 alkynyl, halo, hydroxyl, cyano, oxo, or -C(O)N(R e )2, preferably optionally C 1-6 1-6 alkyl, C 1-6 1-6 alkoxy, halo, hydroxyl, cyano, oxo, or -C(O)N(R e )2; R e each independently is hydrogen or C 1-6 alkyl; n, v and u are each independently 0, 1, 2, 3 or 4; Preferably, in the compound of formula (III), X is N or CH; Y is N; U is O or S; V is O or NH; Z is CH2or C(O); L 1-1 -(CR1R2) x -; x is 1 or 2; w is 0, 1 or 2; L2is -(CR3R4) y -; y is 0, 1, 2, or 3; L3is -L-(W) m -; m is 0, 1 or 2; L is a bond or O; W is C 3-8 monocyclic cycloalkylene or 4-8 membered monocyclic heterocycloalkylene; said C 3-8 monocyclic cycloalkylene and 4-8 membered monocyclic heterocycloalkylene are each independently optionally substituted at any position with one or more R5; R is hydrogen, C 1-6 alkyl or C 3-8 cycloalkyl; R1, R2, R3, and R4are each independently hydrogen, deuterium, halogen, hydroxyl, amino, or C1-C6alkyl; 1-6 alkyl; R5is deuterium, halogen, hydroxyl, amino, C 1-6 alkyl; M is selected from the following groups: (preferably ) or A ring is a phenyl ring or a 5-6 membered heteroaromatic B ring and C ring are each independently a phenyl ring, a 5-6 membered heteroaromati R a , R b , and R c are each independently optionally C 1-6 1-6 alkyl, C 1-6 1-6 alkoxy, haloC 1-6 1-6 alkyl, haloC 1-6 1-6 alkoxy, C 2-6 1-6 alkenyl, C 2-6 1-6 alkynyl, halo, cyano, oxo, or -C(O)N(R e )2; preferably optionally C 1-6 1-6 alkyl, C 1-6 1-6 alkoxy, halo, cyano, oxo, or -C(O)N(R e )2; R e each independently is hydrogen or C 1-6 alkyl; n, v and u are each independently optionally 0, 1, 2, 3 or 4; Preferably, the compound of formula (IV) is X is N or CH; Y is N; U is O or S; V is O, preferably NH; Z is CH2or C(O), preferably C(O); L1is -(CR1R2) x -; x is 1 or 2; L2is -(CR3R4) y -; y is 0, 1, 2, or 3; z is 1 or 2, preferably 1; L is a bond or O, preferably a bond; R is hydrogen, C 1-6 alkyl or C 3-8 cycloalkyl; R', R1, R2, R3, and R4are each independently hydrogen, deuterium, halogen, hydroxyl, amino, or C 1-6 alkyl; M is selected from the group consisting of: A ring is a phenyl ring or a 5-6 membered heteroaromati B ring is a phenyl ring, a 5-6 membered heteroaromatic ring or a R a , R b , and R c are each independently optionally C 1-6 1-6 alkyl, C 1-6 1-6 alkoxy, haloC 1-6 1-6 alkyl, haloC 1-6 1-6 alkoxy, C 2-6 1-6 alkenyl, C 2-6 1-6 alkynyl, halo, cyano, oxo, or -C(O)N(R e )2; preferably optionally C 1-6 1-6 alkyl, C 1-6 1-6 alkoxy, halo, cyano, oxo, or -C(O)N(R e )2; R e each independently is hydrogen or C 1-6 alkyl; n, v and u are each independently optionally 0, 1, 2, or 3, preferably 1; Preferably, the compound of formula (V) is U is O or S, preferably O; V is O or NH, preferably NH; Z is CH2or C(O), preferably C(O); L1is -(CR1R2) x -; x is 1 or 2, preferably 1; L2is -(CR3R4) y -; y is 0, 1 or 2, preferably 1 ; z is 0, 1 or 2, preferably 1; L is a bond or O, preferably a R is hydrogen, C 1-6 alkyl or C 3-8 cycloalkyl, preferably hydrogen; R', R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen, hydroxyl, amino, or C 1-6 alkyl, preferably hydrogen; M is A ring is a phenyl ring or a 5-6 membered heteroaromatic, preferably a phenyl ring; B ring is a phenyl ring, a 5-6 membered heteroaromatic or a 4-8 membered heterocyclic ring, preferably a 4-8 membered heterocyclic ring; R a and R b each independently is optionally C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, halogen, cyano, oxo, or -C(O)N(R e )2, preferably optionally C 1-6 alkyl, C 1-6 alkoxy, halogen, cyano, oxo, or -C(O)N(R e )2; R e each independently is hydrogen or C 1-6 alkyl; Preferably, R a It is a halogen; R b C 1-6 Alkyl or oxo group, such as methyl and oxo group; n is 0, 1 or 2, preferably 1; v is 0, 1, 2 or 3, preferably 2; Preferably, the compound of formula (VI) is U is O or S, preferably O; V is O or NH, preferably O; Z is CH2or C(O), preferably C(O); L1is -(CR1R2) x -; x is 1 or 2, preferably 1; L 2-1 -(CR3R4) y -; y is 0, 1 or 2, preferably 1 ; z is 0, 0, 1 or 2, preferably 1; L3is -L-(W) m -; m is 0 or 1 ; L is a bond or O; W is C 3-8 cycloalkylene, preferably C 3-4 cycloalkylene; R', R1, R2, R3, and R4 are each independently hydrogen, deuterium, halogen, hydroxyl, amino, or C 1-6 alkyl, preferably hydrogen; M is A ring is a phenyl ring or a 5-6 membered heteroaromat B ring is a phenyl ring, a 5-6 membered heteroaromati R a and R b each independently is optionally C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, halogen, cyano, oxo, or -C(O)N(R e )2, preferably optionally C 1-6 alkyl, C 1-6 alkoxy, halogen, cyano, oxo, or -C(O)N(R e )2; R e each independently is hydrogen or C 1-6 alkyl; Preferably, R a It is a halogen; R b C 1-6 Alkyl or oxo groups, such as methyl and oxo groups; n is 0, 1 or 2, preferably 1; v is 0 or 1, preferably 0.

7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein, The compound of formula (I) is selected from any one of the following compounds: (For example )、 (For example )、 (For example )、 (For example Preferably, the compound of formula (I) is selected from any one of the following compounds: More preferably, the compound of formula (I) is selected from any one of the following compounds:

8. A pharmaceutical composition, characterized by, The pharmaceutical composition comprises (i) a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1-7; and (ii) a pharmaceutically acceptable excipient.

9. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any of claims 1-7, or a pharmaceutical composition as claimed in claim 8, for the manufacture of a medicament for the prevention and / or treatment of a microbial infection; preferably, the microbial infection is a bacterial infection, such as a Gram-positive, Gram-negative or Mycoplasma infection, preferably a Streptococcus, Haemophilus or Staphylococcus infection, more preferably a Mycoplasma pneumoniae, Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes or Staphylococcus epidermidis infection.

10. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, characterized in that, It comprises: In the reaction of general formula 1, X1, X, Y, U, V, Z, R', R, L1, L2, L3 and M are as defined in any one of claims 1-7; the compound of formula (I-A) and the compound of formula (I-B) are reacted by reductive amination to obtain the compound of formula (I); When y is 0 in L2, the compound represented by formula (I-B) is or In the reaction of general formula 2, Lev is a leaving group (preferably halogen, -OTs or -OMs); X1, X, Y, U, V, Z, R', R, L1, L2, L3 and M are as defined in any one of claims 1-7; the compound of formula (I-C) and the compound of formula (I-D) are reacted by nucleophilic substitution to obtain the compound of formula (I).

11. A compound of Formula (I-A), (I-B), or (I-D), or a pharmaceutically acceptable salt thereof; wherein X1, X, Y, U, V, Z, R', R and L1 are as defined in any one of claims 1 to 7; wherein L1, L2and M are as defined in any one of claims 1 to 7; wherein R, L2, L3 and M are as defined in any one of claims 1-7; Preferably, the compound of formula (I-A) is any one of the following compounds: (For example )、 ( )、 Preferably, said compound of formula (I-B) is any one of the following: Preferably, said formula (I-D) is